




































 Angiotensinogen is a blood protein that plays a critical role in the regulation of blood 
pressure in the body. This protein exists in two forms, oxidised and reduced, determined by the 
presence or absence of a disulfide bridge between Cys 18 and Cys 138. The ratio of oxidised to 
reduced angiotensinogen is 60:40 in the blood of healthy individuals—an equilibrium that is 
disrupted in women who develop pre-eclampsia, leading to a higher proportion of oxidised 
angiotensinogen in the blood.1 Pre-eclampsia, one of the leading causes of premature births, is a 
severe and potentially fatal pregnancy condition characterised by the sudden onset of symptoms 
such as high blood pressure and proteinuria typically during the third trimester. This condition is 
responsible for an estimated 550,000 deaths globally each year, and with no available treatment 
or cure other than early delivery of the child, there is a desperate need for a reliable and 
predictive diagnostic test for this condition. 
 Can we use angiotensinogen as a biomarker for the early diagnosis of pre-eclampsia? 
Being able to distinguish between reduced and oxidised angiotensinogen and determine the 
relative amounts of each in blood samples would be of a huge diagnostic value for this condition. 
This thesis outlines the expression and purification of recombinant human angiotensinogen in 
Escherichia coli, and the development of an antibody-based SPR assay for angiotensinogen that 
was subsequently used to probe whether reduced and oxidised angiotensinogen can be 
distinguished experimentally. The assay developed was sensitive and reproducible, and 
demonstrated that the reduced and oxidised forms can be distinguished experimentally. The 
antibody bound the two forms with differential affinity, due to differences in both the association 
and dissociation rates of the two forms with the monoclonal antibody.  
Finally, in an attempt to further elucidate the differences between the two redox states of 
angiotensinogen, molecular dynamic simulations were carried out on angiotensinogen in the 
presence or absence of the disulfide bond between Cys 18 and Cys 138. These simulations 
revealed some quite striking differences in the dynamics between the two forms. Reduced 
angiotensinogen was found to be more dynamic in regions critical for binding to renin, providing 
a possible explanation for the reported differential affinity that renin displays for the two forms.1 
Thus, reduced and oxidised angiotensinogen show some quite distinct differences and can be 
distinguished in an SPR-based assay, highlighting their potential for use as a biomarker in a 
diagnostic bioassay.  
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Pre-eclampsia is a severe and potentially fatal pregnancy condition that occurs in 
approximately 2% to 7% of all pregnancies and is one of the leading causes of maternal and 
perinatal morbidity and mortality worldwide. It is estimated that pre-eclampsia is responsible for 
approximately 50,000 maternal and 500,000 infant deaths globally each year.3, 4 The condition is 
characterised by high blood pressure and proteinuria, which develop after the 20th week of 
gestation,5, 6 and often displays sudden onset, developing in a matter of days or even hours with 
no prior warning. Without medical intervention, pre-eclampsia can develop into HELLP 
syndrome (Hemolytic anemia, Elevated Liver enzymes, and Low Platelet count) or even 
eclampsia, which causes neurological symptoms and seizures, leading to organ damage, coma, 
brain damage, and possible death.5, 7, 8 Although symptoms typically abate rapidly postpartum,9 
both pre-eclampsia and eclampsia have been observed to develop anywhere up to four weeks 
following delivery.10 Recently, it has been hypothesized that pre-eclampsia actually exists as two 
separate conditions that should be treated and managed differently:11 early onset pre-eclampsia 
(prior to 34 weeks) and late-onset pre-eclampsia (above 34 weeks gestation). Early onset pre-
eclampsia is typically the more severe form of the condition, which represents approximately 5% 
to 20% of all pre-eclampsia cases and generally results in premature birth; while late-onset pre-
eclampsia, representing the majority of pre-eclamptic cases, on the whole tends to be less severe 
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and is thought, in part, to be due to pre-existing maternal conditions such as obesity, diabetes 
mellitus, and renal disease.5, 12 
 Pre-eclampsia is thus a major health concern. Up to 65% of perinatal deaths are due to 
pre-eclampsia and it is also a major cause of maternal mortality.13, 14 Intrauterine growth 
restriction (IUGR) and premature birth, along with their associated short- and long-term health 
conditions, are just a few of the adverse outcomes that result from the condition, which can have 
severe impacts on the life of the child and are also costly for the healthcare sector.5, 15 
Interestingly, the effects of pre-eclampsia are not only short term—having pre-eclampsia has 
been associated with a significantly elevated risk of developing cardiovascular disease, stroke 
and chronic hypertension later in life, not only for the mother but also the child.16, 17 Whether this 
association is purely confounded due to the shared risk factors and pathophysiology of these 
hypertensive diseases, or whether pre-eclampsia actively causes or triggers cardiovascular 
disease is unknown and, although difficult to tease apart, is something that does need to be 
investigated. Being a hypertensive disorder, pre-eclampsia shares many risk factors with 
cardiovascular disease, such as obesity, insulin resistance, hypertension, as well as elevated 
lipids and coagulation of the blood.18  
 
1.1.2 Blood Pressure Control, Hypertension, and their Implications on Health 
 
Blood pressure is the force that is exerted by circulating blood upon the walls of blood 
vessels19 and is at the heart of a number of disease states. Blood pressure can vary throughout the 
day, according to circadian rhythms,20 and if it gets too high or too low, can have significant 
impacts on health. Blood pressure is primarily controlled by the Renin-Angiotensin System 
(RAS), a hormone cascade that is known to regulate blood pressure through alterations in salt 
and water balance, vascular tone, and the secretion of aldosterone from the adrenal gland.19, 21 
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This multi-step cascade (for an overview of the RAS see Figure 1.1) produces a potent 
vasoconstricting peptide, angiotensin-II, which activates the angiotensin type I receptor (AT1R), 
leading to vasoconstriction and secretion of aldosterone. Aldosterone release results in sodium 
and water retention by the kidney and a subsequent increase in blood pressure.19  
High blood pressure is particularly harmful as it means that the heart has to work harder 
to pump blood into the arteries and around the body, and is commonly termed hypertension. 
Hypertension is a risk factor for the development of atherosclerosis and hardening of the arteries, 
which, if left untreated, can result in stroke, cardiovascular disease, and kidney failure.19 
Hypertension is becoming increasingly common in the developing world and is a leading cause 
of morbidity and mortality globally.22 Hypertension is responsible for nearly 13% of total deaths 
worldwide, with the World Health Organisation estimating that more than 17 million people die 
as a result of cardiovascular disease each year.23 It has been suggested that by 2025 
approximately 29% of the adult population worldwide could be suffering from hypertension.24   
Chronic essential hypertension is a multi-factorial disease, with many risk factors pre-
disposing individuals to develop it including an individual’s weight, age, sex, ethnicity, smoking 
status, levels of physical activity, diet, alcohol consumption, stress, as well as other medical 
conditions.22, 25 Alongside environmental factors, hypertension also has a strong genetic 
component. One gene that has been associated with increased hypertension risk in numerous 
studies is the AGT gene, which encodes the protein angiotensinogen.26, 27 A polymorphism 
within the AGT gene, which results in an amino acid substitution at position 235 (M235T), was 
shown to be significantly associated with hypertension and increased plasma angiotensinogen 
levels,27 and has received much interest from researchers. The protein itself is the substrate of the 
first and rate-limiting step of the RAS cascade,28 and thus plays an important role in the 
regulation of blood pressure. Angiotensinogen levels positively correlate with blood pressure;29 
blood pressure will decrease when antibodies specific to angiotensinogen are injected30 and 
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increase in response to injection with angiotensinogen,31 and transgenic mice expressing rat 
angiotensinogen display elevated blood pressure.32 It has been postulated that there may have 
been an evolutionary advantage to having high circulating angiotensinogen levels when our 
ancestors lived in Sub-Saharan Africa, where there was little salt in the environment. Things 
have rapidly changed in our modern Western world; salt is readily available and present in high 
amounts in our diet, making the once advantageous plasma angiotensinogen levels now 
disadvantageous—evolution just can’t keep up with our fast food way of life!22, 33   
Because of the complex interplay of environmental and genetic risk factors that 
contribute to an individual’s risk of developing hypertension and its subsequent complications, it 
has been a difficult road (and will remain so in the years to come) for clinicians to better come to 
grips with understanding the underlying factors that contribute to hypertension, in order to 
prevent and treat the condition more effectively.22 Lifestyle changes including exercising, 
reducing weight, and lowering salt intake can be very beneficial for some individuals in lowering 
hypertensive risk and treating the disorder.34 However, lifestyle changes alone are often not 
enough, and anti-hypertensive medications are frequently prescribed to treat and manage this 
condition. Common hypertensive therapies include α- and β-blockers, calcium channel blockers 
and diuretics,19, 34, 35 as well as compounds which target the RAS cascade such as angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers.19, 36 Difficulties arise 
in targeting the RAS system, however, as patients often differentially respond to the various anti-
hypertensive therapies in a seemingly unpredictable manner. In addition, over time the body 
overcompensates for the inhibition of the RAS by producing more renin,19 the enzyme 
responsible for the first and rate-limiting step in the cascade, resulting in a decrease in the 
therapeutic benefit of the anti-hypertensive agent. Ideally, inhibition of renin at the first step of 
the RAS cascade would be more effective as it does not lead to a reactive rise in active renin, but 
producing bioavailable potent renin inhibitors has been challenging.37 Despite the difficulties, 
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aliskiren, a potent renin inhibitor has recently been approved for clinical use for the treatment of 
hypertensive disorders.36         
 
1.1.3 The Effects of Pregnancy on the Body and How Pre-eclampsia Alters the Balance  
 
Throughout the course of a normal healthy pregnancy, many physiological changes take 
place in the mother’s body, particularly in the cardiac and renal systems, to adequately enable the 
body to cope with the growing demands for increased blood supply and nutrients.38 After falling 
pregnant, women experience changes to their cardiac output, blood coagulation, and 
inflammatory responses, as well as alterations to their response to insulin and lipid modifications 
in the serum.4, 39, 40 The RAS cascade itself is altered quite considerably from the onset of 
pregnancy, with most components of the system being upregulated (see Table 1.1). Renin 
secretion is increased, and as the placenta grows it stimulates higher levels of angiotensinogen to 
be synthesized, ultimately leading to higher circulating angiotensin II levels.9, 41-43 Surprisingly, 
despite these changes, in healthy pregnancies women appear to be less sensitive to angiotensin II 
levels,9 with pregnant women requiring double the amount of angiotensin II compared with non-
pregnant women to obtain the same increase in blood pressure, and they actually display a 
slightly decreased blood pressure in the first two trimesters before their blood pressure returns to 
normal during the final trimester38—it seems that the changes that take place in the RAS are 
crucial for maintaining a healthy state during pregnancy.  
 This fine balance maintained during a normal pregnancy can, however, be easily upset, 
leading to the hypertensive pregnancy condition known as pre-eclampsia. Pre-eclamptic women 
do not experience the same increase in plasma volume that occurs during normal pregnancies 
and this, coupled with a decrease in the majority of RAS components (Table 1.1) and a 
heightened sensitivity to the vasopressor effects of angiotensin II, lead to serious dysfunction of 
      P a g e   |   6  
the salt-water balance which is critical for the health of both mother and fetus.44 It is thought that 
the altered fluid and salt-water balance severely limits the placental supply, preventing adequate 
placental perfusion and fetal substrate delivery, and raising blood pressure, ultimately leading to 
the clinically manifest symptoms of pre-eclampsia.44-46 Despite the changes in the RAS cascade 
and the condition being extensively studied for many years, the underlying causative 






Angiotensinogen   
Renin   
Renin Activity   
Aldosterone   
Angiotensin II   
Angiotensin II Activity   
Angiotensin (1 – 7)   
ACE   
ACE2   
ACE2 Activity   
AT1R   
 
Table 1.1:  
Serum levels of the RAS components in both normotensive and pre-eclamptic pregnancies compared to 
non-pregnant controls where     indicates significantly increased levels compared with non-pregnancy,             
j  indicates slightly increased levels compared with non-pregnancy,      represents same as non-
pregnancy, and     represents decreased levels when compared with non-pregnant controls (adapted from 
Yang et al. 2013 44 with permission from the Society for Endocrinology © 2013). 
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1.1.4 Oxidative Stress and Pre-eclampsia 
 
Pre-eclampsia is commonly described as a condition characterised by oxidative stress.18, 
47, 48 It is thought that placental dysfunction leads to the excessive production of reactive oxygen 
species, ultimately resulting in endothelial cell dysfunction and the symptoms of pre-
eclampsia.49, 50 One study monitored the levels of selenium in serum and toenails of pregnant 
women and found that women with pre-eclampsia had significantly reduced selenium levels 
compared to the normotensive pregnant and non-pregnant controls.48 Selenium is essential for 
the activity of the selenoproteins, such as glutathione peroxidases, which display antioxidant 
activity. Glutathione peroxidases provide protective effects for the endothelial cells by 
destroying reactive oxygen species such as hydroperoxides and oxidised lipoproteins. 
Worryingly, the study found that even the normotensive controls had depleted selenium levels 
below recommended guidelines and were not receiving the full protection from glutathione 
peroxidases as a result.48  
Reactive oxygen species can have effects on the RAS as well. Oxidative stress enhances 
the cleavage of angiotensin I from angiotensinogen and also increases expression of the AT1R 
receptor, while angiotensin II can exert some of its vasoconstrictor effects through the 
production of reactive oxygen species also.51  Changes to both the maternal and fetal antioxidant 
levels in the circulation have been observed52, 53 and pre-eclampsia also results in increased 
levels of lipid peroxidation in the placenta.54 
 
1.1.5 Treatment and Management of Pre-eclampsia 
 
There is presently no cure or effective treatment for pre-eclampsia—delivery remains the 
one and only option in cases of severe pre-eclampsia when the life of the mother or baby is at 
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risk.9, 16 Symptoms normally subside within a couple of days after giving birth and by 12 weeks 
post-delivery a pre-eclamptic woman’s blood pressure should have returned to normal.9, 18 
However, early delivery often comes at the expense of the health or even life of the child.9, 55  
Ideally the pregnancy needs to continue for as long as possible to allow the infant’s lungs to 
mature prior to birth, and thus conservative management (typically bed rest and anti-
hypertensive therapy) is provided to prolong the pregnancy as long as it is medically safe and 
possible to do so, while at the same time manage the symptoms and prevent them from 
worsening.4, 5  
Magnesium sulfate is commonly employed by clinicians in order to prevent the seizures 
that can be brought on by pre-eclampsia and eclampsia,7, 8 and is recommended by the World 
Health Organisation as the most effective, safe, and low-cost anti-convulsant treatment for 
severe pre-eclampsia and eclampsia.8 It has also been found to be the most important action to 
prevent death from this disease.56  
 Many attempts have been made to treat pre-eclampsia using a variety of medication, 
supplements, and lifestyle changes with little success. Treating pregnant women who have 
chronic hypertension with anti-hypertensive agents, while being effective at treating and 
managing the hypertension, did little to abate the risk of developing pre-eclampsia or reducing its 
severity.57 Similarly, little benefit was observed from taking supplements such as fish oil, 
calcium, or vitamins C and E in terms of reducing pre-eclampsia risk.58-60  
One promising preventive measure, low-dose aspirin, which was originally thought to be 
protective against developing pre-eclampsia, has been hotly debated, with multiple studies 
finding it provides no preventive benefit.58  One meta-analysis did find that low-dose aspirin 
does have some preventive measure, but if and only if treatment is started before 16 weeks 
gestation, while a recent review and analysis of over 20 studies found that low dose aspirin from 
the end of the first trimester could result in risk reduction of developing pre-eclampsia by an 
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estimated 10% in high-risk women.61 Advances in treating pre-eclampsia have been limited due 
to complex nature of the pathogenesis of the disease which is not yet fully understand.4, 9  
 
1.1.6 Pre-eclampsia and Genetics 
 
Like hypertension, pre-eclampsia is a multifactorial disease comprised of a strong genetic 
component4 with an estimated heritable genetic component likely to be somewhere in the range 
of 20% to 40%, which is comparable to the genetic heritability of hypertension.18 Pre-eclampsia, 
too, has been associated with the M235T angiotensinogen polymorphism, but only in some 
populations.62-64 Residue 235 is located on the surface of the angiotensinogen protein25 and 
having a methionine or threonine residue at this position does not appear to have any effect on 
the kinetics of the reaction between renin and angiotensinogen.6 Thus, it is yet to be elucidated 
whether the M235T polymorphism is responsible for playing a direct role in hypertension and 
pre-eclampsia, or if it is a purely a neutral marker in linkage disequilibrium to another marker 
which is yet to be identified.6, 25 In fact, M235T is associated with increased plasma 
angiotensinogen levels, but it has been postulated that this phenotype is due to M235T being 
associated with the G‒6A substitution in the promoter region of the AGT gene.65  
Another missense mutation at position 10 of angiotensinogen, which results in a leucine 
residue being substituted for a phenylalanine (L10F), has also been implicated in the inherited 
predisposition to pre-eclampsia. This mutation gives rise to a doubling of the catalytic efficiency 
of the reaction between renin and angiotensinogen6 and, in the reported case, resulted in the 
affected woman suffering from severe pre-eclampsia, requiring delivery of the fetus at only 28 
weeks. Clearly, polymorphisms present in the angiotensinogen protein can have large 
ramifications, particularly during pregnancy, on the tightly controlled RAS, which can have 
serious health implications. 
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 Aside from the mother’s contribution to the development of pre-eclampsia, it was 
recently shown that the fetus can also contribute to the risk of developing pre-eclampsia through 
the genes it inherits from the father.18, 66 Women who had children either with a man who was 
born of a pre-eclamptic birth,67, 68 or a man who had himself previously had a child with another 
women who developed pre-eclampsia during the course of her pregnancy,69 were shown to be at 
a significantly increased risk of developing pre-eclampsia. Thus, the father’s genetic contribution 
also has a role to play in the development of this condition. Furthermore, it has been suggested 
that genomic imprinting, which gives rise to the preferential expression of either the maternal or 
paternal genes, may also be involved in the manifestation of this disorder.70  
 




The Renin-Angiotensin System (RAS), as already outlined, is a critical player in salt and 
water homeostasis, and in the regulation of blood pressure in the body (see Figure 1.1).19, 21 This 
hormone system is thought to have its origins in the early stages of vertebrate evolution and is 
present across the majority of vertebrate species including elasmobranchs and cyclostomes.71-74 
The RAS has been shown to also play diverse roles in several processes in the body including 
inflammation, thrombosis, development, and growth and remodelling.75-78 In addition to being 
present in the circulation, there is now a wealth of evidence in support of local RAS systems 
existing in the tissues,79, 80 particularly in the heart,79 brain,81 adrenal gland,82 liver, ovaries,83 
testes,84 retina,85 salivary glands,86 vascular endothelium,87 smooth muscle cells,88 and adipose 
tissue,89 as well being present in the placenta.90 The existence of a local RAS is interesting as it 
suggests that the local RAS may exert its effects independent of the circulation
























Figure 1.1:  
Schematic overview of the Renin-Angiotensin System cascade and the proposed routes to changes in 
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RAS in a tissue-specific manner.22 A complete functioning RAS was also found to be present in 
human glioblastomas and thus inhibition of this local RAS may be one way to treat and control 
glioblastoma progression.91  
 
1.2.2 Renin, Prorenin and the (Pro)renin Receptor 
Renin (EC 3.4.23.15), first cloned in 1984, is an aspartic protease which catalyses the 
first and rate-limiting step of the RAS cascade.92 Cleavage of angiotensinogen releases the 
decapeptide angiotensin-I through the action of renin’s two catalytic aspartate residues Asp 38 
and Asp 226 (Figure 1.2, numbering according to Imai et al. 1983).93, 94  
 
Figure 1.2:  
 
The crystal structure of the complex formed when 
human renin (blue) binds human angiotensinogen 
(green). Renin’s two catalytic aspartate residues 
(Asp 38 and Asp 226, in yellow) cleave the N-
terminal 10 amino acid peptide, angiotensin I (red), 
from angiotensinogen. The two cysteine residues, 
Cys 18 and Cys 138, responsible for 
angiotensinogen’s redox switch are shown in orange 
(PDB file 2X0B 1). 
 
 
Aspartic proteases are a structurally homologous family of enzymes of which the 
digestive enzymes pepsin, gastricsin, and chymosin, as well as some retroviral proteinases are 
members.95 Most non-retroviral aspartic proteases are synthesized as an inactive zymogen state 
characterised by a highly basic prosegment that blocks access to the active site, and renin is no 
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exception.96 Prorenin, or inactive renin, contains a 5 kDa propeptide (43 amino acids in length) 
on the N-terminus that tucks into the enzymatic cleft preventing renin from binding its 
substrate.35 Under physiological conditions, less than 2% of prorenin is the open active form and 











Figure 1.3:  
Schematic diagram showing how prorenin can be activated either proteolytically and irreversibly, giving 
rise to active renin, or non-proteolytically in a reversible manner with the unfolding of the propeptide 
revealing renin’s active site. 
 
Proteolytic activation involves the physical removal of the propeptide by the action of a 
protease. Trypsin is typically used in vitro, but the protease responsible for the in vivo activation 
of prorenin has not yet been identified.35 In contrast, non-proteolytic activation is a reversible 
process which involves the unfolding of the prosegment, followed by the enzyme assuming its 
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enzymatically active conformation. This equilibrium can be driven in favour of the open active 
conformation by exposure to low pH (optimally pH 3.3, termed acid activation, which leads to 
complete activation of prorenin), or alternatively low temperatures (typically 4 °C, commonly 
referred to as cryoactivation, which results in partial activation of prorenin of approximately 
15% of total activity).35   
(Pro)renin is expressed in the juxtaglomerular cells of the kidney, where it is secreted 
toward the renal interstitium.35, 98 Prorenin is expressed constitutively, but active renin is thought 
to be stored and then released in response to acute stimuli, without any change in prorenin 
levels.35 Despite being enzymatically inactive, prorenin circulates in the plasma at high 
concentrations (sometimes at levels which are 100 times greater than active renin),99 and it 
puzzled researchers for some time as to the physiological role that prorenin may play, 
particularly considering that high prorenin levels are associated with pregnancy and several 
medical conditions.85 A piece of this puzzle was solved when in 2002, Nguyen et al.100 cloned a 
350 amino acid receptor which binds to both renin and prorenin. Binding to this receptor does 
not result in the degradation or internalisation of the (pro)renin, as is the case when (pro)renin 
associates with the mannose-6-phosphate clearance receptors.97 Rather, the catalytic activity of 
renin is increased four-fold, and prorenin, while showing little activity in solution, gains full 
activity on association with the receptor which has become known as the (pro)renin receptor or 
(P)RR.1, 100 The idea that a receptor is able to non-proteolytically activate a zymogen is not a new 
one; urokinase undergoes similar activation, and exhibits enhanced catalytic activity when bound 
to its receptor.101 The (P)RR may provide a physiological role for circulating prorenin, 
particularly in tissues,102, 103 and is thought to be implicated in the pathogenesis of conditions 
such as diabetic retinopathy, where prorenin levels are very high.85 It is noteworthy, though, that 
the physiological role that the (P)RR may play in vivo is hotly debated by researchers. The 
(P)RR may bear little physiological relevance as the nanomolar affinity with which the receptor 
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binds (pro)renin could prove insufficient to bind the picomolar concentrations of (pro)renin in 
biological fluids found in vivo.104  
 
1.2.3 Angiotensinogen and Angiotensin Production 
 
Angiotensinogen is the only known physiological substrate for renin.105 Angiotensinogen 
is classified as a serpin (serine protease inhibitor) due to its similarity in terms of genetic 
structure106 and overall structural homology to other serpins such as α1-antitrypsin, and 
ovalbumin.107 Despite these characteristics, angiotensinogen shares a low sequence similarity to 
members of the superfamily,106 and has lost its inhibitory function.108 First cloned in 1984,109 
angiotensinogen is 452 amino acids in length107 and is synthesized in the liver110 and secreted 
constitutively to circulate in the plasma at concentrations which are close to the Km of the renin-
catalysed reaction.111, 112 Thus, being the substrate of the regulatory point in the RAS cascade, 
the concentration of angiotensinogen is the rate-determining factor and facilitates the fine-tuned 
regulation of the system, as small changes in angiotensinogen concentrations will affect the 
levels of angiotensin I being produced. Reaction of angiotensinogen with renin results in the 
cleavage of the N-terminal decapeptide to produce angiotensin I. This reaction is species-
specific—human renin will cleave canine, rat, and sheep angiotensinogens, but human 
angiotensinogen is not cleaved by renins other than human renin.113 The remainder of the 
angiotensinogen molecule after cleavage by renin is often called ‘spent angiotensinogen’ or ‘des-
angiotensin I renin substrate’ and is not known to have any physiological role.114 
Angiotensin Converting Enzyme (ACE), the second enzyme in the RAS cascade, is 
found in the lungs and other vascular beds and is responsible for converting angiotensin I to the 
vasoactive octapeptide angiotensin II.9 Angiotensin II exerts most of its biological effects, 
including vasoconstriction, and sodium and water retention, through binding the angiotensin 
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receptors, AT1R and AT2R. Angiotensin II may also exert effects independent of blood 
pressure.115 Angiotensin Converting Enzyme 2 (ACE2), a relatively newly described member of 
the RAS cascade, accepts both angiotensin I and angiotensin II as a substrate, and cleaves off a 
single amino acid residue to produce the vasoactive angiotensin (1 – 9) and angiotensin (1 – 7) 
respectively.44, 46, 116 Angiotensin (1 – 7) exerts vasodilatory action, providing counter-regulation 
of the vasoconstricting properties of angiotensin II, by binding to MAS receptors.116 
 




Cells are constantly being exposed to changes in environmental redox states and have 
evolved multiple ways to sense and cope with these changes.117, 118 Although implicated in 
various diseases in biological systems such as pre-eclampsia, oxidative species may play a more 
general role in the cell by regulating various functions and acting as signalling molecules.119 By 
reacting with biomolecules, oxidants serve as a marker of the redox environment, allowing the 
cell to sense alteration in the redox state.117, 118 Small changes to the fine balance between the 
rates of reactive oxygen species production and breakdown can result in oxidative stress.120 
Oxidative stress can lead to covalent modification of protein side-chains, allowing the cells to 
sense and respond to the changing environment. Cysteine residues in proteins are particularly 
poised to be sensitive to these oxidative changes and can act as redox sensors. The pKa of the 
cysteine sulfydryl group is 8.3, and thus under unstressed physiological conditions normally 
exists as the reduced free thiol protonated form (—SH) in the cytoplasm.117 However, changes in 
the redox environment can lead to the reversible oxidation of cysteine residues to several states 
including disulfide bond formation (—S—S—) with another nearby cysteine residue. Not all 
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cysteine residues can act as redox sensors, as the surrounding micro-environment in the protein 
can alter the pKa of the residue such that the thiolate ion (—S
‒) is either stabilised or destabilised, 
or alternatively the oxidant may not have access to the cysteine residue if it is buried inside the 
protein.118, 120 The dynamic process of disulfide bond breakage and formation in key cellular 
proteins, as a result of exposure to oxidative changes, is known as redox signalling.117 
 Cysteine residues can play crucial roles in contributing to the structure and stability of 
proteins.121 As such, disulfide bond formation due to the surrounding redox environment can 
trigger switches in protein structure and activity, changes that can be even more profound than 
those induced by phosphorylation.122, 123 Several redox switch proteins have been identified to 
date, proteins which have evolved to carry out vital roles depending on the surrounding redox 
state, and these protein cysteine-mediated redox switches have several themes in common 
including a structural transition-mediated functional switch, as well as conformation strain-
driven switch mechanism, and a transition time between redox states in the millisecond range.123 
Examples of such redox switches include the OxyR protein,124 the Drosophila ‘inactivation, no 
after-potential D’ (INAD) visual scaffold protein,125 and angiotensinogen,1 which as we have 




Angiotensinogen contains four cysteine residues, but only Cys 18 and Cys 138 (Figure 
1.4), which form a disulfide bridge, are conserved across all species.105, 126 The reduction 
potential for the free thiol/disulfide bond equilibrium between these residues was shown to be 
‒230 V at pH 7 and 25 °C,1 and it is this disulfide bond which is thought to be crucial for 
constraining the N-terminus in order for the angiotensinogen molecule to adopt a favourable 
conformation for reaction with renin.126 Transferring the N-terminal portion of angiotensinogen 
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to the protein framework of α1-antitrypsin significantly altered the kinetics of the reaction with 
renin, thus the angiotensinogen body contributes to the reaction rather than being purely a 





Figure 1.4:  
Crystal structure of human angiotensinogen with 
the N-terminal angiotensin I peptide (cleaved by 
renin) shown in red. Cys 18 and Cys 138 residues, 
present as a disulfide in the oxidised form or as 
free thiols in the reduced form are shown in 
orange (PDB file 2X0B). 
 
 
Angiotensinogen is secreted in the oxidised bridged form from the endoplasmic reticulum 
and then is subsequently reduced in the plasma, resulting in a consistent ratio of 60:40 of 
oxidised to reduced forms in the circulation regardless of gender or age.1 On incubation with 
renin and the (P)RR, the reaction of renin with the reduced form of angiotensinogen was not 
significantly altered by the presence of the (P)RR, but the oxidised form displayed a four-fold 
increase in the catalytic release of angiotensin I when reacting with renin in the presence of the 
(P)RR1  This is significant, as with the stable ratio in the plasma pool of the two forms, the redox 
switch between the two forms would be particularly poised to take place in the tissues and 
vascular beds, providing a redox-sensitive regulation of angiotensin I release in a tissue-specific 
manner. Interestingly, the stable ratio between the two redox forms of angiotensinogen was 
shown to be altered in women with pre-eclampsia—pre-eclamptic women display a much higher 
proportion of the oxidised form compared with the reduced form in their plasma. This apparent 
switch to an oxidised-dominated plasma pool of angiotensinogen is predicted to be even more 
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pronounced in the tissues and, given the higher catalytic efficiency of renin for the oxidised form 
of angiotensinogen,1 may provide clues as to how the hypertension associated with pre-
eclampsia develops. It is thus conceivable, and attractive to postulate that this difference between 
the two redox states could be used as a biomarker for early detection of pre-eclampsia.   
 
1.4  RECENT ADVANCES IN PRE-ECLAMPSIA DIAGNOSIS AND THE SEARCH FOR POTENTIAL 
BIOMARKERS 
 
Early diagnosis of pre-eclampsia is critical, allowing better monitoring and management 
plans to be put in place before the onset of symptoms, and can lead to better outcomes for both 
mother and child. Despite much research having been done to identify potential biomarkers 
which could be used as an early diagnosis for pre-eclampsia, we still have no accurate predictive 
biomarkers or validated screening tests to identify women who are prone to developing this 
condition, and to date, the only predictive information available to doctors when predicting risk 
is maternal history and risk factors.5, 127-129 Table 1.2 shows some of the biomarkers which have 
been investigated thus far with limited success. It has been suggested that a combinatorial 
approach, combining environmental and maternal risk factors with biomarkers, could be used for 
better success at a screening approach for pre-eclampsia, given that so far no single biochemical 
marker has been identified that is capable of detecting this condition early.5, 45 
One difficulty in the search for predictive biomarkers is the ability for these markers to 
arise in time for intervention to be put in place. Some of these markers only appear at the onset 
of symptoms or shortly beforehand, and thus are not of great value as an early diagnostic tool.129  
The recent discovery of pre-eclamptic women having higher levels of oxidised angiotensinogen 
provides further hope that a biomarker, or combination of biomarkers, that will be useful as a 
diagnostic tool could soon be at hand. As with the reduced selenium levels observed in pre-
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eclamptic women,47 the increased levels of oxidised angiotensinogen was observed in women 
who already had clinical manifestation of symptoms.1 Further longitudinal studies, following 
women the full length of their pregnancy term, will need to be carried out to determine at what 
stage these markers develop as to whether they are causative or of value in a diagnostic setting, 
allowing for an improved management plan to be put in place. 
 
MARKER OR DIAGNOSTIC TOOL REFERENCE 
ADAM-12s 130130 
Adiponectin 131131 
Angiotensinogen levels 129129 
Cell-free fetal nucleic acid in maternal circulation 132132 
Doppler ultrasonography 128128 
Homocysteine 131131 







Placental Growth Factor (PIGF) 128, 135128, 135 
Platelets Flow Cytometry 136136 
Placental Protein-13 (PP-13) 137137 
Pregnancy-Associated Plasma Protein A (PAPP-A) 138138 
Soluble fms-like Tyrosine Kinase 1 (sflt-1) 128, 139128, 139 
Soluble ST2 (sST2) 135135 
Vascular Endothelial Growth Factor (VEGF) 140140 
Table 1.2:  
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1.5 SCOPE OF THIS THESIS 
 
 Pre-eclampsia is a severe pregnancy condition that often develops suddenly with huge 
detrimental ramifications for the health of both mother and child. With no effective treatment or 
cure to date (Section 1.1.5), it is crucial that this condition is identified early on in the pregnancy 
before any life-threatening symptoms develop in order that better monitoring and management 
plans can be put in place. Such a feat would ultimately lead to better outcomes for both the 
mother and child, especially considering pre-eclampsia is one of the leading causes of maternal 
and perinatal morbidity and mortality worldwide. Unfortunately, despite much research interest 
in this field (Section 1.4) and many potential biomarkers being identified, there has been limited 
success to date in identifying a biomarker that is able to predictably and easily identify women 
who are likely to develop pre-eclampsia much in advance of the onset of symptoms.  
As mentioned in Sections 1.3.2 and 1.4 above, the recent discovery by Zhou and 
colleagues in 20101 that, compared to normal healthy persons and healthy pregnant women, pre-
eclamptic women display far greater levels of oxidised angiotensinogen and significantly 
decreased levels of the reduced form, provides renewed hope that there may be a predictive 
biomarker for pre-eclampsia on the horizon. The attractiveness of angiotensinogen’s redox 
switch as a predictive biomarker will only hold if a sensitive, high throughput diagnostic test can 
be developed which will allow distinction between the two forms of this plasma protein. This in 
itself would be an accomplishment given the intrinsic similarity of the two forms that differ only 
in the absence or presence of a disulfide bond between Cys 18 and Cys 138.1 Thus, the big 
question remains as to whether a sensitive bioassay can be developed to distinguish between the 
two redox forms of angiotensinogen. 
One technique which may be a way forward to developing such a bioassay to distinguish 
between reduced and oxidised angiotensinogen is surface plasmon resonance. Surface plasmon 
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resonance (SPR) is an optical label-free technique commonly used to quantify the interactions 
between biomolecules such as proteins, whereby the interactions between a ligand immobilised 
on a gold-plated chip and a second free-flowing biomolecule (analyte) are measured as a change 
in the refractive index on the chip surface.141 In itself, or complemented with other techniques, 
SPR is a powerful technique as it allows the characterisation of multiple interactions 
simultaneously, as well as the calculation of many kinetic and binding parameters, thus it is not 
surprising that this is one of the preferred methods to report the kinetics of protein-protein 
interactions in the literature.141, 142 
Utilising this technique, it may be possible to develop a bioassay for angiotensinogen by 
immobilising angiotensinogen-specific ligands, such as antibodies raised against human 
angiotensinogen or renin itself, onto a chip surface and measuring the interactions that occur 
following injection of angiotensinogen across the surface. One or more functional assays for 
angiotensinogen, if developed, would then open the door to address the ultimate goal: to probe 
whether the two redox forms of angiotensinogen, reduced and oxidised, can indeed be 
distinguished experimentally in such a way to facilitate a functional bioassay which could then 
prove to be a way to identify women prone to developing pre-eclampsia, a challenge which is 
continuing to stumble clinicians and researchers alike.  
This thesis presents an investigation into angiotensinogen ranging from the recombinant 
expression and purification of human angiotensinogen described in Chapter Three, the 
development of methods to detect angiotensinogen using surface plasmon resonance (Chapter 
Four), to the probing of angiotensinogen’s redox switch and the differences between the two 
redox forms which is described in Chapter Five. Details of methods used throughout the research 
outlined in this thesis can be found in Chapter Two, while a discussion of the results and 
concluding remarks can be found in Chapter Six and Chapter Seven, respectively. 







2.1.1 Chemicals and Reagents 
  
 All buffers, reactions, or solutions requiring water throughout the work detailed in this 
thesis utilised Milli-Q water (MQ water; pyrogen-free, DNase-free, RNase-free ultrapure type 1 
Milli-Q water) dispensed from a Milli-Q Reference fitted with a BioPak Polisher (Merck 
Millipore, Billerica, Massachusetts, USA). General chemicals used to make buffers and 
solutions, unless mentioned specifically below, were purchased from a variety of suppliers 
including Amersham Biosciences, Bioline, Life Technologies, Merck, Sigma-Aldrich, and 
Thermo Fisher Scientific. 
 Luria-Bertani (LB) media was prepared using LB Broth Base (Lennox L Broth Base; 
Invitrogen, Carlsbad, California, USA) as per directions and autoclaved before use. LB for LB 
agar plates was prepared with 1% w/v agar added prior to autoclaving. Stock solutions of 20% 
(w/v) glucose (BDH Chemicals, VWR International, Readnor, Pennsylvania, USA) were 
prepared with MQ water and filter sterilised prior to use. Stock solutions of 1 M isopropyl-β-D-
thiogalactopyranoside (IPTG; A & A Biotechnology, Gdynia, Poland) were prepared with MQ 
water and filter sterilised prior to aliquots being frozen and stored at –20 °C. 
 Antibiotics used for all bacterial work were prepared according to the following: 
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- Ampicillin (Amp) was made at 100 mg/mL (ampicillin sodium salt; AppliChem, 
Darmstadt, Germany) with MQ water and filter sterilised. Aliquots were stored at ‒20 °C, 
and Amp was used in media at a concentration of 100 μg/mL. 
- Chloramphenicol (Cam; Roche, Indianapolis, Indiana, USA) was made at 30 mg/mL in 
100% ethanol. Aliquots were stored at ‒20 °C and Cam was used in media at 30 μg/mL. 
- Kanamycin (Kan) stock solutions were prepared at 50 mg/mL (kanamycin sulphate, 
Roche, Indianapolis, Indiana, USA) with MQ water and filter sterilised. Aliquots were 
stored at ‒20 °C, and Kan was used in media at a concentration of 50 μg/mL for 
kanamycin-resistant plasmids or at 15 μg/mL for the kanamycin-resistant origami (DE3) 
cells.     
- Tetracycline (Tet) was made at 12.5 mg/mL (tetracycline HCl, NBL Gene Sciences 
Limited, Northumberland, UK) in 100% methanol. Aliquots were stored at ‒20 °C, and 
Tet was used in media at a concentration of 12.5 μg/mL. 
- Streptomycin (Str) was prepared at a concentration of 50 mg/mL (streptomycin sulphate, 
Sigma-Aldrich, St. Louis, Missouri, USA) with MQ water and filter sterilised. Aliquots 
were stored at ‒20 °C and Str was used at a concentration of 50 μg/mL in media 
 
2.1.2 Vectors, DNA Constructs, and Primers  
 
 The pET_16b_AGT plasmid (ampicillin resistant), which contains the gene for His-
tagged human angiotensinogen, was a kind gift from Yahui Yan and Robin Carrell at the 
University of Cambridge. The pETDuet_DsbC_BlgA plasmid (ampicillin resistant), a construct 
used in our laboratory, contains the gene for disulfide bond isomerase (DsbC) protein which aids 
in correct disulfide bond formation. The cloning vector, pCRTM 2.1-TOPO®, was supplied as part 
of the TOPO® TA Cloning® Kit (InvitrogenTM by Life TechnologiesTM, Carlsbad, California, 
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USA). Meanwhile, the pET-SUMO expression vector was supplied as part of the ChampionTM 
pET SUMO Protein Expression System Kit (InvitrogenTM by Life TechnologiesTM, Carlsbad, 
California, USA). All primers were ordered from Integrated DNA Technologies (IDT, 
Singapore). 
 
2.1.3 Bacterial Strains 
  
The following chemically competent Escherichia coli (E. coli) bacterial cells were used for all 
cloning and protein expression work: 
 




RESISTANCE (IF ANY) 
Cloning Strains:   
 DH5α F¯φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 
(rk-, mk+) phoA supE44 λ¯ thi¯1 gyrA96 relA1 
n/a 
Expression Strains:   
 BL21 (DE3) F¯ ompT hsdSB (rB¯mB¯) gal dcm (DE3) n/a 
 BL21 (DE3) star F¯ompT hsdSB (rB¯ mB¯) gal dcm rne131 (DE3) n/a 
 Rosetta (DE3) F¯ ompT hsdSB (rB¯mB¯) gal dcm (DE3) pRARE (Cam
R) Chloramphenicol 
 Origami (DE3) ∆(ara–leu)7697 ∆lacX74 ∆phoA PvuII phoR araD139 ahpC 
galE galK rpsL F'[lac+ lacIq pro] (DE3) gor522::Tn10 trxB 






 The restriction enzymes NdeI and KpnI-HF, as well as the cutsmart buffer, were 
purchased from New England Biolabs Inc. (NEB, Ipswich, Massachusetts, USA). Bovine Serum 
Albumin (BSA; Albumin Fraction V pH 7.0), used as a protein standard, was purchased from 
AppliChem (Darmstadt, Germany). Lysozyme from chicken egg white, and Trypsin from bovine 
pancreas were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). 
C h a p t e r   T w o       P a g e   |   2 6    
 Recombinant His-tagged reduced and oxidised angiotensinogen (expressed in E. coli, 
derivatised by reaction with N-ethylmaleimide (NEM) in the presence or absence of reducing 
agent) was a gift from Tim Yandle and Darrell Wang at Endolab (Canterbury Health 
Laboratories, Christchurch, New Zealand). Recombinant His-tagged human angiotensinogen, 
and recombinant human glycosylated renin with a C-terminal His-tag (expressed in HEK 293 
cells, activated with trypsin) was a kind gift from Yahui Yan and Robin Carrell at the University 
of Cambridge. Finally, recombinant human glycosylated prorenin with a C-terminal His-tag 




 Mouse Anti-Human IgG Fc-specific monoclonal IgG Antibody (Clone 7QD) was 
obtained from General Bioscience Corporation (Brisbane, California, USA). Antibodies raised 
against angiotensinogen were purchased from R & D Systems (Clone #369439; Minneapolis, 
Minnesota, USA) and from Santa Cruz Biotechnology (sc-7419; Dallas, Texas, USA).  
 
2.1.6 Other Equipment 
 
 All Eppendorf tubes and pipette tips used throughout all experiments were sterilised by 
autoclaving at 121 °C for 20 minutes and were allowed to cool prior to use. Large cultures were 
centrifuged in the SorvallTM RC 6 Plus Centrifuge (Thermo Scientific, Waltham, Massachusetts, 
USA) using the fixed angle F10S-6x500y rotor, while samples of 50 mL or less were centrifuged 
using the Eppendorf Centrifuge 5810R (Eppendorf, Hamburg, Germany) with the fixed angle 
rotors F34-6-38 and F45-30-11.  
 A Minitron incubator shaker (Infors HT, Bottmingen, Switzerland) was used for the 
incubation of all bacterial cell cultures. DNA and some protein concentrations were measured 
using a Nanodrop Spectrophotometer ND-1000 (Thermo Scientific, Wilmington, Delaware, 
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USA). Buffers were filtered either through a Whatman™ Klari-Flex™ 250 mL 0.22 μm PES Filter 
Funnel (Fisher Scientific, Loughborough, UK) or through a 33 mm Millex-GV 0.22 μm PVDF 
syringe filter (Merck Millipore, Billerica, Massachusetts, USA). Finally, all pH measurements 
were performed using the UltraBasic pH/mV meter (Denver Instrument, Bohemia, New York, 
USA). 
 




 Chemically competent E. coli cells were transformed according to the following 
protocol. See appropriate sections below for details of which strains were transformed with 
which plasmid.  
 One vial containing 50 μL of competent cells was thawed on ice. The thawed cells were 
then transferred to a pre-chilled tube containing 1 μL (~100 ng) of plasmid DNA, and flicked to 
mix. Subsequently, the cells were incubated on ice for ten minutes, and then heat shocked for 60 
seconds at 42 °C, before being immediately returned to ice, where they were left to recover for a 
further five minutes. If the DNA construct being transformed contained a kanamycin resistance 
gene, 250 μL of SOC media was added to the cells and then the tube was incubated, shaking at 
180 rpm, in a Minitron incubator for 1 hour at 37 °C. Cells were then plated using aseptic 
techniques on pre-warmed LB agar plates containing the appropriate antibiotics, with either the 
entire 50 μL of transformed cells or 100 μL of transformed cells in SOC media (for kanamycin 
resistant plasmids only) being spread on the plate with a disposable sterile plastic spreader. Cells 
which had not been transformed were plated on an LB agar plate containing the same antibiotics 
as a negative control. Once plates were dry, they were sealed with parafilm and incubated upside 
down overnight at 37 °C in a controlled temperature room. 
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2.2.2 Plasmid Purification 
 
 Using aseptic techniques, an autoclaved pipette tip was used to pick a single colony of 
DH5α cells from the transformation plate (Section 2.2.1), and the colony was then transferred to 
10 mL of sterile LB media containing the antibiotic appropriate to the transformed plasmid. Cells 
were cultured overnight at 37 °C, shaking at 180 rpm in a Minitron incubator. Following 
overnight culturing, 5 mL of culture was harvested by centrifuging at 4 °C, 10,000 rpm for five 
minutes, and the media (supernatant) was discarded leaving the harvested cells in the pellet. The 
plasmid was extracted from the cells and purified using the Purelink® Quick Plasmid Miniprep 
Kit (InvitrogenTM by Life TechnologiesTM, Carlsbad, California, USA) according to the kit’s 
purification procedure by centrifugation. Plasmid DNA was eluted with 50 μL Tris-EDTA (TE) 
buffer (supplied with kit) and the concentration of plasmid was checked by Nanodrop at 230 nm. 
All purified plasmid DNA was stored at ‒20 °C. 
 
2.2.3 DNA Gel Electrophoresis 
 
 Agarose gels were prepared by adding 0.5 g of agarose to 50 mL of Tris acetate EDTA 
(TAE) buffer (1% w/v agarose), and microwaving the solution for approximately two minutes 
until the agarose was completely dissolved. SYBR® Safe DNA Gel Stain (InvitrogenTM, 
Carlsbad, California, USA), 3 μL, was added to the dissolved agarose solution and swirled to 
mix, to allow visualisation of DNA in the gel following electrophoresis. The 1% agarose TAE 
solution was then poured into a gel cast box, and the comb to form wells was inserted. The gel 
was left to set at room temperature. 
 Once set, the agarose gel was removed from the gel casting box and placed in a Minnie 
Gel Unit (Hoefer Inc., San Francisco, California, USA) and sufficient TAE buffer (1X, see 
recipe in Appendix) was added so that the gel was just covered.  DNA loading dye (6X, see 
recipe in Appendix) was added at 1/6 of the sample volume (samples which contained GoTaq® 
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Green Master Mix (Promega Corporation, Madison, Wisconsin, USA) required no loading dye) 
and, once mixed, were loaded into each well. HyperLadderTM 1 kb (Bioline USA Inc., Taunton, 
Massachusetts, USA), 3 μL, was loaded into one of the wells as a molecular weight marker. 
DNA gels were run for 30 minutes at 160 volts (BioRad PowerPac Basic, BioRad Laboratories, 
Hercules, California, USA).  
 Once electrophoresis was complete, DNA was visualised by taking an image of the gel 
using the SynGene Chemi Genius 2 Bio Imaging System and GeneSnap (SynGene, Cambridge, 
UK) using the transilluminator darkroom lighting and the EtBr/UV filter. 
 
2.2.4 Polymerase Chain Reaction (PCR) 
 
 PCR amplification of the human angiotensinogen gene was carried out using Platinum® 
Taq DNA Polymerase High Fidelity (InvitrogenTM by Life TechnologiesTM, Carlsbad, California, 
USA). High Fidelity PCR Buffer (10X) and 50 mM magnesium sulfate was supplied with 
Platinum® Taq DNA Polymerase, while the 50 mM dNTP mix was supplied with ChampionTM 
pET SUMO Protein Expression System Kit (InvitrogenTM by Life TechnologiesTM, Carlsbad, 
California, USA). PCR reactions were set up in PCR tubes according to the following: 
    
PCR COMPONENTS VOLUME FINAL CONCENTRATION 
DNA Template (pET_16b_AGT, 100 ng/μL) 1 μL 2 ng/μL 
10X PCR Buffer 5 μL 1X 
50 mM MgSO4 2 μL 2 mM 
50 mM dNTPs 1 μL 1 mM (0.25 mM each) 
Forward Primer (10 μM) 1 μL 0.2 μM 
Reverse Primer (10 μM) 1 μL 0.2 μM 
Platinum® Taq Polymerase High Fidelity 0.2 μL 1 unit 
Autoclaved MQ water 38.8 μL  
Total Volume 50 μL  
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 The PCR reaction was then run according to the following cycling parameters using a 
MultiGeneTM PCR Thermal Cycler (LabNet International Inc., Edison, New Jersey, USA): 
 
STEP TIME TEMPERATURE CYCLES 
Initial Denaturation 2 min 94 °C 1X 
Denaturation 1 min 94 °C 
25X Annealing 1 min 53 °C 
Extension 1.5 min 72 °C 
Final Extension 7 min 72 °C 1 X 
 
 A final extension time of at least 7 minutes at 72 °C was required to ensure all PCR 
products were full length and 3' adenylated (required for TA cloning). Following the final cycle 
of PCR amplification, the reaction was maintained at 4 °C. PCR amplification products were 
analysed by DNA electrophoresis by loading 5 μL of each PCR reaction with DNA loading dye 
(6X, see recipe in Appendix) into each well of a 1% w/v agarose gel (Section 2.2.3).   
 
2.2.5 Colony PCR 
 
 Colony PCR was carried out on E. coli DH5α colonies produced as a result of ligation 
and transformation to check for the presence and correct size of DNA insert (i.e. human 
angiotensinogen gene) within the DNA plasmid of interest. Using aseptic techniques, each 
colony was picked from an LB agar plate with an autoclaved toothpick and resuspended in 20 μL 
of sterile MQ water. If many colonies were present on the plate, ten colonies were randomly 
picked and screened for the correct DNA insert. PCR amplification was carried out using 
GoTaq® Green Master Mix (Promega Corporation, Madison, Wisconsin, USA). PCR reactions 
were set up in PCR tubes according to the following: 
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PCR COMPONENTS VOLUME
GoTaq® Green Master Mix 7.5 μL 
Forward Primer (10 μM) 0.5 μL 
Reverse Primer (10 μM) 0.5 μL 
Resuspended DH5α colony  2 μL 
Autoclaved MQ water 4.5 μL 
Total Volume 15 μL 
  
 The PCR reaction was then run according to the following cycling parameters using a 
MultiGeneTM PCR Thermal Cycler (LabNet International Inc., Edison, New Jersey, USA): 
 
STEP TIME TEMPERATURE CYCLES 
Initial Denaturation 3 min 95 °C 1X 
Denaturation 45 sec 95 °C 
30X Annealing 15 sec 53 °C 
Extension 105 sec 72 °C 
Final Extension 5 min 72 °C 1 X 
 
 Following the final cycle of PCR amplification, the reaction was maintained at 4 °C. 
PCR amplification products were analysed by DNA electrophoresis by directly loading the entire 
15 μL of each colony PCR reaction into each well of a 1% w/v agarose gel (Section 2.2.3).  
 The remaining 18 μL of each resuspended colony was stored at 4 °C. Each colony 
containing a plasmid with the correctly sized DNA insert was directly added to 10 mL of sterile 
LB media containing the appropriate antibiotic. Cells were cultured overnight at 37 °C, shaking 
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2.2.6 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
 SDS-PAGE gels were run to analyse protein samples, or cell samples for protein 
expression. Samples were prepared by adding a volume of sample reducing dye (see recipe in 
Appendix) equivalent to half the sample volume, and mixing well before being heated for 5 
minutes at 95 °C using the Accublock Digital Dry Bath (LabNet International Inc., Edison, New 
Jersey, USA). Samples were then briefly centrifuged for 30 seconds at 12,000 rpm. If SDS-
PAGE analysis was not immediately being carried out, samples were stored at ‒20 °C.    
 All SDS-PAGE analysis was performed using Bolt® Pre-cast 4-12% Bis-Tris Plus 10 
well or 15 well gels (Novex® by Life TechnologiesTM, Carlsbad, California, USA). Gels, with 
white strip and comb removed, were placed in a BoltTM Mini Gel Tank (Life TechnologiesTM, 
Carlsbad, California, USA), and then the anode and cathode chambers were filled with 1X Bolt® 
MES SDS Running Buffer (supplied as 20X, Life TechnologiesTM, Carlsbad, California, USA), 
ensuring that the wells of the gel were filled with buffer. Samples were loaded into each well; 
Novex® Sharp Pre-stained Protein Standard (Novex® by Life TechnologiesTM, Carlsbad, 
California, USA) was used as a molecular weight (MW) marker by loading 5 μL into one of the 
wells of the gel. SDS-PAGE gels were run for 35 minutes at 165 volts (BioRad PowerPac Basic, 
BioRad Laboratories, Hercules, California, USA).  
 Once electrophoresis was complete, gels were removed from the plastic gel cassettes 
and rinsed with water to remove excess salts and SDS before being stained with Coomassie Blue 
stain (see recipe in Appendix) on a shaker for 15 minutes. The stain was discarded and the gel 
was rinsed with water to remove excess stain before being placed in destain solution (see recipe 
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2.2.7 OPA Fluorescence Assay 
 
 The o-phthalaldehyde (OPA) fluorescent assay was one of the methods that were 
employed to quantify protein concentrations. In the presence of mercaptoethanol, o-
phthalaldehyde reacts with primary amines to produce a blue fluorescent product which has 
maximum excitation at 340 nm and maximum emission at 455 nm.143, 144    
 The OPA reagent was prepared as outlined in the Appendix. A stock solution of 1 
mg/mL bovine serum albumin (BSA) was made by dissolving 10 mg of BSA in approximately 
700 μL of PBS pH 7.4, then making the volume up to 1 mL with PBS, and mixing well. 
Solutions of 0.5 mg/mL BSA in PBS, 0.5 mg/mL BSA in PBS with 1.1 mM NEM, and 0.5 
mg/mL BSA in PBS with 0.33 mM DTT and 1.1 mM NEM were then prepared (as outlined 
below) to approximate the concentrations of NEM and DTT (taking into account dilution 
factors), which were present in the protein samples supplied, to ascertain whether these 
molecules, separately or combined, affect the assay and alter the generation of standard curves in 
any way. 
 0.5 mg/mL BSA 
 
0.5 mg/mL BSA 
+ NEM 
0.5 mg/mL BSA 
+ DTT & NEM 
1 mg/mL BSA in PBS 100 μL 100 μL 100 μL 
5 mM NEM in PBS - 43.75 μL - 
1.5 mM DTT, 5 mM NEM in PBS - - 43.75 μL 
PBS pH 7.4 100 μL 56.25 μL 56.25 μL 
Total Volume 200 μL 200 μL 200 μL 
 
 A dilution series for each of the three sets of the BSA standards was prepared, such that 
a range of concentrations from 0 μg/mL to 500 μg/mL was obtained. 10 μL of each standard/ 
sample (samples diluted if necessary) was pipetted in duplicate into the wells of a 96 well 
μClear® flat-bottomed, black chimney well microplate (Greiner Bio-One, Frickenhausen, 
Germany). Subsequently, 200 μL of fresh OPA reagent was added to each well, and the reagent 
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and samples were mixed well using a multi-channel pipette, taking care that no bubbles were 
present in the wells. The plate was allowed to incubate at room temperature for 15 minutes to 
allow adequate formation of the fluorescent product before the fluorescence in each well was 
measured with the SpectraMax® M5 Multimode Microplate Reader (Molecular Devices, 
Sunnyvale, California, USA) using SoftMax Pro 5.4.1 software with the excitation wavelength 
set to 340 nm and the emission wavelength at 455 nm. Standard curves were generated using 
Microsoft Excel and the equations of the standard curves were used to extrapolate the 
concentration of protein samples, taking into account any dilution factors if necessary. 
 
2.3 CLONING OF THE HUMAN ANGIOTENSINOGEN GENE INTO PETDUET_DSBC VECTOR 
 
 The pETDuet_DsbC_BlgA contains two multiple cloning sites (MCS). DsbC, a 
disulfide bond isomerise protein is cloned into MCS1 between NcoI and HindIII, while β-
lactoglobulin A (BlgA) had already been cloned into MCS2, which was subsequently replaced 
with the human angiotensinogen (hAGT) gene, between the NdeI and KpnI restriction sites. 
Fortunately, pET_16b_AGT already contained an NdeI restriction site at the 5' terminus of the 
hAGT sequence but a KpnI restriction site required at the 3' end of the gene was engineered 
through primer design and PCR. 
  
2.3.1 PCR of hAGT Gene from pET_16b_AGT 
 
 The hAGT gene was PCR amplified with the addition of a 3' KpnI restriction site 
(underlined in primer sequence) as outlined in Section 2.2.4. PCR products were assessed by 
DNA gel electrophoresis (Section 2.2.3) with 5 μL of the completed PCR reaction. The primers 
used for amplification were as follows: 
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Forward Primer: T7 Promoter   5'-TAA TAC GAC TCA CTA TAG GG-3' 
Reverse Primer:  pETDuet_hAGT_KpnI 5'-CGA GGT ACC TTG TTA GCA GCC GGA TCA T-3' 
  
2.3.2 Cloning of hAGT Gene into TOPO Vector   
 
 The following reaction was set up to ligate the hAGT gene into the pCRTM 2.1-TOPO® 
vector (both vector and salt solution were supplied with the TOPO® TA Cloning® Kit 
(InvitrogenTM by Life TechnologiesTM, Carlsbad, CA, USA)): 
 LIGATION COMPONENTS VOLUME
Fresh PCR Product 4 μL 
Salt Solution 1 μL 
pCRTM 2.1-TOPO Vector 1 μL 
Total Volume 6 μL 
 
 The reaction was mixed with a pipette, and left to incubate for five minutes at room 
temperature. Following incubation, 2 μL of the ligation reaction was used to transform DH5α 
cells as described in Section 2.2.1. Transformed cells were plated on a LB + Kan agar plate. Note 
that the TOPO vector confers resistance to both ampicillin and kanamycin, but kanamycin was 
chosen for selection as any residual pET_16b_AGT plasmid (ampicillin resistant) from the PCR 
reaction would result in a false positive on LB + Amp agar plates. 
 
2.3.3 Colony PCR to Check for Presence of hAGT Gene in TOPO Vector 
 
 Ten DH5α colonies were randomly picked and subjected to colony PCR as described in 
Section 2.2.5 using the M13 forward and M13 reverse sequencing primers (supplied with the 
TOPO® TA Cloning® Kit). Colonies that contained a discrete band corresponding to the 
expected insert size of 1733 bp were grown overnight in LB + Kan media and the plasmid was 
purified as per Section 2.2.2. 
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Forward Primer: M13 Forward  5'-GTA AAA CGA CGG CCA G-3' 
Reverse Primer: M13 Reverse  5'-CAG GAA ACA GCT ATG AC-3' 
 
2.3.4 Restriction Digest of TOPO_hAGT and pETDuet_DsbC_BlgA 
 
 A double restriction digest of the TOPO_hAGT plasmid (to isolate the hAGT gene) and 
pETDuet_DsbC_BlgA (to remove the BlgA gene from the plasmid) using the restriction 
enzymes NdeI and KpnI-HF was set up, and left to incubate 2 hours at 37 °C, according to the 
following: 
 
TOPO_hAGT RESTRICTION DIGEST VOLUME
TOPO_hAGT (200 ng/μL) 10 μL 
NdeI 1 μL 
KpnI-HF 1 μL 
Cutsmart Buffer (10X) 5 μL  
Autoclaved MQ water 33 μL 
Total Volume 50 μl 
 
 
PETDUET_DSBC_BLGA RESTRICTION DIGEST VOLUME 
pETDuet_DsbC_BlgA (45 ng/μL) 43 μL 
NdeI 1 μL 
KpnI-HF 1 μL 
Cutsmart Buffer (10X) 6 μL  
Autoclaved MQ water 9 μL 
Total Volume 60 μL 
  
 
2.3.5 Gel Purification of Restricted pETDuet_DsbC Vector and hAGT Gene 
 
 Following restriction digest, the entire restriction digest of both plasmids was loaded 
into separate wells of an agarose gel and underwent DNA gel electrophoresis according to 
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Section 2.2.3. Because of the large volume of the digest reactions (50 μL and 60 μL), each digest 
reaction was split between two wells. Undigested pETDuet_DsbC_BlgA and TOPO_hAGT were 
run on the same gel as controls. Gel bands corresponding to the restricted hAGT gene (1380 bp) 
and restricted pETDuet_DsbC vector (6130 bp) were excised from the gel using a scalpel blade 
and a Dark Reader® Transilluminator (Clare Chemical Research, Dolores, Colorado, USA) to 
visualise the bands, and the restricted DNA was purified from the gel pieces with the Agarose 
Gel DNA Extraction Kit (Roche, Indianapolis, Indiana, USA). Recovery of DNA was checked 
using the Nanodrop spectrophotometer. 
 
2.3.6 Ligation of hAGT Gene into pETDuet_DsbC Vector and Transformation 
 
 Ligation was carried out using T4 DNA Ligase, supplied in Enzyme Solution I (DNA 
Ligation Kit Version 2.1, TaKaRa Bio Inc., Otsu, Shiga, Japan). The following reaction was set 
up to ligate the hAGT gene into the pETDuet_DsbC vector: 
 LIGATION COMPONENTS VOLUME
pETDuet_DsbC Vector (restricted) 0.25 μL 
hAGT Gene Insert (restricted) 2.25 μL 
Enzyme Solution I 2.5 μL 
Total Volume 5 μL 
 
 The reaction was mixed with a pipette, and left to incubate for 15 minutes at room 
temperature. Following incubation, the entire 5 μL of the ligation reaction was used to transform 
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2.3.7 Colony PCR to Check for Presence of hAGT Gene in pETDuet_DsbC 
 
 All DH5α colonies resulting from ligation and transformation were picked and 
subjected to colony PCR as described in Section 2.2.5 using the plasmid-specific Duet UP2 and 
T7 Terminator primers. Colonies that contained a discrete band corresponding to the expected 
insert size of 1620 bp were grown overnight in LB + Amp media and the plasmids were purified 
as per Section 2.2.2. 
Forward Primer: Duet UP2   5'-TTG TAC ACG GCC GCA TAA TC-3' 
Reverse Primer: T7 Terminator  5'-TAG TTA TTG CTC AGC GGT GG-3' 
 
2.3.8 Sequencing of pETDuet_DsbC_hAGT plasmid 
 
 Sequencing was carried out at the Canterbury Sequencing and Genotyping Facility 
(School of Biological Sciences, University of Canterbury, Christchurch, New Zealand) to check 
that the hAGT gene was in the correct frame of the pETDuet plasmid for expression and that no 
mutations had been introduced through the cloning procedures. The plasmid specific Duet UP2 
and T7 Terminator, forward and reverse primers respectively (see Section 2.3.7), were used for 
sequencing the pETDuet_DsbC_hAGT plasmid. 
 
2.4 CLONING OF THE HUMAN ANGIOTENSINOGEN GENE INTO PET-SUMO VECTOR 
 
 The pET-SUMO vector uses the TA cloning approach to provide quick, one-step 
cloning of the PCR product directly into the expression vector immediately after the sequence 
coding for a N-terminal 6X His tag and SUMO (Small Ubiquitin-like Modifier) fusion protein. 
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2.4.1 PCR of hAGT Gene from pET_16b_AGT 
 
 The hAGT gene, including 3' adenylation overhangs, was PCR amplified as outlined in 
Section 2.2.4. PCR products were assessed by DNA gel electrophoresis (Section 2.2.3) with 5 μL 
of the completed PCR reaction. The primers used for amplification were as follows: 
Forward Primer: pET-SUMO_hAGT_F   5'-GAC CGG GTG TAC ATA CAC-3' 
Reverse Primer:  pET-SUMO_hAGT_R  5'-TCA TGC TGT GCT CAG C-3' 
 
2.4.2 Ligation of hAGT Gene into pET-SUMO Vector   
  
 The following reaction was set up to ligate the hAGT gene into the pET-SUMO vector 
(pET-SUMO vector, 10X ligation buffer, and T4 ligase were supplied with the ChampionTM pET 
SUMO Protein Expression System Kit (InvitrogenTM by Life TechnologiesTM, Carlsbad, 
California, USA)): 
LIGATION COMPONENTS VOLUME
Fresh PCR Product 1 μL 
10X Ligation Buffer 1 μL 
pET-SUMO Vector 2 μL 
T4 Ligase (4.0 Weiss units/μL) 1 μL 
Autoclaved MQ Water 5 μL 
Total Volume 10 μL 
 The reaction was mixed with a pipette, and left to incubate for 30 minutes at room 
temperature. Following incubation, aliquots of 2 μL of the ligation reaction were used to 
transform five vials of DH5α cells as described in Section 2.2.1. Transformed cells were plated 
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2.4.3 Colony PCR to Check for Presence of hAGT Gene in pET-SUMO Plasmid 
 
 All DH5α colonies resulting from ligation and transformation were picked and 
subjected to colony PCR as described in Section 2.2.5 using the plasmid-specific SUMO 
Forward and T7 Terminator primers. Colonies which contained a discrete band corresponding to 
the expected insert size of 1612 bp were grown overnight in LB + Kan media and the plasmids 
were purified as per Section 2.2.2. 
Forward Primer: SUMO Forward  5'-AGA TTC TTG TAC GAC GGT ATT AG-3' 
Reverse Primer: T7 Terminator  5'-TAG TTA TTG CTC AGC GGT GG-3' 
 
2.4.4 Sequencing of pET-SUMO_hAGT plasmid 
 
 Sequencing was carried out at the Canterbury Sequencing and Genotyping Facility 
(School of Biological Sciences, University of Canterbury, Christchurch, New Zealand) to check 
that the hAGT gene was in the correct frame of the pET-SUMO plasmid for expression and that 
no mutations had been introduced through the cloning procedures. The plasmid specific SUMO 
Forward and T7 Terminator sequencing primers (see Section 2.4.7) were used for sequencing the 
pET-SUMO_hAGT plasmid. 
 
2.5 RECOMBINANT HUMAN ANGIOTENSINOGEN EXPRESSION TRIALS  
 
 Extensive expression trials were undertaken to ascertain suitable conditions to obtain 
soluble, native, and pure recombinant human angiotensinogen. A range of E. coli strains, 
expression conditions, media types, and lysis conditions were trialled as outlined in the following 
sections.   
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2.5.1 General Expression Protocol 
 
 Using aseptic techniques, an expression strain of E. coli cells was transformed with the 
constructs detailed below, according to the protocol in Section 2.2.1, and cells were plated on LB 
agar plates with appropriate antibiotics and left at 37 °C to grow overnight. The following day, a 
single colony was picked with an autoclaved pipette tip and resuspended in a vial containing 10 
mL LB media with the appropriate antibiotics. This pre-culture was incubated at 37 °C in a 
Minitron incubator shaking at 250 rpm overnight. The next day, the optical density at 600 nm 
(OD600) of the pre-culture was measured using the Smart Spec
TM Plus Spectrophotometer (Bio-
Rad Laboratories, Hercules, California, USA) and then the appropriate amount of pre-culture 
was added to a conical flask containing 50 mL LB (with appropriate antibiotic) so that the 
starting OD600 of the expression flask was 0.1 Absorbance Units (AU).  
 This 50 mL culture was incubated at 37 °C in a Minitron incubator shaking at 250 rpm, 
and, with the OD600 being monitored, the culture was left to grow until an OD600 of 0.6 to 0.8 AU 
was reached. An uninduced sample was then taken by removing a sample with a volume 
equivalent to an OD600 of 1.0 AU (i.e. 1.0/OD600 x 1 mL = volume of sample to be taken). The 
uninduced cell sample was harvested by centrifuging the sample at 4 °C for 5 minutes at 12,000 
rpm to pellet the cells. The supernatant was discarded and the cell pellet was frozen and stored at 
–20 °C.  
 The culture flask was cooled down and induced by adding 50 μL of 1 M IPTG to give a 
final concentration of 1 mM IPTG. The flask was returned to the shaking Minitron incubator to 
express at the desired temperature of 26 °C or 37 °C. After four hours of expression, and again 
after overnight expression, the OD600 was measured and samples were taken, with the volume of 
sample taken being equivalent to an OD600 of 1.0 AU as with the uninduced samples above. Cell 
samples were harvested as described above by centrifuging the samples for 5 minutes at 4 °C and 
12,000 rpm. The supernatants were discarded and cell pellets were frozen and stored at –20 °C. 
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 In order to analyze the cells to check expression levels and solubility of the expressed 
protein, cell pellets were removed from the freezer and thawed on ice. If cells were to be lysed 
by sonication, 200 μL of the desired buffer was added to the cell pellet before the cells were 
sonicated using the Stepped Titanium Microtip (3.9 mm diameter) of the Sonic Ruptor 400 
Ultrasonic Homogenizer (Omni International Inc., Kennesaw, Georgia, USA). Sonication was 
carried out on ice for 5 second intervals until cells were completely resuspended and the solution 
was homogenous. 
 Alternatively, cells were lysed using CelLyticTM B Bacterial Cell Lysis Extraction 
Reagent (10X concentrate, Sigma-Aldrich, St. Louis, Missouri, USA), a lysis reagent that 
contains a combination non-denaturing zwitterionic detergents which gently lyse the cells with 
the help of lysozyme. CelLytic B lysis solution was prepared by combining 100 μL of 10X 
CelLytic B concentrate with 20 μL of 10 mg/mL lysozyme (to give a final concentration of      
0.2 mg/mL lysozyme), and 880 μL of the desired buffer. 200 μL of this 1X CelLytic B lysis 
solution was added to the thawed cell pellet, and the solution was gently pipetted up and down 
until the pellet was completely resuspended.  The cells were then mixed by gently inverting the 
tube for 10 to 15 minutes. 
 Once lysis was complete, either by sonication or CelLytic B, 100 μL of the lysed cells 
was transferred to a clean tube and kept as a sample of total cell lysate. The remaining 100 μL 
was then centrifuged for 5 minutes at 4 °C, 12,000 rpm to separate the soluble fraction from the 
insoluble fraction which forms a pellet at the bottom of the tube. Following centrifugation, the 
soluble supernatant was removed and placed in a clean tube, and kept as a sample of the soluble 
fraction. The remaining pellet was completely resuspended in 100 μL of the buffer used for 
lysis—this is the insoluble fraction. These samples were analysed by SDS-PAGE by loading 5 
μL of each sample in wells of a gel and run as described in Section 2.2.6 above. This expression 
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protocol was carried out for the expression trials detailed in Sections 2.5.2, 2.5.3, and 2.5.4 
below. 
 
2.5.2 His-tagged Human Angiotensinogen (pET_16b_AGT plasmid) 
 
 BL21 (DE3) star competent cells were transformed with the pET_16b_AGT plasmid 
and cultured in three different media types (LB, TB, and 2*TY, see Appendix for recipes) with 
ampicillin as the selective antibiotic. The cells were induced with either 0.1 mM or 1 mM IPTG, 
and were left to express at 26 °C and 37 °C, for four hours and overnight (16 hours). Cells were 
lysed by sonication or CelLytic B with PBS, PBS + 1% Triton X-100, Tris, and Lysis Buffer (see 
Appendix for recipes) as the buffer used for lysis.   
 Rosetta (DE3) competent cells were transformed with the pET_16b_AGT plasmid and 
cultured in two different media types (LB and TB) with ampicillin and chloramphenicol as the 
selective antibiotics. The cells were induced with 1 mM IPTG, and were left to express at 26 °C 
and 37 °C, for four hours and overnight (16 hours). Cells were lysed by sonication or CelLytic B 
with PBS, PBS + 1% Triton X-100, Tris, and Lysis Buffer as the buffer used for lysis. 
 Origami (DE3) competent cells were transformed with the pET_16b_AGT plasmid and 
cultured in LB media with ampicillin, kanamycin, streptomycin, and tetracycline as the selective 
antibiotics. The cells were induced with 1 mM IPTG and were left to express at 26 °C and 37 °C 
for four hours and overnight (16 hours). Cells were lysed with CelLytic B (Lysis Buffer was the 
buffer used for lysis). 
  
2.5.3 Human Angiotensinogen (pETDuet_DsbC_hAGT plasmid) 
 
 BL21 (DE3) competent cells were transformed with the pETDuet_DsbC_hAGT 
plasmid and cultured in LB media with ampicillin as the selective antibiotic. The cells were 
induced with 1 mM IPTG and were left to express at 26 °C and 37 °C, for a period of four hours 
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and overnight (16 hours). Cells were lysed by CelLytic B with Lysis Buffer (see recipe in 
Appendix) used as the buffer for lysis. 
 Origami (DE3) competent cells were transformed with the pETDuet_DsbC_hAGT 
plasmid and cultured in LB media with ampicillin, kanamycin, streptomycin, and tetracycline as 
the selective antibiotics. The cells were induced with 1 mM IPTG and were left to express at    
26 °C and 37 °C, for four hours and overnight (16 hours). Cells were lysed by CelLytic B with 
Lysis Buffer used as the buffer for lysis. 
 
2.5.4 SUMO-tagged Human Angiotensinogen (pET-SUMO_hAGT plasmid) 
 
 BL21 (DE3) competent cells were transformed with the pET-SUMO_hAGT plasmid 
and cultured in LB media (supplemented either in the presence or absence of 1% glucose) with 
kanamycin as the selective antibiotic. If the media was supplemented with 1% glucose, glucose 
was added to the media in both the pre-culture and expression culture flasks. The cells were 
induced with 1 mM IPTG and were left to express at 26 °C and 37 °C, for four hours and 
overnight (16 hours). Cells were lysed by either sonication or CelLytic B with Lysis Buffer used 
as the buffer for lysis. 
 
2.6 EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN ANGIOTENSINOGEN 
 
 Following extensive expression trials and optimization of the expression and lysis 





 Using aseptic techniques, BL21 (DE3) competent E. coli cells were transformed with 
the pET-SUMO_hAGT plasmid according to the protocol described in Section 2.2.1, and cells 
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were plated on LB + Amp agar plates and left at 37 °C to grow overnight. The following day, a 
single colony was picked and resuspended in a flask containing 50 mL LB + Amp + 1% glucose 
media. This pre-culture was incubated at 37 °C in a Minitron incubator shaking at 250 rpm 
overnight. The next day, the OD600 of the pre-culture was measured using the Smart Spec
TM Plus 
Spectrophotometer (Bio-Rad Laboratories, Hercules, California, USA) and then the appropriate 
amount of pre-culture was added to a 2 L baffled conical flask containing 500 mL LB + Amp + 
1% glucose so that the starting OD600 of the expression flask was 0.1 AU.  
 This 500 mL expression culture was incubated at 37 °C in a Minitron incubator shaking 
at 250 rpm, and, with the OD600 being monitored, the culture was left to grow until an OD600 of 
0.6 to 0.8 AU was reached (typically 2 to 3 hours). The culture flask was cooled down and then 
induced by adding 500 μL of 1 M IPTG to give a final concentration of 1 mM IPTG. The flask 
was returned to the shaking Minitron incubator to express at 26 °C for 16 hours (overnight). 
Cells were harvested by splitting the culture in two and centrifuging cells at 4 °C for ten minutes 
at 8,000 rpm. The supernatants were discarded, and the cell pellets were resuspended in 10 mL 
PBS buffer (to wash pellet and remove any residual media) and transferred to 50 mL Falcon 
tubes (Corning®, Tewksbury, Massachusetts, USA), before being centrifuged for a further 20 
minutes at 4 °C and 10,000 rpm to pellet the cells. The supernatant was removed and discarded, 
and the cell pellets were frozen and stored at –20 °C. 
 
2.6.2 Cell Lysis 
 
 A 250 mL cell pellet was removed from the freezer and thawed on ice, before being 
completely resuspended in 20 mL Lysis Buffer containing a small spatula of lyophilised DNase I 
(to reduce viscosity of cell lysate; Roche, Indianapolis, Indiana, USA), Cells were lysed using 
the Microfluidics M-110P Cell Homogenizer® (Microfluidics, Westwood, Massachusetts, USA) 
at 17,000 psi and 4 °C. Cell samples were passed through the homogenizer twice to ensure 
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complete lysis, which results from the shear stresses and decompression that occur when the 
cells are passed through a needle valve at high pressure, causing cell disruption when cells return 
to normal atmospheric pressure. Following lysis, the cell lysate was centrifuged at 10,000 rpm 
for 20 minutes at 4 °C to pellet any insoluble material. The supernatant was transferred to a clean 
50 mL tube and kept on ice ready for purification. 
 
2.6.3 His-tag Purification 
 
 Purification by means of immobilised metal ion affinity chromatography (IMAC) was 
carried out using HisPurTM Cobalt (Co) Resin (Thermo Scientific, Rockford, Illinois, USA). A   
5 mL gravity flow column (Pierce Biotechnology, Rockford, Illinois, USA) was packed with 2 
mL resin, and the storage buffer was allowed to flow through and was discarded. The resin was 
then washed with 20 mL MQ water (10 column volumes), before being equilibrated with 10 
column volumes of Lysis Buffer. The equilibrated resin was then transferred to the tube 
containing the soluble fraction of the cell lysate, and incubated for 30 minutes in a 4 °C 
controlled temperature room on a rotary wheel at a slow speed. This was then repacked into the 
gravity flow column and the flow through collected. The flow through was applied to the column 
once more to ensure maximum binding of the His-tagged SUMO fusion protein to the resin. The 
bound resin was then washed with 10 column volumes of PBS 10 mM imidazole pH 7.4 to 
remove any extraneous, weakly bound proteins. SUMO-AGT was then eluted with 10 mL of 
PBS 50 mM imidazole pH 7.4, collected in 1 mL fractions. Fractions were analysed by SDS-
PAGE (Section 2.2.6) and those fractions containing SUMO-AGT were pooled and concentrated 
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2.6.4 Size Exclusion Chromatography 
 
 As a second and final step of purification, size exclusion chromatography (SEC) was 
performed to separate proteins by size in order to remove unwanted proteins that co-eluted with 
SUMO-AGT in the first IMAC step of purification. A 24 mL Superdex 200 gel filtration pre-
packed column (GE Healthcare Life Sciences, Uppsala, Sweden) was connected to the AKTA 
Express (GE Healthcare Life Sciences, Uppsala, Sweden) and washed with three column 
volumes of MQ water before being equilibrated with 75 mL of PBS pH 7.4 buffer at a flow rate 
of 0.3 mL/min. The concentrated protein sample was then loaded onto the column and run, for a 
total buffer volume of 30 mL, at a flow rate of 0.25 mL/min at 4 °C, and collected in a 96 well 
plate in 1 mL fractions. Fractions that corresponded to the A280 peak on the chromatograph 
(UniCorn 5.11 Workstation, GE Healthcare Life Sciences, Uppsala, Sweden) were analysed by 
SDS-PAGE (Section 2.2.6) and fractions containing pure SUMO-AGT were pooled and 
concentrated using a Vivaspin® 6 10,000 Da MWCO PES spin concentrator (Sartorius, 
Goettingen, Germany). Pure protein was snap frozen with liquid nitrogen and stored at –80 °C. 
 
2.6.5 Cleavage of SUMO Tag 
 
 Cleavage using SUMO Protease (1 U/μL, supplied with SUMO Protease Buffer as part 
of the ChampionTM pET SUMO Protein Expression System Kit (InvitrogenTM by Life 
TechnologiesTM, Carlsbad, California, USA)) was carried out to remove the His-tag and SUMO 
fusion protein from the N-terminus of angiotensinogen. For every 20 μg of SUMO-AGT fusion 
protein to be cleaved, 10 units of protease (10 μL) was added to the protein solution with 4 μL of 
10X SUMO Protease Buffer (‒ salt), and made up to a total volume of 40 μL with MQ water and 
mixed well. The reaction was left to incubate for 3 hours at room temperature, before being 
flowed through a pre-equilibrated 1 mL Co resin gravity column to remove the cleaved SUMO 
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tag and the SUMO protease from the solution. The flowthrough was collected and contained 
pure recombinant human angiotensinogen.    
 
2.7 EXPRESSION AND PURIFICATION OF SUMOYLATED CHLORAMPHENICOL 
ACETYLTRANSFERASE 
 
 The expression control protein, SUMO-chloramphenicol acetyltransferase (SUMO-
CAT; pET-SUMO/CAT plasmid supplied with the ChampionTM pET SUMO Protein Expression 
System Kit (InvitrogenTM by Life TechnologiesTM, Carlsbad, California, USA) was expressed 
and purified as a SUMOylated protein to be used as a negative control in surface plasmon 
resonance experiments. Using aseptic techniques, BL21 (DE3) competent E. coli cells were 
transformed with the pET-SUMO/CAT plasmid according to the protocol described in Section 
2.2.1, and cells were plated on LB + Amp agar plates and left at 37 °C to grow overnight. The 
SUMO-CAT protein was then expressed and purified according to the same protocol described 
for SUMO-AGT in Sections 2.6.1, 2.6.2, and 2.6.3 above. SUMO-CAT protein was eluted from 
the Co resin using PBS 150 mM imidazole pH 7.4 as the elution buffer, concentrated with a 
Vivaspin® 6 10,000 Da MWCO PES spin concentrator (Sartorius, Goettingen, Germany), and 
then subjected to size exclusion chromatography as described in Section 2.6.4. Pure protein was 
snap frozen with liquid nitrogen and stored at –80 °C. 
 
2.8 SURFACE PLASMON RESONANCE EXPERIMENTS 
 
 All surface plasmon resonance (SPR) experiments were carried out on the ProteOnTM 
XPR36 Protein Interaction Array System using ProteOnTM GLC Sensor Chips at 25 °C using 
ProteOnTM 0.35 mL, or 2 mL deep well 96 well plates (all purchased from Bio-Rad Laboratories, 
Hercules, California, USA). Following much optimisation of ligand immobilisation levels, buffer 
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conditions, analyte concentrations, injection parameters, and regeneration conditions, SPR 
experiments were carried out as described in Sections 2.8.1 to 2.8.6 below: 
 
2.8.1 Buffer and Protein Solution Preparation 
 
 All buffers and solutions run on the SPR were prepared fresh and filtered using 0.2 μm 
syringe-driven, or vacuum-driven filters, before being sonicated for 20 minutes (Digitech 
Ultrasonic Cleaner, Digitech Systems, Kolkata, India) to degas and break apart any remaining 
particulate in solution. Activation and deactivation solutions for amine coupling were supplied as 
part of the ProteOnTM amine coupling kit (Bio-Rad Laboratories, Hercules, California, USA). All 
protein samples were centrifuged at 4 °C for 5 minutes at 12,000 rpm to pellet any aggregate that 
may be present in the sample, prior to the concentration being checked in triplicate by Nanodrop 
A280 (protein concentration was calculated by dividing the A280 by the protein’s extinction 
coefficient) and/or by OPA fluorescent assay in order to obtain accurate protein concentrations. 
Phosphate buffered saline with Tween-20 (PBST, see recipe in Appendix) was used as the 
running buffer in all experiments and in the blank buffer injections. 
 
2.8.2 Sensor Chip Initialisation and Pre-Conditioning 
 
 Each time a new or used sensor chip was inserted into the SPR machine, a wet 
initialisation (50% v/v glycerol) was performed. Following several system flushes with the 
running buffer, the sensor chip surface of a new chip was conditioned prior to any 
immobilisations by carrying out successive 30 μL pulses of 0.25% Tween-20, 50 mM NaOH, 
and 100 mM HCl for 60 seconds each at a flow rate of 30 μL/min, first in the vertical direction 
(ligand) followed by the horizontal direction (analyte). Eight blank buffer runs in the analyte 
direction followed by an additional eight blank buffer runs in the ligand direction were then 
carried out to remove all traces of the pre-conditioning solutions and equilibrate the chip surface 
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prior to any experiments taking place (100 μL of PBST injected at a flow rate of 100 μL/min for 
60 seconds for each blank buffer run). 
  
2.8.3 Interaction of Recombinant Human Angiotensinogen with Anti-Angiotensinogen 
Antibody 
 
 A multiplex approach was taken to investigate the interactions that take place between 
recombinant human angiotensinogen and the human serpin A8/angiotensinogen monoclonal 
antibody (mouse IgG1 clone #369439; R & D Systems, Minneapolis, Minnesota, USA)—
henceforth referred to as ‘anti-AGT mAb’. Mouse anti-human IgG Fc specific monoclonal IgG 
antibody (clone 7QD; General Bioscience Corporation, Brisbane, California, USA)—referred to 
as ‘anti-IgG mAb’—was immobilised to one ligand channel to serve as a reference channel 
while anti-AGT mAb was immobilised to a further four channels at the same level of ligand 




 The sensor chip surface of the ligand channels was activated by a 150 μL injection of a 
1:1 mixture of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) and 0.1 M N-
hydroxysuccinamide (NHS) for 300 seconds at a flow rate of 30 μL/min to activate the 
carboxymethyl dextran on the sensor chip surface, to produce reactive succinimide esters. 
Ligand was then immobilised on each channel by injecting 150 μL of 0.75 μg/mL antibody (in 
10 mM sodium acetate buffer pH 4) for 300 seconds at a flow rate of 30 μL/min—anti-IgG mAb 
was immobilised across ligand channel 1 (L1, reference channel), while anti-AGT mAb was 
immobilised across ligand channels (L2 to L5). Ligand immobilisation was directly followed by 
deactivation with 1 M ethanolamine HCl pH 8 at a flow rate of 30 μL/min for 300 seconds to 
deactivate any unreacted succinimide esters.  
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 Following two blank buffer injections, four stabilisation steps were performed in the 
ligand direction to stabilise the ligand surface and remove any weakly bound ligand molecules. 
Two 30 μL pulses of 10 mM sodium acetate pH 3.0 were followed by two 30 μL pulses of 10 
mM glycine HCl pH 2.0, with each 18 second injection having a flow rate of 100 μL/min. 
Multiple blank buffer injections, first in the ligand direction and then the analyte direction, were 
performed until a stable baseline was achieved across all channels. 
  
2.8.3.2 Interaction with SUMO-AGT 
 
 A dilution series of pure SUMO-AGT with a dilution factor of two was prepared in 
PBST to give SUMO-AGT concentrations of 3 μM, 1.5 μM, 0.75 μM, 0.375 μM, 0.1875 μM, 
and 0.0938 μM. A 409 μL injection of each SUMO-AGT concentration was flowed across the 
chip in the analyte direction at a flow rate of 25 μL/min and allowed to associate with the anti-
AGT mAb for a total contact time of 981 seconds (16 minutes 21 seconds). At the end of the 
injection, running buffer was flowed across all analyte channels for 600 seconds to allow 
dissociation. This was then followed with regeneration of the ligand surface—a 30 μL pulse of 
glycine HCl pH 2.0 for a total of 18 seconds at a flow rate 100 μL/min to remove any 
undissociated analyte. At least four blank buffer injections were performed to allow the ligand to 
recover and ensure a stable baseline was re-established. This interaction run was also repeated 
using pure SUMO-CAT as a negative control. 
   
2.8.3.3 Interaction with Reduced and Oxidised Angiotensinogen 
 
 A dilution series of pure oxidised angiotensinogen (derivatised with NEM) with a 
dilution factor of two was prepared in PBST to give oxidised angiotensinogen concentrations of 
2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.125 μM, and 0.0625 μM. A 409 μL injection of each oxidised 
angiotensinogen concentration, in descending order, was flowed simultaneously across the chip 
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in the analyte direction at a flow rate of 25 μL/min and allowed to associate with the anti-AGT 
mAb for a total contact time of 981 seconds (16 minutes 21 seconds). At the end of the injection, 
running buffer was flowed across all analyte channels for 1800 seconds (30 minutes) to allow 
dissociation. This was then followed with regeneration of the ligand surface—a 30 μL pulse of 
glycine HCl pH 2.0 for a total of 18 seconds at a flow rate 100 μL/min to remove any 
undissociated analyte. At least four blank buffer injections were performed to allow the ligand to 
recover and ensure a stable baseline was re-established. The order of the concentration series of 
oxidised angiotensinogen was then randomised and the interaction run was repeated such that 
each concentration of oxidised angiotensinogen was flowed across a different analyte channel to 
the previous interaction run. 
 A dilution series of pure reduced angiotensinogen (derivatised with DTT, followed by 
NEM) was prepared identically to oxidised angiotensinogen to give the same concentrations 
listed above. A 409 μL injection of each reduced angiotensinogen concentration, in descending 
order, was flowed simultaneously across the chip in the analyte direction at a flow rate of          
25 μL/min and allowed to associate with the anti-AGT mAb for a total contact time of 981 
seconds (16 minutes 21 seconds). At the end of the injection, running buffer was flowed across 
all analyte channels for 1800 seconds (30 minutes) to allow dissociation. This was then followed 
with regeneration of the ligand surface—a 30 μL pulse of glycine HCl pH 2.0 for a total of 18 
seconds at a flow rate 100 μL/min to remove any undissociated analyte. At least four blank 
buffer injections were performed to allow the ligand to recover and ensure a stable baseline was 
re-established. The order of the concentration series of reduced angiotensinogen was then 
randomised and the interaction run was repeated such that each concentration of reduced 
angiotensinogen was flowed across a different analyte channel to the previous interaction run. 
 Finally, the three highest concentrations of oxidised and reduced angiotensinogen were 
injected simultaneously across all channels in the same run, first in a ordered fashion, and then as 
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a repeat in a randomised order in the second interaction run, such that in each run oxidised 
angiotensinogen was flowed across three channels and reduced angiotensinogen was flowed 
across the other three channels.    
 
2.8.4 Interaction of Recombinant Human Angiotensinogen with Recombinant Glycosylated 
Human Renin via Amine Coupling 
 
 Recombinant human glycosylated renin was immobilised directly onto the chip surface 
via amine coupling using several approaches, to measure the kinetic parameters of the 
interactions between renin and angiotensinogen. 
  
2.8.4.1 Immobilisation of Prorenin and Renin 
 
 Prorenin was proteolytically activated to renin by trypsin digest—0.1 mg/mL prorenin 
was digested with trypsin at a concentration of 5 μg/mL for 2 minutes at 37 °C, before the 
reaction was quenched with 0.5% formic acid or 2 mM phenylmethanesulfonyl fluoride (PMSF). 
SDS-PAGE analysis was used to confirm complete cleavage of the prosegment.  
 The sensor chip surface was activated by a 150 μL injection of a 1:1 mixture of 0.4 M 
EDAC and 0.1 M NHS for 300 seconds at a flow rate of 30 μL/min. Ligand was then 
immobilised on each channel by injecting 150 μL of 0.01 mg/mL prorenin or renin (in 10 mM 
sodium acetate buffer pH 4) for 300 seconds at a flow rate of 30 μL/min. Ligand immobilisation 
was directly followed by deactivation with 1 M ethanolamine HCl pH 8 at a flow rate of 30 
μL/min for 300 seconds. Multiple blank buffer injections, first in the ligand direction and then 
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2.8.4.2 Immobilisation of Prorenin and Renin on a Spacer 
 
 Immobilisation of prorenin and renin was performed exactly as described above, except 
that the activation/immobilisation/deactivation steps described in Section 2.8.4.1 above were 
preceded by an additional three steps. Firstly, the carboxymethyl dextran sensor chip surface was 
activated with a 1:1 mixture of 0.4 M EDAC and 0.1 M NHS (30 μL/min for 300 seconds), 
which was then followed by the immobilisation of 150 μL of a spacer molecule, 
hexamethylenediamine (Sigma-Aldrich, St. Louis, Missouri, USA), at a concentration of 11 
mg/mL in PBST pH 7.4 for a contact time of 300 seconds. The surface was then deactivated with 
1 M ethanolamine pH 8.5 before the immobilisation of prorenin or renin, as described in Section 
2.8.4.1. 
  
2.8.4.3 Interaction with Angiotensinogen 
  
 A dilution series of pure angiotensinogen (reduced or oxidised) with a dilution factor of 
two was prepared in PBST pH 7.4 to give angiotensinogen concentrations of 200 nM, 100 nM, 
50 nM, 25 nM, 12.5 nM, and 6.25 nM. A 100 μL injection of each angiotensinogen 
concentration was flowed simultaneously across the chip in the analyte direction at a flow rate of 
50 μL/min and allowed to associate with the prorenin or renin for a total contact time of 120 
seconds. At the end of the injection, running buffer was flowed across all analyte channels for 
600 seconds to allow dissociation. This was then followed with regeneration of the ligand 
surface—a 30 μL pulse of glycine HCl pH 2.0 for a total of 18 seconds at a flow rate 100 μL/min 
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2.8.4.4 Activation of Prorenin by Trypsin Digest on Sensor Chip 
 
 Prorenin, already immobilised on the sensor chip surface at a concentration of 0.01 
mg/mL, was proteolytically digested by flowing trypsin across the ligand channel. Trypsin, 208 
μL at a concentration of 0.5 mg/mL in MQ water, was injected, across the ligand channel that 
contained immobilised prorenin at a flow rate of 25 μL/min for 500 seconds. The reaction was 
quenched by a 30 μL pulse of 0.5% formic acid for 18 seconds at a flow rate of 100 μL/min. 
Multiple blank buffer injections, first in the ligand direction and then the analyte direction, were 
performed until a stable baseline was achieved across all channels, before interaction runs with 
angiotensinogen, as described in Section 2.8.4.3, were repeated. 
 
2.8.5 Interaction of Recombinant Human Angiotensinogen with Recombinant Glycosylated 
Human Renin via Aldehyde Coupling 
 
 As an alternative approach to the amine coupling immobilisation of renin described in 
Section 2.8.4, renin was immobilised onto the sensor chip surface using aldehyde coupling, 
which tethers proteins to the chip surface by their glycosylation residues rather than by amine 




 The sensor chip surface was activated by a 180 μL injection of a 1:1 mixture of 0.4 M 
EDAC and 0.1 M NHS for 180 seconds at a flow rate of 25 μL/min to activate the 
carboxymethyl dextran on the sensor chip surface to produce reactive succinimide esters. A 175 
μL injection of 5 mM carbohydrazide (in MQ water; Sigma-Aldrich, St. Louis, Missouri, USA) 
was flowed across the surface for 420 seconds at a flow rate of 25 μL/min to introduce hydrazide 
groups to the sensor chip surface, which was then subsequently followed by deactivation with 
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175 μL of 1 M ethanolamine HCl pH 8 injected at a flow rate of 25 μL/min for 420 seconds to 
deactivate any unreacted succinimide esters. Renin (oxidised with 1 mM sodium meta periodate 
(Sigma-Aldrich, St. Louis, Missouri, USA) according to the protocol in the Biacore Sensor 
Surface Handbook (BR-1005-71 Edition AB) was then immobilised at a concentration of 0.01 
mg/mL (in 10 mM sodium acetate buffer pH 4 or pH 5) by injecting 210 μL of protein solution 
across two ligand channels for 420 seconds at a flow rate of 30 μL/min. Two 250 μL injections 
of 0.1 M sodium triacetoxyborohydride (Sigma-Aldrich, St. Louis, Missouri, USA dissolved in 
0.1 M sodium acetate pH 4) were performed for 10 minutes each at a flow rate 25 μL/min to 
reduce and stabilise the covalent bond formed between the ligand and surface. An unmodified 
surface was used as a reference channel. Multiple blank buffer injections, first in the ligand 
direction and then the analyte direction, were performed until a stable baseline was achieved 
across all channels. 
 
2.8.5.2 Interaction with SUMO-AGT 
 
 A dilution series of pure SUMO-AGT with a dilution factor of two was prepared in 
PBST to give SUMO-AGT concentrations of 3 μM, 1.5 μM, 0.75 μM, 0.375 μM, 0.1875 μM, 
and 0 μM. A 250 μL injection of each SUMO-AGT concentration was flowed across the chip in 
the analyte direction at a flow rate of 50 μL/min and allowed to associate with the immobilised 
renin for a total contact time of 300 seconds. At the end of the injection, running buffer was 
flowed across all analyte channels for 600 seconds to allow dissociation. This was then followed 
with regeneration of the ligand surface—a 30 μL pulse of glycine HCl pH 2.0 for a total of 18 
seconds at a flow rate 100 μL/min to remove any undissociated analyte. At least four blank 
buffer injections were performed to allow the ligand to recover and ensure a stable baseline was 
re-established. This interaction run was repeated using pure SUMO-CAT as a negative control. 
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2.8.6 Data Analysis 
 
 All data were exported from the ProteOnTM Manager (Bio-Rad Laboratories, Hercules, 
California, USA). The data were processed using Scrubber 2 (Prot version, Biologic Software, 
Campbell, Australian Capital Territory, Australia) and fit to a simple 1:1 Langmuir binding 
model (or a more complex binding model if necessary) using ClampXP software145 to obtain 
kinetic association and dissociation constants. Monte Carlo analysis was also performed using 
ClampXP for each dataset by performing 50 independent rounds of model fitting with a 
maximum iteration of 25 cycles per fit, a variation of 1000%, and added noise of 4 RU. 
 Statistical analysis was carried out on the mean anti-AGT mAb surface kinetic constant 
values for oxidised and reduced angiotensinogen by performing independent sample t-tests (two-
tailed, 95% confidence level) to test whether the kinetic values for the two forms of 
angiotensinogen differed significantly. Minitab 16 (Lead Technologies, Inc., Charlotte, North 
Carolina, USA) was used to perform the statistical analysis, and the data were checked for 
normality using the normality test prior to analysis.   
 
2.9 REACTION OF RECOMBINANT HUMAN ANGIOTENSINOGEN WITH MPEG 5000/10000 
 
 Polyethylene glycol (PEG) with a maleimide functionality (methoxy polyethylene 
glycol maleimido-propionamide, mPEG) was used to demonstrate that the angiotensinogen 
protein could be derivatised in either the reduced or oxidised form. Stock solutions of mPEG 
5000 and mPEG 10000 (Chirotech Technology Ltd., Cambridge, UK) were prepared fresh 
immediately prior to use in PBS pH 7.2 at concentrations of 30 mM and 20 mM respectively.  A 
stock solution of tris(2-carboxyethyl)phosphine (TCEP; Sigma-Aldrich, St. Louis, Missouri, 
USA) was also prepared freshly, just prior to use, in PBS pH 7.2 at a concentration of 100 mM.  
 Pure SUMO-AGT at a concentration of 1.4 mg/mL (in PBS pH 7.2) was incubated in 
either the presence or absence of 10 mM TCEP for one hour at 25 °C shaking in an Eppendorf 
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Thermomixer® Comfort (Eppendorf, Hamburg, Germany). TCEP did not need to be removed 
prior to the mPEG incubation as the compound does not contain any free thiols that could react 
with the maleimide functionality. Subsequently, mPEG 5000 or mPEG 10000 was added to the 
protein solution to give a final mPEG concentration of 10 mM, and was mixed well. Upon 
mixing, a 20 μL sample of each reaction was immediately taken and prepared for SDS-PAGE 
analysis (see Section 2.2.6) and samples were stored at –20 °C for later analysis. 
 The SUMO-AGT mPEG reactions were returned to the thermomixer and left to 
incubate at 25 °C while shaking and protected from light. Further 20 μL samples were taken after 
1.5 hours, 4 hours, and overnight incubation and prepared for SDS-PAGE analysis. As a control, 
a sample of SUMO-AGT in the presence or absence of reducing agent was also run on the same 
SDS-PAGE gel, so that any changes in molecular weight that occurred would be clearly shown.     
 
2.10 MOLECULAR DYNAMIC SIMULATIONS 
 
 Molecular dynamic simulations were performed at Monash University (Melbourne, 
Australia). Molecular dynamics simulations were carried out on human angiotensinogen (PDB 
structure 2WXW), in both the reduced form (Cys 18 and Cys 138 reduced) and oxidised form 
(Cys 18 and Cys 138 disulphide bonded). Missing loops and side chain residues were modeled 
using MODELLER.146 All chain termini were capped with neural groups (acetyl and 
methylamide). With completed structures, the simulations were solvated in a cubical simulation 
box with a minimum distance of 1.4 nm from the protein to the box wall, followed by the 
addition of 150 mM NaCl to the aqueous phase. Simulations initially measured at 11.19 nm x 
11.19 nm x 11.19 nm containing 133,011 water molecules, 139 sodium ions and 127 chloride 
ions for a total of 136,910 atoms. 
 All simulation systems were subjected to energy minimization, followed by a three 
stage equilibration protocol with positional restrains holding all protein atoms with 1,000 kJ  
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mol-1 nm-2 for 100 ps, restraints on all backbone atoms with 1,00 kJ mol-1 nm-2 for 100 ps and 
restraints on C-alpha atoms with 100 kJ mol-1 nm-2 for 100 ps, respectively. Each system was 
then subjected to free simulation with configurations stored every 10 ps for analysis. 
 The prepared reduced and oxidised systems were run at 300 K for 500 ns, in triplicate, 
with each replicate starting from a different distribution of initial velocities. All simulations were 
performed using GROMACS version 4.0.7,147 in conjunction with the GROMOS 54A7 united-
atom force field.148 Ionizable residues were set to their standard protonation states at pH 7. Water 
was represented explicitly using the simple-point-charge (SPC) model.149 All simulation systems 
were equilibrated in an NVT ensemble and production runs performed in an NPT ensemble 
under periodic conditions. Temperature was maintained close to its reference value of 300 K by 
V-rescale temperature coupling. Pressure was maintained close to a reference value of 1 atm by 
isotropic coupling with a berensden pressure bath.150 Non-bonded interactions were evaluated 
using a twin-range cut-off scheme: interactions falling within the 0.8 nm short-range cutoff were 
calculated every 2 fs whereas interactions within the 1.4 nm long cutoff were updated every 10 
fs, together with the pair list. A generalized reaction-field correction was applied to the 
electrostatic interactions beyond the long-range cutoff,151 using a relative dielectric permittivity 
constant of ɛRF = 62 as appropriate for SPC water.152 
 All bond lengths to hydrogen atoms were constrained using the P-LINCS algorithm153 
and water geometry was constrained using the SETTLE algorithm.154 The time step used for 
integrating the equations of motion was 2 fs. 
 Analyses of the simulations were performed using the tools provided in the GROMACS 
package 4.0.7,147 and custom scripts in conjunction with ProDy.155 Graphs and plots were 
produced using Matplotlib.156 Molecular graphics were prepared with PyMol version 1.3.2157 and 
Visual Molecular Dynamics (VMD) 1.9.2.158 








 Prior to the introduction of recombinant protein expression, angiotensinogen could only 
be studied by purifying it from the plasma of humans and other animals in multi-step purification 
schemes with generally low yields. For instance, Bouhnik et al. purified rat angiotensinogen in a 
six step procedure involving ammonium sulphate precipitation, and multiple chromatography 
steps, followed by isoelectric focussing, with an overall yield of only 7%.159 Similarly, Grisé et 
al. reported the partial purification of angiotensinogen from human plasma in a five step process 
including ammonium sulphate precipitation, followed by four chromatographic steps resulting in 
a 100-fold purification with a yield of only 15.9%.160 More recently, human angiotensinogen was 
elegantly immunopurified from plasma in a one-step process with a yield of approximately 90% 
by using an immunoaffinity column containing anti-angiotensinogen monoclonal antibodies 
immobilised on cyanogen bromide-activated Sepharose.25 Despite advances in purification of 
angiotensinogen from plasma, plasma purification is limited by the amount of angiotensinogen 
present in plasma, with a large volume of plasma required to obtain a substantial amount of 
angiotensinogen.     
 The publication of the cDNA sequence of the human angiotensinogen gene in 1984 
heralded the move towards recombinant expression of angiotensinogen.109 With advances in 
fusion protein technology for enhanced solubility and affinity purification purposes, as well as 
many expression hosts now readily at our disposal, the expression of recombinant 
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angiotensinogen has been described in both bacterial and mammalian expression systems,1, 161, 162 
allowing far greater amounts of angiotensinogen to be more readily available to be studied.  For 
instance, Zhou et al. reported the expression of recombinant glycosylated angiotensinogen in 
human embryonic kidney cells, and these researchers also made use of the SUMO-fusion system 
to facilitate recombinant bacterial expression of angiotensinogen.1 Recombinant technology has 
facilitated the simple isolation and purification of proteins, often in only one or two steps, 
through the introduction of affinity fusion tags such as polyhistidine (His), and glutathione-s-
transferase (GST) tags, which can be removed following purification, allowing for quick, low-
cost purification of recombinant proteins and high yields.163  
Compared with eukaryotic expression systems, expression using the bacterial host E. coli 
provides a simple, rapid and inexpensive method of protein expression, but it does also have its 
drawbacks.163-165 Proteins produced using E. coli as the expression host lack post-translational 
modifications, such as glycosylation—modifications that could be important for protein structure 
or function.164 In addition, recombinant proteins (particularly of eukaryotic origin) overexpressed 
in E. coli have the propensity to form insoluble inclusion bodies, further complicating the 
expression and purification procedure.163-165 These are all factors that need to be taken into 
consideration when choosing expression and purification strategies.  
 This chapter describes the construction of two expression plasmids containing the human 
angiotensinogen gene, and the screening and optimisation of angiotensinogen expression in E. 
coli cells in order to ascertain the best expression conditions for recombinant production of 
human angiotensinogen. Large-scale expression and purification was subsequently carried out to 
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3.2 CLONING OF THE HAGT GENE INTO PETDUET_DSBC VECTOR 
 
PCR amplification of the human AGT gene (from the pET_16b_AGT plasmid) to include 
the addition of the KpnI restriction site at the 3’ end of the gene led to the generation of a 1533 
bp sized fragment of DNA which, when subjected to DNA gel electrophoresis, migrated as a 














Many colonies were obtained as a result of the amplified gene being ligated into the 
pCRTM 2.1-TOPO vector and subsequent transformation of the ligation mixture into DH5α cells. 
Screening of ten of these colonies by colony PCR revealed that ligation of the hAGT gene into 
the TOPO vector was successful with eight of the ten colonies screened containing a discrete 
band of the expected gene insert size of 1733 bp (when amplified using the M13 forward and 
reverse primers) as shown in Figure 3.2. Colonies that did not contain the hAGT gene had a band 
of approximately 200 bp, which is consistent with the size of PCR product expected when the 
Figure 3.1:  
DNA gel electrophoresis analysis of PCR 
amplification of the human angiotensinogen gene 
from the pET_16b_AGT plasmid (with the addition of 
the KpnI restriction site) to be cloned into 

















C h a p t e r   T h r e e     P a g e   |   6 3    
region between the forward and reverse primer sites is amplified in an empty plasmid (i.e. no 















 Following plasmid purification, both the TOPO-hAGT plasmid and the 
pETDuet_DsbC_BlgA plasmid were subjected to a double restriction digest using the restriction 
enzymes NdeI and KpnI-HF. A double digest of the pETDuet_DsbC_BlgA plasmid was 
performed to remove the BlgA gene from the plasmid, while the TOPO-hAGT plasmid was 
digested to cut the hAGT gene out of the plasmid ready for ligation into the pETDuet_DsbC 
plasmid. Following the digestion, both restricted DNA plasmids were run on an agarose gel 
(Figure 3.3) so that the hAGT gene insert and the restricted vector pETDuet_DsbC vector could 
be purified. As a control, the unrestricted plasmid DNA was also run on the same gel so that 
restriction would be clearly observable and could be differentiated from unrestricted plasmid. 
Figure 3.2:  
DNA gel electrophoresis analysis of colony PCR to check for the presence of the hAGT gene insert, 
carried out on ten of the colonies obtained following ligation of the hAGT gene into the pCRTM 2.1-TOPO 
vector. Colonies 1 and 4 – 10 all contained the correctly sized hAGT gene insert. Colonies 2 and 3 were 
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The intact TOPO_hAGT and pETDuet_DsbC_BlgA plasmids (prior to restriction) did not 
migrate to the expected sizes of 5464 bp and 6610 bp respectively, due to circular DNA having a 
different electrophoretic mobility to linear DNA—it is clear, however, from this gel that 
restriction had indeed taken place, with the restricted TOPO vector and pETDuet_DsbC vectors 
migrating to the expected sizes of 4084 bp and 6130 bp respectively. The hAGT gene insert is 
shown as a discrete band at 1380 bp, as expected, while the BlgA gene was only just visible on 


















Figure 3.3:  
DNA gel electrophoresis analysis of the double restriction digest of the TOPO_hAGT and 
pETDuet_DsbC_BlgA plasmids to isolate the hAGT gene insert and the pETDuet_DsbC plasmid ready 
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Following gel purification and ligation of the hAGT gene into the pETDuet_DsbC vector, cells 
were transformed with the ligation mixture resulting in a total of 15 colonies being obtained. 
Colony PCR screening of these colonies revealed that ten of these colonies contained the hAGT 
gene (confirming successful ligation of the hAGT gene into pETDuet_DsbC), with the insert 
DNA migrating to the expected insert size of 1620 bp, while the remaining five colonies were 
















The pETDuet_DsbC_hAGT plasmid was purified from each of the ten colonies, and 
sequencing confirmed that the hAGT gene had the correct sequence (i.e. no mutations were 
introduced as a result of the cloning procedures) and the gene was in the correct frame of the 
plasmid for expression. 
Figure 3.4:  
DNA gel electrophoresis analysis of colony PCR to check for the presence of the hAGT gene insert, 
following ligation of the hAGT gene into the pETDuet_DsbC vector. Colony PCR screening of five of the 
fifteen colonies obtained is shown. Colonies 1 – 4 contained the correctly sized hAGT gene insert. Colony 
5 was a false positive and contained no gene insert. 
ColoniesDNA Size 
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3.3 CLONING OF THE HAGT GENE INTO PET-SUMO VECTOR 
 
PCR amplification of the human AGT gene (from the pET_16b_AGT plasmid), ready for 
ligation into the pET-SUMO vector, resulted in the generation of a 1359 bp sized fragment of 
DNA (as expected) which, when subjected to DNA gel electrophoresis, migrated as a discrete 













In total, seven colonies were obtained as a result of the amplified gene being ligated into 
the pET-SUMO vector and the subsequent transformation of the ligation mixture into DH5α 
cells. Screening of these seven colonies by colony PCR revealed that ligation of the hAGT gene 
into the pET-SUMO vector was successful with four of the seven colonies screened containing a 
discrete band of the expected gene insert size of 1612 bp (when amplified using the plasmid 
specific SUMO forward and T7 reverse primers) as shown in Figure 3.6. Colonies that did not 
contain the hAGT gene had a band of approximately 200 bp, which is consistent with the size of 
Figure 3.5:  
DNA gel electrophoresis analysis of PCR 
amplification of the human angiotensinogen gene 
from the pET_16b_AGT plasmid ready for cloning 
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PCR product expected when the region between the forward and reverse primer sites is amplified 














The plasmid was purified from each of the four colonies, and sequencing was performed 
to check whether the hAGT gene had the correct sequence (i.e. no mutations were introduced as 
a result of the cloning procedures) and the gene was in the correct frame of the plasmid for 
expression. It was also particularly important to check the orientation of the hAGT gene in the 
pET-SUMO vector. This was because the pET-SUMO cloning system makes use of the TA 
cloning technique, whereby the single 3’-adenylated overhangs, produced by Taq polymerase 
during the extension cycle of PCR, ligate efficiently into the linearised vector containing          
3’-thymidine overhangs. Thus, unlike cloning mediated by restriction enzymes, which provide 
orientation-specific ligation of the gene of interest into the destination plasmid, TA cloning 
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Colonies 
Figure 3.6:  
DNA gel electrophoresis analysis of colony PCR to check for the presence of the hAGT gene insert, 
following ligation of the hAGT gene into the pET-SUMO vector. Colony PCR screening of all seven 
colonies obtained is shown. Colonies 1 – 4 contained the correctly sized hAGT gene insert. Colonies 5 - 7 
were false positives and contained no gene insert. 
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that only one of the four colonies contained the hAGT gene in the correct orientation, the other 
three positive clones contained the hAGT gene ligated into the pET-SUMO vector in the reverse 
orientation.    
 
3.4 EXPRESSION TRIALS 
 
 Having created two different plasmids containing the hAGT gene, in addition to 
obtaining the pET_16b_AGT construct, extensive expression trials were subsequently carried out 
to ascertain the optimum conditions required to overexpress and purify recombinant human 
angiotensinogen to maximise the yield of native pure protein.  
 Several E. coli cell strains were used during expression trials. BL21 (DE3) star cells 
contain a mutation in the RNaseE gene (rne131) that confers enhanced stability of mRNA 
transcripts, compared to the standard BL21 (DE3) strain, leading ultimately to higher yields of 
protein. It was thought that Rosetta (DE3) cells, which supply genes for tRNAs of rare codons on 
the pRARE plasmid, may have helped with the expression of the hAGT gene as it contains 
several codons that are rarely used in E. coli. As another approach, Origami (DE3) cells were 
also trialled as it was thought that these cells may have provided some benefit by aiding in the 
correct folding of the angiotensinogen protein. Mutations in the thioredoxin reductase (trxB) and 
glutathione reductase (gor) genes of these cells have the ability to greatly enhance the formation 
of disulfide bonds in the cell’s cytoplasm. Given that angiotensinogen contains four cysteine 
residues, any misfolding could lead to aberrant disulfide bond formation, and ultimately 
aggregation and insolubility of the recombinant protein.  
Firstly, the pET_16b_AGT construct, which codes for the N-terminally deca-His-tagged  
angiotensinogen protein, was transformed into the three E. coli strains BL21 (DE3) star, Rosetta 
(DE3), and Origami (DE3). SDS-PAGE analysis of these cells, when induced, showed good 
overexpression of the angiotensinogen protein, which migrated to a size of approximately         
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52 kDa on the gels. Unfortunately irrespective of cell strain, growth temperature, expression 
time, or growth media, the angiotensinogen protein was shown to be largely insoluble and was 
found only in the insoluble pellet fraction. Trials with different buffer conditions for lysis, or 
lowering of the IPTG concentration for expression induction (lower IPTG levels may have 
slowed protein expression, increasing the yield of soluble protein), did little to improve the 
solubility of His-tagged angiotensinogen.        
 Secondly, the pETDuet_DsbC_hAGT construct was transformed into BL21 (DE3) and 
Origami (DE3) cells. This construct encodes the gene for untagged human angiotensinogen (49.9 
kDa) which is co-expressed with DsbC, a 23 kDa protein that acts as a disulfide bond isomerise 
and chaperone to facilitate correct disulfide bond formation.166 Despite DsbC expressing well on 
induction with IPTG, no overexpression of angiotensinogen could be observed on SDS-PAGE 
analysis in either E. coli cell strain, regardless of expression temperature or time. Sequencing 
confirmed that the pETDuet_DsbC_hAGT construct contained the hAGT gene in the correct 
frame for expression and the sequence was correct, ruling out any nonsense mutations that could 
result in premature termination of translation. Thus it was unclear as to the reason for the failure 
of this construct to overexpress angiotensinogen, and it was not pursued any further. 
 Finally, the pET-SUMO_hAGT plasmid was transformed into BL21 (DE3) cells. This 
construct, which confers kanamycin resistance, was not trialled in the Origami (DE3) strain due 
this strain’s intrinsic resistance to kanamycin. The pET-SUMO_hAGT plasmid encodes the gene 
for angiotensinogen, with an N-terminal His-tag followed by the SUMO fusion tag prior to the 
start of the angiotensinogen sequence. The SUMO protein, an 11 kDa Saccharomyces cerevisae 
Smt3 protein, has been shown to both increase expression levels and enhance protein solubility, 
and can subsequently be removed by the specific SUMO Protease, Ulp, following expression and 
purification167, 168 and was an approach undertaken successfully by Zhou et al.1 SDS-PAGE 
analysis of cells transformed with this construct showed good overexpression of the SUMO-
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AGT protein following overnight expression, with the SUMO-AGT protein migrating to a size 
of just above 60 kDa (consistent with its expected molecular weight of 63.1 kDa). Although 
insoluble when expressed at 37 °C, what was surprising was the effect that the addition of 1% 
glucose to the growth media had on the solubility of the SUMO-AGT protein when expressed at 
26 °C, as shown in Figure 3.7. Transformed cells cultured and induced in LB media alone led to 
the production of SUMO-AGT which was almost completely insoluble and present in the pellet 
fraction. Addition of 1% glucose to the growth media dramatically enhanced the solubility of the 
SUMO-AGT protein, so much so that the SUMO-AGT protein was now completely soluble and 




































 Figure 3.7: 
SDS-PAGE analysis of BL21 (DE3) cells expressing the SUMO-AGT protein at 26 °C. The molecular 
weight marker (Novex® Sharp Pre-stained Protein Standard) was loaded in lanes 1 and 9. Uninduced cells 
were run in lane 2. Lanes 3, 4, and 5 contain the total cell lysate, pellet, and soluble fractions, 
respectively, of cells induced with IPTG and grown in LB media supplemented with 1% glucose. Lanes 6, 
7, and 8 contain the total cell lysate, pellet, and soluble fractions, respectively, of cells induced with IPTG 
and grown in LB media alone. Cells were lysed with CelLytic B and 0.2 mg/mL lysozyme, which can be 
seen on the gel at a MW of 14.3 kDa.     
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How can glucose make such a difference to the solubility of the SUMO-AGT protein? 
Glucose appears to play a modulative role in the regulation of recombinant protein expression. 
Expression of the SUMO-AGT protein from the pET-SUMO_hAGT plasmid is under the 
regulatory control of the T7lac promoter. Until induction, expression of the T7 RNA polymerase 
(regulated by the lacUV5 promoter of the host strain) is repressed because the Lac repressor, 
LacI, is bound to the promoter region preventing its transcription by other RNA polymerases.169-
171 When allolactose, or its synthetic mimic IPTG, is added to the bacterial culture, it binds to the 
Lac repressor and alleviates repression, paving the way for the transcription and expression of T7 
RNA polymerase, which, now unregulated, is free to bind to the T7 promoter on the pET-
SUMO_hAGT plasmid and transcribe the hAGT gene, inducing expression of the SUMO-AGT 
protein. In a perfect system, the repression of expression would be complete such that no leaky 
expression of the desired protein would occur. However, this is rarely the case. Despite the 
increased level of repression of the T7lac promoter over the standard T7 promoter, some leaky 
expression of the desired protein prior to induction will often be observed due to the occasional 
expression and high activity of T7 RNA polymerase169, 171—which is where glucose comes in. 
The addition of 1% glucose is able to maintain tight regulation of the promoter and reduce basal 
or leaky protein expression by preventing the accumulation of cyclic adenosine monophosphate 
(cAMP) within the cell.171 cAMP accumulation, in the absence of glucose, initiates transcription 
of the gene for T7 RNA polymerase from the lacUV5 promoter, even in the absence of inducer, 
by activating the catabolite gene activator protein (CAP).169, 171 Thus glucose plays a role in 
catabolite repression, greatly decreasing any undesired expression of the protein of interest prior 
to induction.  
Although, little to no basal expression of the SUMO-AGT protein was evident in the 
uninduced cells by SDS-PAGE analysis (Figure 3.7), this does not rule out that small levels of 
expression of SUMO-AGT may be occurring prior to induction. Cells cultured in the presence or 
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absence of glucose showed very little difference in their rates of growth, thus it appears that 
glucose might simply be slowing down the rate of transcription and expression of the SUMO-
AGT protein by maintaining cAMP levels to a minimum until all the glucose is used up. With 
glucose slowing protein expression so that SUMO-AGT is not being produced at a breakneck 
pace within the cell on induction, there appears to be a higher yield of soluble protein possibly 
by allowing more time for correct folding, as well as by slowing the huge accumulation of the 
SUMO-AGT protein intracellularly, since aggregation and inclusion body formation is far more 
likely as protein concentrations increase within the cell.163, 164          
 With expression conditions optimised, several lysis methods were trialled to ascertain the 
best and most facile way to lyse the cells for larger scale expression to obtain the highest yield of 
soluble SUMO-AGT for purification. The three means of cell lysis trialled were sonication, cell 
homogenization, and CelLytic B. Sonication is a common method of bacterial cell lysis that is 
carried out by immersing a probe in the cell suspension that gives off pulses of high frequency 
sound waves which shear cells.165, 172 Although commonly employed for cell lysis, it has the 
disadvantage of generating heat, resulting in denatured protein, and thus sonication is carried out 
on ice to minimise heat generation. A much gentler alternative to sonication is to use a cell 
homogenizer that uses high pressure to lyse cells by shear forces, which, depending on the 
protein of interest, can result in higher yields of soluble protein than sonication165, 172—the only 
disadvantage being that much larger volumes of cell suspensions (>20 mL) are required for this 
lysis method. Lastly, CelLytic B is another method of cell lysis (employed during expression 
trials) that facilitates the gentle lysis of bacterial cells by the action of non-denaturing 
zwitterionic detergents aided by the addition of lysozyme. As opposed to sonication and the cell 
homogenizer, CelLytic B tends to result in much higher yields of the protein of interest,173 but 
although it will not solubilise inclusion bodies, CelLytic B does tend to solubilise a larger 
amount of the other proteins present in the cell lysate compared to other lysis methods, which 
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could complicate downstream purification strategies, and it also adds a substantial amount of 
detergent to the protein extract, which would need to subsequently be removed.  
 The results of lysis trials are shown in the SDS-PAGE gel in Figure 3.8. Sonication led to 
mostly insoluble SUMO-AGT, although a small proportion was present in the soluble fraction. 
Lysis by the cell homogenizer also led to a large amount of insoluble SUMO-AGT, but there was 
still a substantial amount present in the soluble fraction. CelLytic B lysis, on the other hand, led 
to completely soluble SUMO-AGT protein; in fact lysis by this method resulted in virtually no 
insoluble material at all with only a very small pellet obtained following centrifugation of the 
cell lysate. Due to CelLytic B’s propensity to solubilise everything in the cell lysate, including 
two protein bands that sit just below the band of SUMO-AGT on the gel (Figure 3.8) which also 
overexpress on induction with IPTG, it was decided that cell homogenization would be used as 
the method of cell lysis prior to purification despite its lower yield of soluble protein. Although 
the nature of these two proteins with a similar molecular weight to SUMO-AGT was not known, 
given that their expression was induced by IPTG, it is possible that these are truncated SUMO-
AGT proteins, shortened either due to early termination of transcription/translation or through 
proteolytic degradation following lysis. If this is the case, then their presence in the soluble 
fraction of the cell-lysate could unnecessarily complicate purification. Thus, cell homogenization 
was chosen as the preferred method for cell lysis.           
 
3.5 EXPRESSION AND PURIFICATION OF HUMAN ANGIOTENSINOGEN 
 
With expression and lysis conditions for the SUMO-AGT protein optimised, larger-scale 
expression and purification could now be carried out. Cells expressing SUMO-AGT 
overexpressed the protein just as well in larger culture volumes (500 mL) as they did in smaller 
cultures. Cells were lysed by cell homogenisation in a buffer containing 50 mM potassium



















phosphate, 400 mM sodium chloride, 100 mM potassium chloride, 10% glycerol, 0.5% Triton X-
100, and 10 mM imidazole at pH 7.8 (Lysis Buffer, see Appendix). Protein was purified by 
IMAC (cobalt resin) followed by size exclusion chromatography resulting in highly pure 
SUMO-AGT. Figure 3.9 shows the various fractions resulting from the His-tag affinity 
purification (IMAC) step. SUMO-AGT (63.1 kDa) bound well to the resin and eluted at an 
imidazole concentration of 50 mM with a couple of other protein species which had a MW of   
30 kDa or less. Spin concentration, with a 30,000 MWCO concentrator, of the pooled fractions 
Figure 3.8: 
SDS-PAGE analysis of BL21 (DE3) cells expressing the SUMO-AGT protein at 26 °C lysed by three 
different methods. The molecular weight marker (Novex® Sharp Pre-stained Protein Standard) was 
loaded in lane 1 while uninduced cells were loaded in lane 8. Lanes 2, 3, and 4 contain the total cell 
lysate, pellet, and soluble fractions, respectively, of cells lysed by sonication. Lanes 5, 6, and 7 contain 
the total cell lysate, pellet and soluble fractions, respectively, of cells lysed using the cell homogenizer. 
Lysis by CelLytic B and lysozyme is displayed in the last three lanes, with lanes 9, 10, and 11 containing 
the total cell lysate, pellet and soluble fraction, respectively. All samples were lysed in Lysis Buffer. 
MW 




















C h a p t e r   T h r e e     P a g e   |   7 5    
containing SUMO-AGT served not only to concentrate the protein but also to remove the 


















 Size exclusion chromatography using a gel filtration column (24mL Superdex 200) was 
used as a final polishing purification step. By separating proteins according to size,165 gel 
filtration allowed the removal of the smaller proteins from the purified protein resulting in a pure 
sample of SUMO-AGT. This step was also used as a means of buffer exchange to remove the 
imidazole from the protein buffer. Elutions were collected in 1 mL fractions and SDS-PAGE 
analysis revealed that SUMO-AGT eluted as the first big peak (see Figures 3.10 and 3.11) with a 
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Elution Fractions
Figure 3.9: 
SDS-PAGE analysis of IMAC purification of SUMO-AGT from cell lysate using HisPur cobalt resin. The 
first lane contains the molecular weight marker (Novex® Sharp Pre-stained Protein Standard). 
Subsequent lanes contain the total cell lysate, the pellet fraction, and the soluble fraction (what was 
loaded onto the column), followed by the flow through and wash fractions as labelled. The lane 
containing the bound resin shows SUMO-AGT bound well to the resin. The SUMO-AGT protein was 
eluted in PBS pH 7.4 containing 50 mM imidazole and collected in 1 mL fractions.  
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smaller peak with a maximum at approximately 26 mL were also subjected to SDS-PAGE 
analysis but no protein was present in these fractions at concentrations visible on the gel. Seven 
elution fractions corresponding to the elution from 10 mL to 16 mL in Figure 3.10 and 3.11 were 
pooled and concentrated as they contained the majority of the SUMO-AGT protein and 














Finally, cleavage of the SUMO fusion tag, including the N-terminal His-tag, was carried 
out using SUMO Protease to release native untagged recombinant human angiotensinogen. By 
running the cleavage reaction through an IMAC column, the pure untagged angiotensinogen was 
collected in the flow through, while the SUMO tag, SUMO Protease, and any uncleaved SUMO-
AGT remained bound to the resin. Figure 3.12 summarises the entire purification of SUMO-
AGT including the final cleavage and purification step which gave rise to pure recombinant 
human angiotensinogen (49.8 kDa). 
Figure 3.10: 
Size exclusion chromatograph of SUMO-AGT purified on a 24 mL Superdex 200 gel filtration column at 
4 °C at a flow rate of 0.25 mL/min.  Elutions were collected in 1 mL fractions. The main peak from 10 
mL of elution contained pure SUMO-AGT, while smaller protein species began to elute from 
approximately 16 mL onwards corresponding to the shoulder of the main peak.      
















Although cleavage of the SUMO tag results in pure untagged angiotensinogen which was 
the ultimate goal, a large amount of protease would be required to obtain sufficient amounts of 
angiotensinogen since 1 unit of SUMO Protease is defined as the amount of protease required to 
cleave 2 μg of fusion protein in 1 hour at 30 °C. Thus, 500 units of SUMO Protease would be 
required to generate only 1 mg of native recombinant angiotensinogen, assuming 100% 
cleavage, which sharply raises the cost of producing angiotensinogen recombinantly. In addition, 
an undesired outcome of the cleavage reaction is the reduction of angiotensinogen’s Cys 18 and 
Cys 138 disulfide bond due to the dithiothreitol (DTT) present in the protease buffer, required 
for the activity of SUMO Protease—meaning that the angiotensinogen would no longer be 
present in the oxidised disulfide bonded form needed for further experiments. Because of this, it 
was decided that pure recombinant angiotensinogen would be left with the SUMO fusion tag 
Figure 3.11: 
SDS-PAGE analysis of size exclusion chromatography elution peak fractions from the purification of 
SUMO-AGT. The MW ladder (M; Novex® Sharp Pre-stained Protein Standard) is in the first lane and 
subsequently each SEC fraction is labelled to correspond to the elution fraction (in mL) displayed on the 
elution profile in Figure 3.10 above. Smaller protein species are indicated by the green arrows (  ) on 
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intact, greatly reducing the costs of recombinant production of the human angiotensinogen 
protein, as well as preventing the unintentional reduction of the disulphide bond between the two 



























SDS-PAGE analysis of the entire expression and purification of recombinant human angiotensinogen. 
Each lane is labelled appropriately from the cell lysate fractions of BL21 (DE3) cells expressing SUMO-
AGT to the protein following His-tag purification (IMAC) and subsequent gel filtration (SEC) purification 
steps, and finally tag cleavage resulting in pure angiotensinogen. The MW ladder (Novex® Sharp Pre-


















C h a p t e r   T h r e e     P a g e   |   7 9    
3.6 EXPRESSION AND PURIFICATION OF SUMO-CAT 
  
The decision to leave the SUMO tag intact on recombinant human angiotensinogen 
meant that it was important to have another SUMOylated protein as a negative control for SPR 
experiments to ensure that the SUMO fusion protein was not responsible for any interactions 
observed. For this reason, SUMOylated chloramphenicol acetyltransferase (SUMO-CAT), 
encoded by the pET SUMO/CAT plasmid that was supplied with the pET SUMO Protein 
Expression System kit as an expression control, was expressed and purified for use as a 
SUMOylated negative control. CAT is the enzyme responsible for bacterial resistance to the 
antibiotic chloramphenicol, serving to inactivate the antibiotic by catalysing the O-acetylation of 
chloramphenicol, which prevents the antibiotic binding to its site of action on the ribosome.174  
The SUMO-CAT fusion protein expressed well following induction with IPTG, 
migrating to a size of just below 40 kDa on an SDS-PAGE gel which is consistent with its 
molecular weight of 39 kDa. The fusion protein is highly soluble, with only a very small amount 
of the protein present in the insoluble pellet on centrifugation to clarify the cell lysate following 
lysis by cell homogenization (see Figure 3.13). Figure 3.13 summarises the entire expression and 
purification of the SUMO-CAT protein. Purification of SUMO-CAT was carried out in the same 
way as purification for SUMO-AGT, the only difference being the concentration of imidazole 
required in the elution buffer to elute the protein from the HisPur cobalt resin during His-tag 
purification. In contrast to SUMO-AGT, which eluted at a concentration of 50 mM imidazole, 
the majority of SUMO-CAT did not elute until a concentration of 150 mM imidazole was flowed 
through the column. IMAC purification resulted in reasonably pure SUMO-CAT, and the 
subsequent gel filtration step did little to further purify the protein, but since this protein was 
required as a negative control only, additional purification steps were deemed unnecessary. 
 
 





















 Recombinant human angiotensinogen was successfully expressed and purified from 
BL21 (DE3) E. coli cells. Extensive expression trials with three different plasmids encoding the 
human angiotensinogen gene, several expression hosts, and different expression conditions 
revealed that soluble protein could be obtained when angiotensinogen was expressed with the 
SUMO fusion tag at 26 °C in LB media supplemented with 1% glucose. Cell homogenization 















SDS-PAGE analysis of the entire expression and purification of recombinant SUMO-CAT fusion 
protein. Each lane is labelled appropriately from the cell lysate fractions of BL21 (DE3) cells expressing 
SUMO-CAT to the protein following His-tag purification (IMAC) and subsequent gel filtration (SEC) 
purification steps.  The MW ladder (Novex® Sharp Pre-stained Protein Standard) was loaded in the first 
lane and uninduced cells were loaded in the second lane. 
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protein was subsequently purified from the cell lysate by a two-step purification involving firstly 
immobilised metal ion affinity chromatography to isolate the His-tagged protein, followed by 
size exclusion chromatography to remove any proteins that co-eluted with SUMO-AGT in the 
first purification step, resulting in pure recombinant SUMOylated human angiotensinogen.  
The SUMO fusion tag could then be cleaved off the purified fusion protein with SUMO 
Protease to produce pure recombinant human angiotensinogen. It was decided to leave the 
angiotensinogen protein tagged, however, not only to minimise recombinant protein costs, but 
also to prevent the reduction of the disulphide bond between Cys 18 and Cys 138, which came 
hand in hand with tag cleavage due to the reducing agent present in the protease buffer that was 
essential for the protease’s activity. Lastly, another SUMOylated protein, SUMO-CAT, was 
expressed and purified in a similar manner in order that it could be used as a negative 
SUMOylated control protein in SPR experiments. 
 








 Surface plasmon resonance (SPR) is an optical technique that has provided a versatile 
tool for researchers as they attempt to understand, characterise, and marvel at the diverse, 
numerous, and at times unpredictable interactions between biomolecules that exist in our natural 
world. Although the technique itself was first described in 1968,175 it wasn’t until the 1990’s that 
SPR biosensors became available in a commercial capacity for research purposes.176 SPR 
biosensors offer the advantage of being able to monitor biomolecular interactions in real-time, 
and are versatile, sensitive, and automated,176-179 ultimately providing the ideal platform for the 
rapid label-free analysis of the interactions that take place between a diverse range of 
biomolecules including proteins, DNA, antibodies, and small molecules.176, 179 Carefully 
designed SPR experiments can yield a large amount of information about the interaction being 
investigated, including whether the molecules do indeed interact, the elucidation of kinetic 
association and dissociation constants, and information in support of proposed binding 
mechanisms.141, 142, 179, 180 It is no wonder, therefore, that this technique is commonly used to 
characterise interactions between biomolecules with over 1400 articles published annually 
describing experiments involving biosensors.141, 142, 177 
 SPR biosensors such as the BiacoreTM (GE Healthcare) and Biorad’s ProteOnTM XPR36 
make use of chip-based technology, an autosampler, a microfluidics system and an optics system 
that communicates with a computer so that the interactions can be monitored in real-time.179, 180 
To investigate the interaction between two proteins, one protein (termed the ligand) is typically 
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immobilised covalently on the surface of a sensor chip by making use of one of many surface 
chemistries available.176 The second protein, known as the analyte, is then injected, flowed 
across the sensor chip surface in aqueous solution, and allowed to interact with the immobilised 
ligand. Analyte molecules accumulate on the sensor chip surface as the binding phase proceeds, 
and this increase in mass, at or close to the surface of the chip (within approximately 100 nm), 
results in an increase in refractive index.141, 179, 181 This change in refractive index is measured 
and plotted in real-time as response units (RU) vs time,180 resulting in the generation of a 
sensorgram as depicted in Figure 4.1.  
Following this association phase where the two proteins interact, running buffer is flowed 
continuously across the immobilised ligand surface to allow the bound complex to dissociate, 
and this is typically referred to as the dissociation phase (see Figure 4.1). If the sensorgram has 
not returned to baseline following dissociation, some analyte may remain bound to the ligand, 
and a regeneration step may be needed to remove any remaining bound analyte, typically using 
short pulses of low or high pH, high salt, or detergents.180 These biosensors are so sensitive that 
even small changes in the ionic strength or pH of a buffer will result in a change in the refractive 
index that will be detected by an SPR machine, thus much care must be taken in the preparation 
of all buffers and solutions to be used on these machines to prevent aberrant or false responses. 
In addition, careful consideration must be made to ensure the appropriate control surfaces are 
used for referencing to correct for differences in the refractive index of the samples, as well as 
any non-specific binding that may occur.180, 181 
The ProteOnTM XPR36 is particularly powerful in that it facilitates up to 36 different 
interactions to be measured simultaneously through the use of a 6 x 6 array of six horizontal and 
six vertical channels on a single chip.177, 179 Details of the sensor chip used by the ProteOnTM 
XPR36 are shown in Figure 4.2. The chip itself is composed of a glass prism with a very thin 
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gold layer on the top surface (Figure 4.2a). Above the gold layer, is a thin layer of a carboxylated 
alginate polymer (much like tangled netting), allowing immobilisation of ligand molecules close 
to the chip surface via a variety of immobilisation surface chemistries.179, 180 Ligands can be 
immobilised in the six vertically-orientated ligand channels, and following a 90° rotation, analyte 
molecules are flowed through the six parallel horizontally-orientated analyte channels177, 179 
(Figure 4.2b and 4.2c). This 6 x 6 array created by the intersection of the vertical and horizontal 
channels facilitates a multiplexing approach to data collection, allowing data to be collected at 36 
data points simultaneously in one experiment—a technique which is referred to as One-shot 
KineticsTM.179 This approach was further extended by Abdiche et al. who described a method to 
create a 36-ligand array,177 vastly improving high-throughput analysis of analyte-ligand pairs, 
and streamlining assay development.  
Because of the many advantages offered by the ProteOnTM XPR36, in addition to the 
SPR technique’s sensitivity and ability to probe biomolecular interactions in real-time, this SPR 
instrument was chosen for the development of an assay for angiotensinogen. Although there are 
reports in the literature of components of the RAS system being studied with SPR, most of the 
literature concerns the binding of (pro)renin to the (P)RR receptor, or the binding of inhibitors 
such as aliskiren to renin, immobilised primarily using a capture approach.36, 103, 182, 183 Very little 
SPR work has been published involving angiotensinogen however, with only a single paper 
found after an extensive literature search. Cohen et al. used a BiacoreTM instrument to measure 
the kinetic constants of the M235 and T235 variants of angiotensinogen to antibodies, as part of 
their work towards developing an immunoassay that allows the determination of the 
concentration of angiotensinogen, as well as the ratio of the two clinically relevant 
angiotensinogen variants in plasma.25 Unfortunately, the authors only published the resulting 
kinetic constants of the analysis, and failed to present the measured data or the resulting fitted 
models, so it is difficult to glean much information from their SPR experiments. 





















In the work described in this chapter, several different approaches to detect 
angiotensinogen were used to develop a bioassay for this protein. The first approach employed 
the use of antibodies raised against angiotensinogen and is described in Section 4.2. As an 
alternative approach, Section 4.3 describes the immobilisation of renin directly onto the chip 
surface, providing yet another way to detect angiotensinogen using SPR technology. 
Figure 4.2: 
Schematic representation of a ProteOnTM XPR36 sensor chip (a) consisting of a glass prism coated with 
a thin layer of gold on the top surface of the chip. Above this is a layer of modified alginate polymer on 
which ligand is immobilised covalently. A 6 x 6 array (b) is formed on the chip due to the six vertical 
ligand channels (blue) and six horizontal analyte channels (pink) intersecting (purple) allowing up to 36 
ligand-analyte interactions to be measured simultaneously in a single run. Due to the perpendicular 
nature of the array, analyte flowed through one channel is able to interact with all six ligand channels 
(c).   
Glass Prism 
Modified Alginate 
Polymer Layer Gold Surface 
a)  b)
c) 
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4.2 SPR BIOASSAY FOR ANGIOTENSINOGEN USING AN ANTIBODY 
 
 This bioassay development required the use of antibodies raised against human 
angiotensinogen. The ‘human serpin A8/angiotensinogen antibody’ (clone # 369439) produced 
by R&D Systems was primarily used in the following experiments, and will be referred to as 
‘anti-AGT mAb’ from now on. This antibody is a monoclonal mouse IgG1 antibody that was 
raised against full length recombinant human angiotensinogen (derived from a mouse myeloma 
cell line). Although this antibody has not been epitoped, it has been shown to have no cross-
reactivity with other human serpins that may be present in plasma (see product datasheet). A 
second antibody produced by Santa Cruz Biotechnology, ‘angiotensin (N-10)’ (polyclonal goat 
antibody sc-7419) was also trialled initially, but due to inconsistencies in the antibody’s response 
to angiotensinogen using SPR, the use of this antibody in a bioassay was not pursued further. 
 The first step in developing this SPR assay involved identifying the optimum conditions 
for immobilisation of the anti-AGT mAb onto the sensor chip surface. The level of ligand 
immobilisation, and hence the density of the ligand molecules on the sensor chip surface, is 
critical for obtaining good kinetic results—too high and the reaction can become limited by mass 
transport effects,180, 181 too low and the response on analyte binding will be too low to be 
distinguished from instrument noise. Mass transport limitations occur when the rate of analyte 
diffusion from the aqueous solution to the chip surface (mass transport) is slower than the rate of 
the analyte binding to the immobilised ligand, resulting in mass transport being the rate-limiting 
step, and ultimately alteration of the apparent kinetics of analyte binding.181 Fortunately, mass 
transport limitations can be minimised in most cases by lowering the ligand density and 
increasing the flow rate.180, 181 Working with lower density surfaces tends to result in more 
random short-term noise in binding responses, but this is generally preferred to the artefacts such 
as complex binding events and mass transport limitations that can occur with higher density 
ligand surfaces.142 
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 Amine coupling was chosen to immobilise the anti-AGT mAb antibody onto the surface 
of the sensor chip. This is by far the most straightforward and commonly used method for 
tethering ligands to sensor chip surfaces.180, 184 For amine coupling, the chip surface is activated 
by using EDAC/NHS to activate the carboxyl groups of the carboxymethyl polymer layer to 
create reactive succinimide esters, leaving the carboxyl groups particularly poised to react 
directly with the primary amines present on the antibody’s surface (primarily lysine residues), 
resulting in a covalent attachment or tethering of the antibody onto the chip surface180, 181, 184 
(Figure 4.3). The sensor chip surface is then deactivated with ethanolamine HCl to block any 
unreacted succinimide esters, preventing any further reaction with primary amines. This step also 













Activation and deactivation were carried out according to the default ProteOnTM XPR36 
settings. Trials of the anti-AGT mAb in a sodium acetate buffer of varying pH revealed that 
sodium acetate pH 4 was the optimal coupling buffer, facilitating the highest levels of 
Figure 4.3: 
A schematic representation that depicts amine coupling immobilisation of a protein ligand to a sensor 
chip surface. The carboxyl groups on the polymer layer of the chip surface are activated with 
EDAC/NHS to create reactive succinimide esters which readily react with the primary amines present on 
lysine residues on the protein ligand to create a covalent irreversible bond to the chip surface.   
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immobilisation. Different levels of ligand immobilisation were trialled by varying the 
concentration of the anti-AGT mAb from 5 μg/mL to 0.75 μg/mL, which gave immobilisation 
levels from as high as 2000 RU down to approximately 250 RU. Subsequent optimisation and 
experiments were carried out with the lowest concentration of anti-AGT mAb trialled           
(0.75 μg/mL), as the resulting immobilised ligand density still gave adequate binding responses 
when tested with recombinant angiotensinogen, and was the surface least likely to be affected by 
any mass transport effects making it ideal for carrying out kinetic measurements. The 
sensorgram obtained from the activation, immobilisation, and deactivation of the surface using 















Because the association rate of the binding of angiotensinogen to the anti-AGT mAb was 







The sensorgram obtained when 0.75 μg/mL anti-AGT mAb antibody is immobilised via amine coupling to 
the sensor chip surface of a GLC chip. The surface is first  activated with a 1:1 mixture of EDAC/NHS 
before the ligand is immobilised  in a coupling buffer of sodium acetate pH 4. The surface is then 
deactivated  with ethanolamine HCl pH 8. The increase in RU following deactivation (from baseline 
prior to activation) is indicative of the level of ligand immobilised on the sensor chip surface. 
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optimised to obtain maximal curvature and height of the binding response curves, allowing the 
concentration-dependent responses of angiotensinogen binding to be observed and more accurate 
kinetic analysis to be performed. The ProteOnTM XPR36 machine operates with a maximum set 
injection volume, meaning that the maximum association or contact time, is determined by the 
flow rate—the slower the flow rate, the longer the contact time. Flow rates from 100 μL/min to 
25 μL/min were trialled and the slower flow rates were shown to have no effect on the slope of 
the association curve, indicating that slowing the flow rate down does not increase mass 
transport limitations in this case. Slower flow rates did allow the association phase to be 
substantially extended, and with the use of 2 mL deep well microplates rather than the standard 
0.35 mL well microplates, a total contact time of 981 seconds (16 minutes and 21 seconds) could 
be achieved with a flow rate of 25 μL/min. Longer contact times were beyond the machine’s 
capability because injection volumes of greater than 409 μL were not permitted. The ProteOnTM 
XPR36 does offer the co-inject function that allows a second injection of analyte, enabling the 
contact association time to be extended further, but when trialled, the second injection introduced 
anomalies in the sensorgram at the point of the second injection which would not allow accurate 
kinetic analysis to be carried out, and it was decided not to use the co-inject function in further 
experiments. A long dissociation time of 1800 seconds (30 minutes) was chosen following 
association, to allow sufficient dissociation to occur so that observable decay was visible.  
Another parameter that needed to be optimised was the concentrations of 
angiotensinogen to be used in analyte interaction runs. The ability to run six different analyte 
concentrations simultaneously in parallel greatly streamlined this process as it meant that a 
whole dilution series of concentrations could be screened in a single run. Concentrations up to 
and including 3 μM of recombinant His-tagged or SUMO-tagged angiotensinogen were screened 
and gave binding responses of up to 50 RU. The major limiting factor in this process was the 
availability of recombinant angiotensinogen, as each run required a substantial amount of protein 
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due to the large injection volume. With replicates and all of the optimisation required prior to 
final data collection, this amounted to a considerable amount of angiotensinogen being 
consumed. Had more protein been readily available, data could have been collected at higher 
analyte concentrations, which may have allowed ligand saturation to be reached.  
 In order for this anti-AGT mAb surface be reused for multiple runs, regeneration 
optimisation had to be carried out to ensure that the surface adequately regenerated, so that the 
results of one analyte run could be accurately replicated. Demonstrating that an assay is 
repeatable and gives reproducible results over multiple runs is crucial for a robust assay and is 
one step towards showing that a given set of results is valid. If regeneration conditions are too 
harsh, the antibody surface will become damaged and a loss of activity will result in a decrease 
in binding response over subsequent regeneration cycles. Conversely, if the regeneration 
conditions are not harsh enough, some angiotensinogen will be left bound to the antibody surface 
following each analyte run, leading to a decrease in binding capacity through time. Regeneration 
for 18 seconds and 36 seconds using glycine HCl at pH 2.0, 2.5 and 3.0 was carried out over 
multiple cycles to determine the optimal conditions. A pulse of glycine HCl at pH 2.0 for 18 
seconds was deemed sufficient to remove all remaining bound angiotensinogen without causing 
any significant loss of antibody activity, allowing the ligand surface to bind angiotensinogen 
reproducibly over many runs. 
 Finally, an appropriate surface had to be chosen as a reference to correct for any non-
specific binding of the analyte to the surface as well as any differences in the refractive index 
between the sample buffer and running buffer. A blank channel, either unactivated, or activated 
and deactivated, could have been employed as the reference surface, but after careful 
consideration it was decided that anti-IgG mAb (a mouse IgG antibody) would instead be 
immobilised on a ligand channel at the same concentration as anti-AGT mAb and used as a 
reference channel, as this would most closely approximate the environment of the anti-AGT 
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mAb surface. Further systemic artefacts during a run could be corrected by double referencing 
the binding responses against an injection in the analyte direction containing only buffer.    
 With all optimisation complete, the assay was ready for use to measure the binding of 
recombinant angiotensinogen. The assay was primarily used to measure the binding of His-
tagged angiotensinogen, which is described in the next chapter. The binding responses observed 
when SUMO-AGT was used as the analyte are shown in Figure 4.5. The analyte interaction run 
was carried out as optimised above, in a running buffer of PBST pH 7.4 at a flow rate of 25 
μL/min for a total contact and dissociation time of 981 seconds and 600 seconds respectively. 









The sensorgram obtained when a dilution series of recombinant SUMOylated human angiotensinogen is 
flowed across an anti-AGT mAb antibody surface. SUMO-AGT was flowed across the surface at a flow 
rate of 25 μL/min for a total contact time of 981 seconds. Following association, running buffer was 
flowed across the surface for 10 minutes to allow dissociation to occur.  
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angiotensinogen, giving a maximal response of approximately 50 RU. The binding did not reach 
ligand saturation, which may have been achieved with higher analyte concentrations, but there is 
sufficient curvature for kinetic analysis to be carried out.     
Unlike responses with His-tagged angiotensinogen, which fit to a simple 1:1 interaction 
model, kinetic analysis of the responses obtained with SUMOylated angiotensinogen revealed 
that SUMO-AGT displayed more complex binding. A simple 1:1 Langmuir binding model 
describes the reaction that occurs between two molecules (analyte, A, and ligand, B) to form the 
complex AB (analyte-ligand complex) which can be written as the following equation: 
 
A + B    AB   (1) 
  
where ka is the association rate constant and kd is the dissociation rate constant. This relationship 
gives rise to the kinetic rate equation: 
 
     =   ka[A][B] – kd[AB]   (2) 
 
with [A] denoting the concentration of free analyte, [B] the concentration of immobilised ligand, 
and [AB] describes the concentration of analyte-ligand complex. This model assumes that the 
analyte and ligand are homogenous and that all binding events are independent,180, 181 and would, 
in general, be the kinetic model expected when a monoclonal antibody binds an antigen, as it 
recognises a single epitope on the antigen’s surface. Using ClampXP, fitting of this kinetic 
model to the SUMO-AGT responses resulted in a poor fit of the model when overlaid with the 
measured data, however, as shown in Figure 4.6. Several other kinetic models for more complex 
binding events were also tested to ascertain whether a better fit could be obtained (Figure 4.6). 



























complex, which could be the case if the binding of SUMO-AGT to the mAb triggered a 
conformational change (AB)* in the bound complex AB,185 described by the following equation: 
   






Kinetic fits of responses obtained when SUMO-AGT binds to the anti-AGT mAb surface. The data is 
shown in black, while the kinetic fits are overlaid in colour. The four kinetic models (simple 1:1 
Langmuir binding, conformational change, mass transport, and surface heterogeneity) were fit to the 
same data displayed in Figure 4.5 using ClampXP software. 
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   The mass transport kinetic model incorporates a term km that describes the initial rate of mass 
transport of the analyte to the ligand-bound surface,186 and is described by Equation 4: 
 
Abulk   Asurface +  B   AB  (4) 
 
 The fourth and final model trialled was the surface heterogeneity model, which makes the 
assumption that there are two separate binding events occurring that contribute to the binding 
responses observed. This would be the case if a ligand has two sites capable of binding an 
analyte (denoted by B and B*),186 or in the case of polyclonal antibodies which recognise more 
than one epitope on the antigen’s surface. This type of binding can be described by Equations 5 
and 6, and observed responses are a sum of both reactions occurring on the surface at the same 
time. 
 
   A + B    AB    (5)  
 
   A + B*   AB*    (6) 
 
  Of the four models trialled, only the surface heterogeneity model was shown to provide a 
good fit to the observed binding responses (Figures 4.6 and 4.7a). The residuals for this kinetic 
fit (Figure 4.7b) are low and randomly distributed, indicating a good fit to the data set. 
Interestingly, although each model returned vastly different association and dissociation rates, 
three of the four models (1:1 Langmuir binding, surface heterogeneity, and mass transport) gave 
KD values of approximately 150 nM, which is in good accordance with the KD values obtained 
































including their associated errors are displayed in Table 4.1, along with the values obtained when 
the data were fit to the simple 1:1 binding model and the mass transport model (even though 
these two models do not provide a good fit to the data) for comparison.  
Figure 4.7:  
Results of the model fitting of the surface heterogeneity model to the binding responses of SUMOylated 
angiotensinogen to the anti-AGT mAb surface. The model (a) is shown in red overlaid on the measured 
data in black. The residual plot of the model fitting is shown in (b).   
a) 
b) 
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 Little information can be obtained from these kinetic analyses, however, and it is 
difficult to know which model is the correct one. While a good kinetic fit can, along with other 
experimental data, provide evidence in support of a proposed binding mechanism, it does not in 
itself validate a model. It is important to note that much care must be taken when evaluating 
different binding models to fit data as to whether the chosen model accurately describes the 
events physically taking place on the sensor chip surface, as several models could produce a 
similar fit to the same data. In fact, Rich et al. warn against ‘model surfing’ and stress that the 
simpler the binding model, the better, as it more likely approximates the binding events that are  
actually occurring.142 Given that the kinetics of SUMO-AGT binding to the anti-AGT mAb show 
a complex binding mechanism, which deviates from the observed simple 1:1 binding of His-




Model and Equation ka (M
‒1 s‒1) kd (s
‒1) KD (nM) 
Simple 1:1 Langmuir binding model: 
 A + B → AB 
 
2183 ± 7 
 
(3.10 ± 0.05) x 10-4 
 
142 ± 2 
Mass Transport 1:1 binding model: 
 A + B → AB 
 
2185 ± 10 
 
(2.98 ± 0.05) x 10-4 
 
137 ± 2 
Surface heterogeneity model: 
 A + B → AB 
 A + B* → AB* 
 
7452 ± 214 
1300 ± 19 
 
(1.12 ± 0.04) x 10-3 
(3.89 ± 0.01) x 10-7 
 
150 ± 6 
30 ± 11 
Table 4.1:  
Kinetic constants obtained from the model fitting of the simple 1:1 Langmuir binding model, the mass 
transport 1:1 binding model, and the surface heterogeneity model to the binding responses of 
SUMOylated angiotensinogen interacting with the anti-AGT mAb surface. Model fitting was carried out 
using the ClampXP program. 
C h a p t e r   F o u r       P a g e   |   9 8    
alteration in kinetic behaviour may be due to the SUMO tag itself. As a negative control, 
SUMOylated CAT was flowed across the anti-AGT mAb surface as an analyte under the same 
conditions and no interactions were observed. Thus, it seems probable that while the SUMO tag 
itself does not bind to the antibody, the SUMO portion of the recombinant fusion protein may be 
altering the structure of the angiotensinogen molecule in such a way that non-simple 1:1 binding 
is displayed. 
 Overall, this assay set-up and optimisation has shown that it is possible to set up and 
assay recombinant angiotensinogen using SPR in a repeatable manner to give reproducible 
results, by utilising the anti-AGT monoclonal antibody supplied by R & D Systems. Although 
meaningful kinetic fits to the SUMOylated angiotensinogen binding responses could not be 
obtained, recombinant His-tagged angiotensinogen displays much simpler 1:1 Langmuir 
binding—a model that would be expected of such a system. This assay will be further explored 
in Chapter Five.   
 
4.3 SPR BIOASSAY FOR ANGIOTENSINOGEN USING RENIN 
 
 As an alternative approach to detecting angiotensinogen using a monoclonal antibody 
(Section 4.2), renin immobilised to a sensor chip surface could be another, perhaps more 
specific, way in which an SPR-based assay for angiotensinogen could be developed. Studies 
involving renin on SPR instruments have already been reported in the literature.36, 103, 182, 183 The 
binding of renin to inhibitors such as aliskiren and remikiren have been reported in the presence 
and absence of the (P)RR.36, 182 The binding of renin and prorenin to the (P)RR103, 182 or to 
antibodies,183 has also been studied using SPR. The majority of these studies employed a capture 
approach for immobilisation whereby an antibody was directly coupled to the chip surface that 
was then used to capture and bind the (pro)renin or (P)RR in a non-covalent manner. Only a 
single study reported the use of a direct coupling method to immobilise renin.36 None of these 
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studies investigated the interaction that occurs between renin and angiotensinogen using an SPR 
technique, however. To this end, direct coupling methods were used to immobilise renin to an 
SPR sensor chip surface to see if the reaction that takes place between renin and angiotensinogen 
can be measured using surface plasmon resonance.   
 Firstly, using amine coupling prorenin was immobilised either directly or on top of a 
spacer molecule, hexamethylenediamine, to the sensor chip surface. Prorenin is the inactive 
zymogen of renin, hence it was no surprise that no interactions were observed when 
angiotensinogen was allowed to flow across the prorenin surface. As prorenin can be 
cryoactivated non-proteolytically at approximately 4 °C, a cold analyte run was carried out in an 
attempt to activate the prorenin surface, whereby ice-cold angiotensinogen samples and running 
buffer were used. Unfortunately, no cryo-activation could be observed, as no responses were 
generated when angiotensinogen was flowed across the chip surface. An on-chip tryptic digest 
was performed to proteolytically activate the prorenin surface, and although a net decrease in 
refractive index (drop in the RU baseline) was observed, suggesting that the prosegment had 
been cleaved to activate renin, this surface again produced no responses with angiotensinogen. 
      Active renin (proteolytically activated by tryptic digest in solution and confirmed by 
SDS-PAGE (Figure 4.8)) was also immobilised using amine coupling directly or via the spacer 
hexamethylenediamine onto a sensor chip. Despite adequate levels of immobilisation, these renin 
surfaces also failed to interact and generate responses with angiotensinogen. These results thus 
begged the question as to whether the immobilisation process itself was somehow inactivating 
renin in such a way that it was no longer able to bind to angiotensinogen. Amine coupling, as 
described in Section 4.2, tethers ligand molecules to sensor chip surfaces using primary amines, 
which means that the ligand can be immobilised to the chip surface via any lysine residues 
present on the protein’s surface. This facilitates immobilisation in essentially 














random orientations with the possibility of multiple couplings on the one ligand molecule, which 
could constrain the protein’s conformation—reducing or even abolishing enzymatic activity.  
Active renin contains 15 lysine residues and closer inspection of the crystal structure 
revealed that a large proportion of the lysine residues on renin are situated on the top face of 
renin in close proximity to the active site (Figure 4.9). Analysis of the renin amino acid sequence 
using PropKa (Protein pKa Predictor version 3.1, developed by the Jensen Research Group, 
Department of Chemistry, University of Copenhagen)187 uncovered that while 13 of renin’s 15 
lysine residues had a predicted pKa in the range of 10 to 11 (which is expected for this 
functionality), two residues, Lys 238 and Lys 239, stood out as having a substantially lower pKa 
of 9.26 and 9.36 respectively, indicated in yellow in Figure 4.9. These two lysines, having a 















SDS-PAGE analysis of recombinant His-tagged glycosylated 
prorenin before (second lane) and after proteolytic cleavage 
of prorenin’s prosegment with trypsin to give active renin 
(third lane). The MW ladder (Novex® Sharp Pre-stained 
Protein Standard) was loaded in the first lane. 



























X-ray crystal structure of human renin (PDB 3VCM) showing the lysine residues available for amine 
coupling highlighted in red (Lys 238 and Lys 239 in yellow) and the catalytic aspartate residues in the 
active site shown in blue. The renin structure (white) is viewed from (a) above, looking down at the active 
site, (b) from below, and (c) and (d) from either side. 
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out (pH 4), hinting that amine coupling may be directed to and far more likely to occur at these 
sites. Armed with this information, it was postulated that given the distribution of lysine residues 
and in particular Lys 238 and 239, the renin molecules were being tethered to the sensor chip 
surface either face down or on the side, in such an orientation that the active site is simply not 
accessible for angiotensinogen to bind for steric reasons, at least most of the time. Tethering of 
renin to the surface in close proximity to the active site could also have had an effect on the 
conformation/positioning of some of the residues present in renin’s active site, potentially 
impacting on the enzyme’s ability to carry out its catalytic function if angiotensinogen were to 
bind.      
 These observations point to a valid reason as to why direct immobilisation of renin to 
sensor chip surfaces via amine coupling has not been reported in the literature. This is not the 
first observation of renin having no activity on direct immobilisation either. In 2012, as this work 
was being carried out, Gossas et al. published work in which they attempted to measure the 
binding of small molecule inhibitors such as aliskiren and remikiren to renin by SPR, but they 
also found that the inhibitors failed to bind to the renin surface despite good levels of 
immobilisation. To address this, they utilised another direct immobilisation technique known as 
aldehyde coupling and found that the renin surface generated in this way was stable with a high 
analyte binding capacity, permitting the binding of the inhibitors to renin to be measured.36 
Aldehyde coupling facilitates the tethering of ligands (oxidised with sodium metaperiodate to 
generate reactive aldehyde groups on glycosyl residues such as sialic acid) to a sensor surface by 
their glycosylation residues.184 Human renin has two glycosylation sites at Asn 5 and Asn 75,188 
both of which are located in positions distal to renin’s active site (Figure 4.10). Covalent 
attachment of renin in this way may therefore provide a more specific orientation of immobilised 
renin molecules, while at the same time preventing any tethering in close proximity to the active
















site. The chemistry involved for aldehyde coupling immobilisation to a surface is described in 
detail by O’Shannessy et al.,189 and is summarised in Figure 4.11. 
Due to the reported success of aldehyde coupling with renin, recombinant human 
glycosylated renin was immobilised using this technique to determine whether tethering via 
renin’s glycosylation residues would facilitate interactions with angiotensinogen, a much larger 
analyte than the renin inhibitors. Aldehyde coupling was carried out following the protocol 
described in the Biacore Sensor Surface Handbook (GE Healthcare, downloadable from 
https://www.biacore.com/lifesciences/products/Consumables/guide/). Because this protocol is 
optimised for Biacore SPR biosensors that operate differently from the ProteOnTM XPR36, some 
changes to the protocol (outlined in Table 4.2) had to be made, primarily in terms of flow rates 
Figure 4.10: 
X-ray crystal structure of human renin (PDB 3VCM) showing residues Asn 5 and Asn 75 (yellow) which 
represent the two sites of glycosylation on renin. The catalytic aspartate residues are shown in orange to 
indicate the position of the active site. 
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and contact times. Due to the inherent toxicity of hydrazine and sodium cyanoborohydride, these 
compounds were substituted for the less toxic alternatives carbohydrazide and sodium 




















Immobilisation of renin mediated by aldehyde coupling worked well and led to good 
levels of immobilisation, with immobilisation at pH 4 giving higher levels of ligand density than 









The sensorgram obtained when 0.01 mg/mL recombinant human renin is immobilised via aldehyde 
coupling to the sensor chip surface of a GLC chip. The surface is first  activated with a 1:1 mixture of 
EDAC/NHS, before hydrazide groups are introduced to the surface with carbohydrazide . The surface 
is then deactivated  with ethanolamine HCl pH 8 to deactivate any remaining reactive succinimide 
esters. Then renin (oxidised with sodium metaperiodate) is immobilised  onto the chip surface in a 
coupling buffer of sodium acetate pH 4 or 5. As a final step, the covalent bond formed between the ligand 
and the chip surface is stabilised by flowing across a double injection  of the reducing agent sodium 
triacetoxyborohydride. The increase in RU from baseline following reduction is indicative of the level of 
ligand immobilised on the sensor chip surface.  
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above in Figure 4.12. Ligand immobilisation at both pH 4 and 5 was trialled, as it has been 
demonstrated that the pH that yields the highest levels of immobilisation may not always be the 
optimal conditions for immobilisation in terms of the ligand’s activity.179 An unactivated blank 
channel was used as a reference channel, while SUMO-CAT was used as a negative analyte 
control. With bated breath, angiotensinogen was flowed across the renin surface and excitingly 
angiotensinogen (SUMO-AGT) was found to interact with the renin surface to produce binding 
responses in a concentration dependent manner, with the pH 4 immobilised surface giving larger 
binding responses (Figure 4.13a)—finally, success after much trial and error! 
Subsequent analyte runs using the same concentrations of angiotensinogen revealed that 
although binding responses were still obtained in a concentration-dependent manner, the binding 
capacity of the surface had greatly decreased, as the responses were of a much smaller 
magnitude (Figure 4.13b). This could either be a result of the regeneration conditions being too 
harsh and causing a loss of enzymatic activity through time, or conversely due to poor 
regeneration leading to a build up of bound angiotensinogen on the chip surface. An 18 second 
pulse of glycine HCl pH 2.0 was used as a regeneration solution for these experiments, and 
although quite harsh, was not thought to be too damaging to the renin surface. Gossas et al. had 
carried out extensive regeneration scouts and found the aldehyde-coupled renin surface to be 
stable for several days without a significant loss of binding capacity even when subjected to 30 
second pulses of low and high pH solutions, as well as solutions containing high ionic strength, 
complexing agents, detergents, organic solvents, or chaotropic substances.36 It is therefore likely 
that the observed decrease in binding capacity with subsequent analyte runs is simply due to 
incomplete removal of the bound angiotensinogen molecules following dissociation. 
Due to time constraints, further optimisation of this assay to permit final data collection 
was not possible, and for this reason no further kinetic analysis was performed on the collected 
data. This assay is thus presented here as a proof of concept that the binding of angiotensinogen 
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to renin can be measured and studied by directly immobilising renin to a sensor chip surface 
using aldehyde coupling, and is likely to constitute the first report of the interaction between 
renin and angiotensinogen being studied using surface plasmon resonance. With more time and 
resources, this assay could be further optimised into a functional assay used to detect and study 




 This chapter presents the development of two SPR-based bioassays for the detection and 
quantification of human angiotensinogen. The first assay makes use of monoclonal antibodies to 
produce a stable ligand surface capable of detecting angiotensinogen and giving reproducible 
results over several injection cycles. The second assay involves the immobilisation of human 
renin to a sensor chip surface by tethering renin’s glycosylation residues to the surface via 
aldehyde coupling, producing a renin surface that demonstrates clear concentration-dependent 
binding responses in the presence of angiotensinogen. Despite the second assay requiring further 
fine-tuning, both assays clearly exemplify that human angiotensinogen can be assayed using 
surface plasmon resonance and they provide a useful tool at researchers’ disposal for further 
research into angiotensinogen and its medical relevance.  
 









With the foundations now laid by the work described in Chapters Three and Four, it was 
time to address the big questions and ultimate goal of this thesis: 1) is it possible to 
experimentally make a distinction between the reduced and oxidised forms of angiotensinogen? 
2) What really is the difference between the two redox states of the protein that results in the 
differential reactivity of renin to these two forms? And 3) can these differences be used to 
develop a diagnostic bioassay for pre-eclampsia? The results of this chapter are thus presented in 
order to probe the redox switch of this medically important protein in an attempt to gain a better 
understanding of angiotensinogen’s two redox states and ultimately test whether these two forms 
can be distinguished experimentally in an SPR-based bioassay. 
Firstly, making use of sulfydryl chemistry, angiotensinogen was reacted with 
polyethylene glycol that contained a maleimide functionality to quantify the redox state of the 
protein under reducing and non-reducing conditions (Section 5.2). Secondly, the antibody-based 
SPR assay for angiotensinogen described in Chapter Four was used to test whether reduced and 
oxidised angiotensinogen can be discriminated experimentally (Section 5.3), in a step towards a 
diagnostic bioassay being developed. Finally, by undertaking molecular dynamic simulations 
(Section 5.4), the reduced and oxidised forms of angiotensinogen were further probed at a 
molecular level in an attempt to unravel the differences between the two forms, underpinning 
their differential reactivity. 
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5.2 QUANTIFICATION OF THE FREE CYSTEINES IN REDUCED AND OXIDISED 
ANGIOTENSINOGEN 
 
Angiotensinogen contains four cysteine residues, but only two of these residues, namely 
Cys 18 and Cys 138, are evolutionarily conserved across species and are involved in the 
formation of an intramolecular disulfide bond. Zhou et al. described this disulfide bridge as 
labile, having a reduction potential of ‒230 mV at pH 7 and 25 °C.1 Following expression, 
angiotensinogen is secreted from the endoplasmic reticulum in the oxidised form, in a 
predictable fashion, and is subsequently reduced to the free cysteine reduced state in the 
circulation.1 These researchers went on further to show that, in the plasma pool, angiotensinogen 
exists as a stable ratio of 40:60 of the reduced to oxidised forms, regardless of age or gender in 
healthy individuals, while women in their third trimester who were suffering from pre-eclampsia 
had altered proportions of angiotensinogen in their plasma pool, displaying far greater levels of 
the oxidised form.1 In order to determine these plasma ratios, researchers performed SDS-PAGE 
and western blotting on plasma samples that had been reacted with polyethylene glycol 5000 
containing a maleimide functionality (mPEG 5000). Because oxidised angiotensinogen contains 
only two free cysteine residues to react with the mPEG molecules, while reduced 
angiotensinogen contains a total of four cysteines, the two redox forms were visually 
distinguishable due to the difference in mass following conjugation to mPEG 5000 (depicted in 
Figure 5.1).  
Undertaking a similar approach, recombinant angiotensinogen (expressed in E. coli) was 
reacted with mPEG 5000 in the presence or absence of the reducing agent TCEP to quantify the 
redox state of the recombinantly produced protein. Because bacterial cell protein expression does 
not always lead to disulfide bond formation due to the reducing environment
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within the cell’s cytoplasm,190, 191 it was necessary to determine whether both redox states could 
be generated for further experiments. SUMOylated angiotensinogen was used for these reactions 
and, since the SUMO fusion tag does not contain any cysteine residues, it should not have an 
effect on the reaction of mPEG with angiotensinogen’s four cysteine residues. The reactions 
were incubated overnight in a shaking incubator at 25 °C and samples were taken at the time 
points of 1.5 hours, 4 hours, and 18 hours (overnight) following the addition of mPEG to the 
protein solution. Samples of protein, in the presence or absence of reducing agent, were taken 
prior to, and immediately following, the addition of mPEG as controls. The reactions were 
carried out in PBS at pH 7.2 so that side reactions of mPEG with lysine residues, which occur at 
higher pH’s,192 were minimised. The results of these reactions were revealed by SDS-PAGE 
















SDS-PAGE analysis of the time course of the reaction between recombinant SUMOylated 
angiotensinogen with mPEG 5000 in the presence or absence of reducing agent. The molecular weight 
marker (Novex® Sharp Pre-stained Protein Standard) was loaded in the first lane. The oxidised protein 
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 On first glance, the effect that the addition of mPEG had was strikingly obvious, and 
unexpectedly so. The samples of angiotensinogen taken immediately following mPEG addition 
resulted, in both cases, in angiotensinogen displaying an apparent decrease in molecular weight 
of approximately 10 kDa. Thus, the mPEG molecules seem to be altering the electrophoretic 
mobility of the protein in the gel, even in the samples taken immediately following mPEG 
addition, prior to any conjugation having taken place. The addition of mPEG also caused 
smearing of the proteins on the gel. PEG has been reported to bind to SDS micelles, causing an 
alteration in the electrophoretic mobility of proteins—the magnitude of which is largely 
determined by the size of the protein of interest and its proximity to the PEG front during 
electrophoresis.193 As a consequence, this unfortunately meant it was difficult to obtain accurate 
protein sizes using electrophoresis, but it was nonetheless clear that adding mPEG had increased 
the protein size. SUMOylated angiotensinogen has a molecular weight of 63.1 kDa, and on 
conjugation with mPEG 5000, oxidised angiotensinogen is expected to have a molecular weight 
of 73.1 kDa, while reduced angiotensinogen is predicted to have a molecular weight of 83.1 kDa. 
Incubation with mPEG for 1.5 or 4 hours in the absence of reducing agent led to 
angiotensinogen-mPEG conjugates that were, predominately, of a smaller molecular weight 
when compared to the same time points in the presence of reducing agent, indicative that Cys 18 
and Cys 138 are disulfide bonded prior to reduction. Although the separation of the protein into 
the oxidised and reduced forms is not clear cut with multiple species present, there is a distinct 
difference in the weight of the species generated when reacted with mPEG in the presence or 
absence of reducing agent, allowing the possibility of angiotensinogen to be derivatised in either 
the reduced or oxidised form. Repeating the experiment with mPEG 10000 instead of mPEG 
5000 gave identical results except that the protein bands on the gel were even more smeared and 
the mPEG adducts were a larger molecular weight, as expected (each mPEG is 10 kDa compared 
to 5 kDa for mPEG 5000). 
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Interestingly, following overnight incubation with mPEG, angiotensinogen, in the 
absence of reducing agent, unexpectedly increased in molecular weight, generating species that 
were of a similar size to the reduced conjugate species. This suggests that during longer 
incubations, the reaction of mPEG with free thiols was driving the reversible labile disulfide 
bond formation/breakage reaction in the forward direction toward disulfide breakage, essentially 
by scavenging free cysteines as they became available, resulting in a subsequent loss of the 
disulfide-bonded oxidised species over time, and a gradual increase in the reduced 
angiotensinogen species. Because of this, any derivatisation of angiotensinogen into the reduced 
and oxidised forms by capping the cysteine thiols with maleimide and its derivatives must be 
done on as short a time-scale as possible to prevent conversion of the oxidised form into the 
reduced form. 
Overall, this demonstrates that angiotensinogen, expressed recombinantly in bacterial 
cells, is predominately, although not 100%, present in the oxidised disulfide bonded form of the 
protein. Subsequent reduction and breakage of the disulfide bridge between Cys 18 and Cys 138 
with a reducing agent results in all four cysteines being available for conjugation with a 
maleimide compound, preventing reformation of the disulfide bond between these two residues.       
 
5.3 SPR ASSAY FOR REDUCED AND OXIDISED ANGIOTENSINOGEN 
 
 Having developed an SPR-based assay capable of detecting human angiotensinogen 
using monoclonal antibodies (Chapter Four), it was now possible to see if reduced and oxidised 
angiotensinogen could be distinguished experimentally using this technique. A multiplexing 
approach was undertaken for data collection, which, in addition to repeat analyte injections, was 
able to show that the results obtained were not only accurate, but also reproducible. The anti-
AGT mAb antibody was immobilised at the same concentration on four activated ligand 
channels to generate four anti-AGT mAb surfaces of the same ligand density. The resulting 
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levels of immobilised antibody following deactivation are shown in Table 5.1, and demonstrate 
that the ligand density on all channels was very similar. A further channel was immobilised with 
the anti-IgG mAb at the same concentration of antibody to serve as a reference surface. 
 
ANTI-AGT MAB SURFACE LEVEL OF IMMOBILISATION (RU) 
 Surface 1 235 
 Surface 2 248 
 Surface 3 247 





 Recombinant reduced and oxidised His-tagged human angiotensinogen expressed in E. 
coli cells was used in these experiments, and was a kind gift from Tim Yandle and Darrell Wang 
(Endolab, Canterbury Health Laboratories). Prior to receiving this protein, the angiotensinogen 
had been derivatised at Endolab as either reduced or oxidised angiotensinogen in the presence of 
N-ethylmaleimide (NEM) and dithiothreitol (DTT), or NEM alone, respectively, and mass 
spectrometry studies of these two forms confirmed that the proteins existed in the correct 
disulfide bonded (oxidised) or free cysteine (reduced) redox states (unpublished data, personal 
communication with Stephen Brennan, University of Otago, Christchurch). The reduced and 
oxidised angiotensinogen samples were run as analytes on the SPR as a concentration series with 
a starting concentration of 2 μM and a dilution factor of two, such that concentrations of 2 μM,  
1 μM, 500 nM, 250 nM, 125 nM, and 62.5 nM of both reduced and oxidised angiotensinogen 
were measured. Each concentration set of angiotensinogen was injected multiple times to obtain 
Table 5.1: 
Levels of anti-AGT mAb antibody immobilisation following deactivation on each of the ligand channels 
used for reduced and oxidised angiotensinogen data collection.   
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replicate measurements. Oxidised angiotensinogen samples were injected firstly in an ordered 
fashion, and then in a randomised order, and the same approach was carried out with reduced 
angiotensinogen, to show that the binding responses measured were independent of the analyte 
channel used. Finally, the binding responses of the three highest concentrations of 
reduced/oxidised angiotensinogen were measured in the same analyte run, firstly in ordered 
fashion, and as a repeat in a randomised order. Thus, all the binding data for each channel was 
composed of at least two replicates for each concentration of reduced and oxidised 
angiotensinogen.   
Because SPR is such a sensitive technique, any differences in protein concentration could 
have had an effect on the results so it was critical that accurate concentration of each of the 
proteins was obtained. Although the Nanodrop spectrophotometer was used to determine protein 
concentrations during the initial assay development and optimisation, it was deemed that this 
method was inaccurate for determining precise concentrations of the reduced and oxidised 
angiotensinogen samples as both NEM and DTT, present in the protein samples, have an 
absorbance at 280 nm, resulting in differences in the apparent protein concentrations measured. 
To circumvent this, another method was employed instead to determine accurate protein 
concentrations, namely the o-phthalaldehyde (OPA) fluorescent protein assay. In the presence of 
mercaptoethanol, o-phthalaldehyde reacts with primary amine groups in proteins (i.e. terminal 
amino acids of proteins and the ε-amino group of lysine residues) to produce a blue fluorescent 
product which has maximum excitation at 340 nm and maximum emission at 455 nm.143, 144 This 
fluorescent protein assay is advantageous, not only due to its sensitivity, but also because it is 
compatible with a wide range of buffer additives including detergents and reducing agents. In 
addition, both reduced and oxidised angiotensinogen contain identical primary amine content, so 
there should be no bias due to differing amine content. To ensure that the sensitivity of this assay 
is unaffected by DTT and NEM, standard curves were generated using BSA at a range of 
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concentrations in the presence and absence of these compounds (Figure 5.3). NEM and DTT, 
either alone or combined were shown to have no effect on the assay with a linear calibration 

















The reduced and oxidised angiotensinogen analyte runs were performed as per the 
protocol developed in Section 4.2. Briefly, samples were injected at a flow rate of 25 μL/min for 
a total contact time of 981 seconds, followed by a dissociation time of 1800 seconds. PBST pH 
7.4 was used as the running buffer for all experiments and also to prepare the dilutions of 
angiotensinogen samples. All experiments were performed at 25 °C, and a single regeneration 
step (18 second pulse of glycine HCl pH 2) followed by four blank buffer runs were performed 
Figure 5.3: 
BSA standard curves generated using the o-phthalaldehyde fluorescent protein assay. The BSA samples 
were prepared either in PBS pH 7.4 alone, or with the addition of NEM, or DTT and NEM at 
concentrations equivalent to those present in the angiotensinogen protein samples.   
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between each analyte runs. All data sets were double referenced against both the anti-IgG mAb 
reference surface, and against buffer injections containing no protein. The binding responses 
(including replicates) obtained as a result of oxidised or reduced angiotensinogen interacting 
with the anti-AGT mAb surfaces can be seen in Figures 5.4 and 5.5, respectively.  
 The binding responses, although noisy, clearly show concentration-dependent responses 
as a result of the reduced and oxidised angiotensinogen binding the anti-AGT mAb surfaces. 
Replicates of each analyte concentration overlay well, and there are only subtle differences in the 
magnitude of responses between ligand channels that correlate with the small differences in 
immobilised ligand density on these surfaces (Table 5.1), demonstrating that these results are 
reproducible. Although ligand saturation was not reached, each set of sensorgrams shows visible 
curvature in the association phase and decay in the dissociation phase, which is ideal for kinetic 
analysis. Even prior to kinetic analysis, the differences between reduced and oxidised 
angiotensinogen binding to the ligand surfaces at the same analyte concentrations are clearly 
visible when overlaid, as can be seen in Figure 5.6. 
 Kinetic analysis of these responses was able to unravel these differences further. All 
kinetic analysis was carried out using ClampXP, a data analysis program that uses numerical 
integration and non-linear global curve fitting algorithms to fit measured data to kinetic binding 
models.145 To demonstrate that the assay was able to generate reproducible results, the data set 
from each anti-AGT mAb ligand channel was analysed and fit to a kinetic model separately and 
independently of the other ligand channels. The binding data from reduced and oxidised 
angiotensinogen were fit to a simple 1:1 Langmuir binding model (described in Section 4.2).























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Oxidised angiotensinogen binding responses from each anti-AGT mAb surface (data shown in Figure 
5.4) were fit to a 1:1 Langmuir binding model using ClampXP. The data is shown in black while the 
kinetic model fits are overlaid in red. The residual plot of the model fitting is also shown beneath each 
sensorgram.  



























Reduced angiotensinogen binding responses from each anti-AGT mAb surface (data shown in Figure 
5.5) were fit to a 1:1 Langmuir binding model using ClampXP. The data is shown in black while the 
kinetic model fits are overlaid in red. The residual plot of the model fitting is also shown beneath each 
sensorgram.  
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The models overlaid nicely on the measured data from each anti-AGT mAb surface, and the 
residual plots also indicated that the kinetic fits are an excellent description of the data. The plots 
show that the residuals are randomly scattered about the baseline with an amplitude of ± 4 RU, 
which would be expected given the noise shown on the sensorgrams (Figures 5.7 and 5.8). The 
kinetic constants and standard deviations resulting from the best fit data for each surface, for 
both reduced and oxidised angiotensinogen, are summarised in Table 5.2. The standard 
deviations from the fitting of the kinetic parameters are small, indicating that the rate constants 
for each data set are well defined. Both the kinetic association (ka) and dissociation (kd) rate 
constants were different for the two redox forms, with oxidised angiotensinogen displaying a 
slower association rate and faster dissociation rate than reduced angiotensinogen (ka: 1121 M
‒1 
s‒1 vs. 1510 M‒1 s‒1 and kd: 1.78 x 10
‒4 s‒1vs. 1.55 x 10‒4 s‒1, respectively). Figure 5.9 shows that 















ka versus kd plot of the kinetic parameters determined for reduced (blue) and oxidised (red) 
angiotensinogen binding to each anti-mAb ligand surface by fitting the simple 1:1 Langmuir binding 
model to each data set (each data point represents one anti-mAb antibody surface). 
. 







Anti-AGT mAb Surface ka (M
-1 s-1) kd (s
-1) KD (nM) 
Surface 1 1182 ± 4 (1.78 ± 0.01) x 10‒4 150 ± 1 
Surface 2 1153 ± 4 (1.73 ± 0.01) x 10‒4 150 ± 1 
Surface 3 1055 ± 4 (1.84 ± 0.01) x 10‒4 174 ± 1 
Surface 4 1093 ± 3 (1.77 ± 0.01) x 10‒4 162 ± 1 
REDUCED ANGIOTENSINOGEN 
Anti-AGT mAb Surface ka (M
-1 s-1) kd (s
-1) KD (nM) 
Surface 1 1439 ± 6 (1.61 ± 1) x 10‒4 112 ± 1 
Surface 2 1534 ± 6 (1.49 ± 1) x 10‒4 97.3 ± 0.9 
Surface 3 1596 ± 6 (1.51 ± 1) x 10‒4 94.8 ± 0.9 
Surface 4 1473 ± 5 (1.59 ± 1) x 10‒4 108.1 ± 0.8 
AVERAGES 
 ka (M
-1 s-1) kd (s
-1) KD (nM) 
Oxidised Angiotensinogen 1121 ± 4 (1.78 ± 0.01) x 10‒4 159 ± 1 
Reduced Angiotensinogen 1510 ± 6 (1.55 ± 0.01) x 10‒4 103.1 ± 0.9 
Independent Samples t-Test (p-value) <0.0001 <0.0001 <0.0001 
 t-value -107.89 32.53 83.10 
 degrees of freedom 5 5 5 
Table 5.2: 
Kinetic values obtained from the fitting of the simple 1:1 Langmuir binding model to the binding 
responses of reduced and oxidised recombinant angiotensinogen on each anti-AGT mAb surface 
(data and model fits shown in Figures 5.7 and 5.8) Model fitting was carried out using ClampXP. 
Independent samples t-tests were performed on the mean anti-AGT mAb surface ka, kd, and KD 
values for oxidised and reduced angiotensinogen to test the statistical significance of the differences 
between the two redox forms.  
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The differences in the association and dissociation rate constants led to different 
dissociation constants (KD = kd/ka) for the angiotensinogen-antibody complex, depending on the 
redox state of the protein. Oxidised angiotensinogen was determined to have a mean KD value of 
159 nM while reduced angiotensinogen had a mean KD value of only 103.1 nM. The dissociation 
constant is a measure of the affinity of the anti-AGT mAb antibody for the angiotensinogen 
protein, and thus, gives an idea of how tightly angiotensinogen binds to the ligand surface. 
Therefore, reduced angiotensinogen, having a lower KD value, binds to the anti-AGT mAb more 
tightly than oxidised angiotensinogen. Furthermore, statistical analysis revealed that the 
differences in the ka, kd, and KD values between reduced and oxidised angiotensinogen were 
statistically significant, having p-values of < 0.0001 (Table 5.2). Despite the small sample size  
(n = 4 for both reduced and oxidised angiotensinogen), each set of kinetic rate constants was 
derived from the kinetic fit of the model to multiple replicates, thus the statistical significance 
should accurately represent the differences observed, especially given the small standard 
deviations that were defined for each of the rate constants. 
To validate that the kinetic models for the 1:1 Langmuir binding of reduced and oxidised 
angiotensinogen to the anti-AGT mAb surface were fitted correctly, each data set was subjected 
to Monte Carlo analysis, a feature of the ClampXP program. Monte Carlo tests are carried out to 
determine whether the obtained set of kinetic rate constants for a particular fit can be consistently 
generated using vastly different starting parameter values.194 Despite starting the fitting process 
of each data set from kinetic parameters that varied from the initial value by as much as 1000%, 
the 50 cycles of Monte Carlo fits demonstrated that, even with the addition of random short-term 
noise, all results converged on the same set of ka and kd values, strongly supporting the validity 
of the kinetic model fitting to each data set. In addition, each data set was independently fitted to 
a simple 1:1 Langmuir binding model using the Scrubber program and the same results were 
obtained. Finally, as each of the anti-AGT mAb surfaces are independent from each other, the 
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kinetic rate constants obtained from model fitting of the data collected from each ligand surface 
serve to both validate the model fits obtained, and demonstrate that the results are reproducible. 
 Overall, these results clearly demonstrate that by using the antibody-based SPR assay that 
was developed in Section 4.2, recombinant non-glycosylated reduced and oxidised 
angiotensinogen can be experimentally distinguished in a reliable and reproducible fashion. The 
anti-AGT mAb antibody surface has a statistically significant higher affinity for the reduced 
form of angiotensinogen when compared with the oxidised form, due to differences in both the 
association and dissociation rates of the two redox states of angiotensinogen protein when 
interacting with the immobilised antibody. These differences are especially significant in light of 
the intrinsic similarity of the two redox states of angiotensinogen, which differ only in the 
presence or absence of a disulfide bond, and the results certainly give credit to the sensitivity of 
the SPR technique to be able to facilitate the detection of these minute structural differences.   
 
5.4 MOLECULAR DYNAMIC SIMULATIONS 
 
 The idea that the entire angiotensinogen protein, rather than just the N-terminal portion, 
may play a role in the reaction with renin is not a new one. Streatfeild-James et al. elegantly 
showed that angiotensinogen’s tertiary structure plays a pivotal role in the reaction with renin,  in 
terms of the reaction rate, and also with regard to the affinity that renin displays for 
angiotensinogen.126 Zhou et al. went on further to show that binding of angiotensinogen to renin 
is accompanied by a 10 Å displacement of the CD loop containing Cys 138 that simultaneously 
presents the N-terminal peptide to renin’s active site cleft, movements carried out in a concerted 
manner mediated by angiotensinogen’s disulfide bond.1 The solving of the x-ray crystal 
structures of angiotensinogen, alone, and bound to renin, revealed that the interactions that occur 
in the renin-angiotensinogen complex are not limited to angiotensinogen’s N-terminal substrate 
and renin’s active site cleft, but rather encompass a considerable 670 Å of predominantly 
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hydrophobic contact surface area between the bodies of the two proteins.1 These studies provide 
strong evidence in opposition of the once widely held hypothesis that angiotensinogen was 
simply a passive carrier of the angiotensin peptide,126 and hint towards the critical role that the 
Cys 18 and Cys 138 residues may play in facilitating these structural changes.  
To delve deeper into the mechanisms by which the two redox states of angiotensinogen 
interact differentially with renin, and also with the anti-AGT mAb antibody, human 
angiotensinogen was subjected to molecular dynamics (MD) simulations. These simulations 
were performed to ascertain whether the experimentally observed differences between the 
reduced and oxidised forms can be explained by the protein’s molecular motions, mediated or 
perhaps prevented by the Cys 18 and Cys 138 disulfide bond. Molecular dynamic simulations are 
able to ‘breathe life’ into the static images of a protein structure captured by x-ray 
crystallography, and allow us a glimpse into the energy landscape and structural conformations a 
protein may explore over a small time-scale that are otherwise unable to be visualised by the 
naked eye.195, 196 Modelling of a given protein at the molecular level is achieved by 
computational simulation of atomic trajectories by the numerical solving of Newton’s equations 
of motion in a system of N interacting atoms,196, 197 ultimately generating a trajectory of 
molecular movements over a given time-scale (typically in the ns range, although μs simulations 
have been reported195, 196, 198). 
To this end, MD simulations were carried out on human angiotensinogen (PDB structure 
2WXW) in the presence or absence of the disulfide bond between Cys 18 and Cys 138 at 300 K 
(approximately 25 °C) in triplicate for simulation trajectories of 500 ns. Initial analysis was 
carried out by calculating the root mean square deviations (RMSD) and root mean square 
fluctuations (RMSF) across the triplicate trajectories for both reduced and oxidised 
angiotensinogen. The RMSD plot shows the deviations of the Cα atoms from the initial energy 
minimised structure, and revealed that for the first 350 ns the reduced angiotensinogen presents 
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with a higher RMSD than the oxidised form (Figure 5.10), but in the final 150 ns, the oxidised 
protein deviates further away from the starting coordinates yielding mean RMSD values of    
4.18 Å for oxidised and 4.32 Å for reduced angiotensinogen—a difference of only 0.14 Å that is 
not highly significant given that the RMSD values are an average metric, suggesting that the two 















It is difficult to make any solid conclusions about the specific dynamics of the two redox 
states from the RMSD plots alone, and closer inspection of the RMSF plot, which highlights the 
deviation differences for each residue, revealed that there are in fact quite distinct differences 
between the dynamics of reduced and oxidised angiotensinogen. As can be seen in Figure 5.11, 






RMSD plot of the Cα atoms from oxidised (brown) and reduced (blue) human angiotensinogen over 500 
ns. Each plot shows the mean RMSD over the three replicates as well as the minimum/maximum 
deviation. 
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a maximum deviation of 10 Å, compared to the maximum deviation of 8 Å for oxidised 
angiotensinogen. Furthermore, reduced angiotensinogen presents much greater deviations in the 
region between residues 5 and 30, which includes the angiotensin-I peptide and renin cleavage 
site, as well as Cys 18. It appears that reduction of the disulfide bond between Cys 18 and Cys 
138 increases the dynamics surrounding helix A2 of angiotensinogen. Interestingly, this increase 
in dynamics around Cys 18 in reduced angiotensinogen appears to come hand in hand with a 
decrease in the dynamics in the region encompassing residues 45 to 65 (helix A1). Increases in 
the dynamics of the reduced form were also observed around residues 80 – 90, 130 – 140, 360 – 


















The complete structure of human 
angiotensinogen (PDB file 2WXW) used 
for MD simulations is shown, with the 
missing loops and side chain residues 
modelled using MODELLER. The 
angiotensinogen protein is shown in white 
with the N-terminal angiotensin-I peptide 
in green and the Cys 18 and Cys 138 
residues involved in the disulfide bond 
highlighted in orange. 
Regions identified by MD simulation as 
being more dynamic in the reduced form 
are shown in red, while less dynamic 
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Movies generated from the simulated trajectories of reduced and oxidised 
angiotensinogen quite strikingly reveal that the loss of the disulfide bridge between Cys 18 and 
Cys 138 results in a large increase in the dynamics of the surface alpha helices surrounding helix 
A2—a phenomenon not observed in the oxidised form of angiotensinogen, suggesting that there 
may be an energetic acceptance for solvation in the N-terminal region of angiotensinogen on 
breakage of the disulfide bond. Also noteworthy is the loss of the secondary structure of helix A2 
that was observed in the simulation trajectory of reduced angiotensinogen only. The 50 most 
common conformations adopted by the reduced and oxidised forms of angiotensinogen during 
the trajectory are shown in Figure 5.13, while Figure 5.14 illustrates snapshots of the trajectories 
for each of the redox forms every 50 ns. These clearly show the differences between the two 
structures, as well as the distinct disruption to secondary structure that occurs particularly in the 
areas encompassing helix A2 and as well as helix C (residues surrounding 120 – 146).    
It is clear from these MD simulations that the loss of the disulfide bridge between Cys 18 
and Cys 138 results in angiotensinogen being far more dynamic in the regions surrounding the 
two cysteine residues, with distinct disruptions to secondary structure taking place. These results 
were to a certain extent expected, as on disulfide bond breakage there would no longer be any 
physical constraint holding the N-terminal region in place. Thus, the extra mobility of these 
regions in the reduced form of angiotensinogen is potentially frustrating or occluding the binding 
of renin to angiotensinogen as compared with the oxidised form. This is in line with the 
experimental data presented by Zhou et al. that showed renin had differential binding affinities 
for the two forms, with a fourfold increase in renin-binding affinity in the presence of the (P)RR 
with oxidised angiotensinogen only.1 The differential binding affinity of anti-AGT mAb for the 
two redox forms of angiotensinogen could also be explained in part by these increased dynamics. 
The anti-AGT mAb displayed a higher affinity for the reduced form compared with the oxidised  
 
















form, and this may be due to the more dynamic reduced form being more readily able to present 
the antibody with its epitope in a favourable conformation for binding, compared with the 
oxidised form in its constrained conformation. 
Furthermore, Zhou et al. identified that helix C and the CD-loop of angiotensinogen 
make contact with the N-terminal lobe of renin in the renin-angiotensinogen bound complex,1 
and since both of these regions were found to be more dynamic in the reduced state, it seems 
likely that these dynamic areas may disrupt binding of reduced angiotensinogen to renin. As 
these simulations were being carried out, Brás et al. published work in which they performed 








The top 50 clustered conformations of reduced and oxidised human angiotensinogen over MD simulation 
trajectories of 500 ns. The structures are coloured by residue index from red to blue. 

















(PDB 2X0B) on all residues that are found at the interface between the two proteins when 
bound.199 This approach enabled them to quickly identify residues (termed hot and warm spots) 
that were important for binding interactions, as mutation to alanine resulted in significant 
increases in the binding free energies.199 Interestingly, of the eight hot spot residues on 
angiotensinogen that they identified, six of these were also found to be more dynamic in the 
reduced form of angiotensinogen in the MD simulations presented here. In addition, five of the 
ten warm spot residues were found to be more dynamic in reduced angiotensinogen, while a 
further three of these ten warm spots were less dynamic in the reduced form compared with 




Simulation snapshots taken every 50 ns for reduced and oxidised human angiotensinogen over a MD 
simulation trajectory of 500 ns. The structures are coloured by RMSD from the average residue position, 
from white being 0 Å to red being ≥ 6 Å. The starting angiotensinogen structure is shown inset for 
comparison with helix A2 in yellow and helix C in blue. 
hAGT 
2WXW  
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reduced angiotensinogen in regions containing many interfacial residues that are critical for 
forming binding interactions with renin. 
The MD simulations presented here for reduced and oxidised angiotensinogen clearly 
demonstrate that breakage of the disulfide bond which exists between Cys 18 and Cys 138 in 
angiotensinogen results in more dynamic regions within the protein structure, as well as 
disruption of secondary structure in regions that are critical for forming binding interactions on 
complex with renin. Although the overall dynamics of each redox state are similar, a closer look 
at the residues in the trajectories reveals quite distinct differences in the dynamics between the 
two forms. Thus, these trajectories provide a tentative explanation as to the reported differential 
binding affinity of renin for the reduced and oxidised forms of angiotensinogen, and also suggest 
that the increased dynamics of the reduced protein’s structure may free up and present the anti-
AGT mAb’s binding epitope more readily than the oxidised form of angiotensinogen is capable, 
resulting in the antibody having a higher affinity for reduced angiotensinogen when tested using 




 In summary, this chapter presents an investigation into the reduced and oxidised forms of 
angiotensinogen, and the differences that exist between these two forms. Angiotensinogen was 
shown to be predominantly expressed in the disulfide bonded oxidised form when produced 
recombinantly in E. coli. These two forms can also be reliably and reproducibly differentiated 
using an antibody-based SPR assay for angiotensinogen. This assay demonstrated that the two 
redox states were shown to differ significantly in both their association and dissociation rates to 
the anti-AGT mAb antibody, and thus the antibody displays differential binding affinity for the 
two forms—a significant step toward the development of a diagnostic bioassay. To elucidate the 
mechanisms underlying the observed differences between the reduced and oxidised forms, 
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molecular dynamic simulations were carried out and strikingly revealed that reduced 
angiotensinogen is more dynamic in regions critical for renin binding, as a result of the loss of 
the crucial disulfide bond between Cys 18 and Cys 138. 
  





6.1 PRODUCTION OF RECOMBINANT HUMAN ANGIOTENSINOGEN 
 
Successful expression and purification of recombinant angiotensinogen was achieved 
from a bacterial expression system after much trial and error using the SUMO fusion tag; an 
approach that had been undertaken before by others.1 Although this approach allowed the 
isolation of native recombinant angiotensinogen following tag cleavage using SUMO Protease, 
the cleavage reaction also unintentionally resulted in the loss of the disulfide bond between Cys 
18 and Cys 138 due to the DTT present in the protease buffer that was required for the activity of 
the protease. This, coupled with the cost of the SUMO protease, led to the decision to leave the 
tag intact on the angiotensinogen protein so that the angiotensinogen would be in the desired 
oxidised form. This could have perhaps perturbed the tertiary structure of the angiotensinogen 
protein, particularly as the tag was attached to the N-terminus of angiotensinogen—the business 
end of the protein molecule. 
 Evidence of potential perturbation to protein structure was seen in the deviation of the 
SUMO-AGT binding kinetics compared with the simple 1:1 Langmuir binding observed for  
His-tagged angiotensinogen in the antibody-based SPR assay. Although the SUMO tag itself 
does not appear to interact with the anti-AGT mAb surface (no interactions were observed with 
SUMO-CAT), this does not rule out the impact that the SUMO tag may be having on the tertiary 
structure of the angiotensinogen protein. The SUMO fusion tag is relatively large (11 kDa) when 
compared to the size of angiotensinogen (50 kDa) and it is unknown how these two proteins may 
be interacting, as it is possible that the SUMO protein could be packing against the 
angiotensinogen protein surface. Further structural characterisation will need to be undertaken to 
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further elucidate whether the SUMO protein is altering the angiotensinogen protein in any way, 
and thus whether the SUMO-tagged angiotensinogen protein is an appropriate substitute to be 
working with in terms of the protein being representative of native angiotensinogen. X-ray 
crystallography, small angle x-ray scattering, and dynamic light scattering studies on 
SUMOylated angiotensinogen may shed more light in this regard. 
One solution to this, of course, would be to express angiotensinogen either untagged or 
with a smaller tag, such as a His-tag, that would be far less likely to have an impact in terms of 
altering angiotensinogen’s reactivity or perturbing the tertiary structure of angiotensinogen. The 
expression trials carried out during this work found the His-tagged version of angiotensinogen 
(from pET_16b_AGT construct) to be completely insoluble, while the untagged version was not 
found to overexpress from the pETDuet plasmid. These expression trials were not exhaustive 
however and several more approaches could have been trialled if more time had been permitted. 
The addition of 1% glucose was found to greatly increase the solubility of SUMOylated 
angiotensinogen, but was not trialled for the expression of angiotensinogen from the 
pET_16b_AGT and pETDuet_DsbC_AGT constructs, and is an approach that may have been 
helpful in these cases as well. Another approach not trialled was expression at lower 
temperatures, which results in slower expression, facilitating more time for correct protein 
folding. Expression of the protein from other DNA constructs may also have been another way 
to achieve soluble angiotensinogen, and many different plasmids are now commercially 
available, including plasmids that facilitate co-expression of the protein of interest with 
chaperone proteins that greatly aid in the production of correctly folded protein. In addition, only 
the E. coli bacterial expression system was tried, but more success may have been achieved with 
a eukaryotic expression system.       
 Overall, despite the difficulties, this work demonstrates that pure recombinant non-
glycosylated human angiotensinogen (predominantly in the oxidised form) can be successfully 
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expressed and purified from bacterial cells using the SUMO fusion tag. Cleavage of the SUMO 
tag can be carried out if downstream applications requires native untagged angiotensinogen, but 
this tag removal does also result in the loss of the critical disulfide bond between Cys 18 and Cys 
138, which was undesirable and thus was avoided in this work by leaving the tag intact.  
 
6.2 ASSAY DEVELOPMENT AND VALIDATION OF RESULTS 
 
 Working with a mouse monoclonal antibody raised against human angiotensinogen, it 
was possible to develop a sensitive and reproducible SPR assay for angiotensinogen that 
displayed nanomolar affinity for recombinant non-glycosylated human angiotensinogen. 
Although this is not a particularly high affinity for a monoclonal antibody (picomolar and even 
femtomolar affinities for antibodies have been reported),200 this affinity is within the ideal range 
for measurement using SPR.201 Binding of the antibody surface to His-tagged angiotensinogen 
resulted in a simple 1:1 Langmuir binding mechanism being observed, allowing facile kinetic 
fitting of a binding model to the measured data. The binding of an antigen to a monoclonal 
antibody would be expected to display simple 1:1 binding due to the antibody recognizing a 
single epitope on the antigen’s surface. Thus, it was interesting that the binding responses 
measured when SUMOylated angiotensinogen bound the antibody surface deviated from the 
simple 1:1 binding model. Rather, the binding responses fit well to a surface heterogeneity 
model, but as discussed in Chapter Four it is difficult to know if this binding model accurately 
represents the binding events occurring at the sensor chip surface. It is highly possible that the 
SUMO tag is altering the tertiary structure of angiotensinogen, or perhaps associating with 
angiotensinogen in such a way that the epitope is being shielded, altering the binding kinetics or 
partially preventing binding altogether. Interestingly enough, the 1:1 Langmuir binding model, 
and the 1:1 mass transport binding model, despite not describing the measured binding data well, 
returned KD values of approximately 140 nM—very similar to the KD value of 150 nM obtained 
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for the same binding responses when fit to the surface heterogeneity model. These values are all 
in good accordance with those obtained for oxidised angiotensinogen, further evidence in 
support of the recombinant angiotensinogen existing in the disulfide bridged oxidised form prior 
to exposure to a reducing agent.  
 One limitation that slowed assay development was the availability of large amounts of 
recombinant angiotensinogen, particularly in the optimisation steps of the SPR assay that 
consumed a considerable amount of protein. If more protein had been readily available (being 
plagued with protein insolubility meant that in-house expression of SUMO-AGT was only 
achieved in the final months of this project), ligand saturation by using higher concentrations of 
analyte could have been obtained. Ligand saturation means that the ligand surface has reached its 
maximum binding capacity, which would allow more accurate fitting of kinetic models and also 
provides an additional means for obtaining KD values by equilibrium analysis for the interaction 
between the antibody and angiotensinogen. This would provide a further validation of the kinetic 
results if equilibrium and kinetic analysis yield the same KD values.  
Careful experimental design was undertaken to ensure that the SPR results obtained were 
reliable and could be readily reproduced when measuring the binding responses of reduced and 
oxidised angiotensinogen to the antibody surface. The analyte binding responses were measured 
on four independent ligand surfaces that had very similar levels of immobilised antibody, which 
served as separate replicates. Each channel generated very similar results indicating that this 
assay is highly reproducible. In addition, each concentration of analyte was injected at least 
twice across each ligand surface, with each replicate injection taking place in a different analyte 
channel. The replicates overlaid well for each concentration despite the noisiness of the curves, 
again providing strong evidence that this assay is able to generate reliable data over several 
injection cycles. Each dataset was analysed independently using two different software 
programs; the two programs generated the same kinetic results and the results were very 
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concordant between the four antibody surfaces, suggesting that the results for reduced 
angiotensinogen and oxidised angiotensinogen are accurate. The correct fitting of the kinetic 
models were further verified by carrying out Monte Carlo analysis on each dataset, which 
revealed that the kinetic rate constants could be reliably fitted to the measured data irrespective 
of the starting parameter values and random short term noise. 
Switching the analyte and ligand is another good check to validate the kinetic results 
obtained, but unfortunately the timeframe of this project did not permit further validation of the 
results in this manner. In this approach, angiotensinogen would be immobilised to the sensor 
chip surface and anti-AGT mAb antibody would be used as the analyte. If the binding responses 
observed during this set up were in good accordance with the results presented here, this would 
provide very good evidence that these results are an accurate representation of the interactions 
taking place between the antibody and angiotensinogen in its respective redox forms. Care would 
need to be taken though when carrying out such a swap of binding partners, if this was an 
approach pursued in the future to validate the present results. The antibody, being a far larger 
protein, could quite possibly be subject to mass transport effects so careful experimental design 
would be needed to minimise these effects. In addition, the MD simulation results presented in 
Chapter Five demonstrate that there are clear differences in the dynamics between the two forms 
of angiotensinogen. Whether these dynamic differences would be permitted to occur when 
immobilised to a sensor chip surface is unknown, and it may be that a capture approach or an 
alternative method to amine coupling may need to be used for immobilisation, as was found to 
be the case with renin.  
 
6.3 DIFFERENCES BETWEEN REDUCED AND OXIDISED ANGIOTENSINOGEN  
 
 Reaction with mPEG clearly demonstrated that, similar to eukaryotic expression, 
angiotensinogen produced recombinantly in a bacterial expression system (SUMO-AGT) is 
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expressed predominantly in the oxidised form with the disulfide bond intact, which is supported 
by the SPR data obtained. Exposure to reducing agent was also shown to be capable of breaking 
this disulfide bond, allowing all four cysteine residues to be free to conjugate with mPEG. 
Binding of PEG to the SDS micelles during SDS-PAGE electrophoresis did unfortunately mean 
that accurate determination of the size of each of the mPEG-angiotensinogen conjugates was not 
possible, other than a clear increase in protein molecular weight on conjugation with mPEG 
being visible, an observation that has been reported previously in the literature.193, 202 If more 
time had been permissible, the experiment could have been repeated, and the gels run with a 
much lower concentration of SDS in the running buffer, which was shown by Odom et al. to 
completely eliminate the aberrant migration caused by PEG present in the protein samples.193   
From the results described in Chapter Five, it is clear that there are distinct differences 
between reduced and oxidised angiotensinogen. The SPR assay using the mouse monoclonal 
antibody was able to make a distinction between the two redox forms by displaying differential 
affinity for the two forms, due to differences in both the association and dissociation rates— 
differences that were shown to be highly significant. As mentioned previously, the epitope of the 
R & D Systems antibody used in the assay has not been determined, thus it can only be 
speculated as to the epitope on angiotensinogen that the antibody recognises, since the antibody 
was raised against a full length glycosylated human angiotensinogen immunogen. Given that the 
antibody displays differential binding affinity for the two redox forms of angiotensinogen, it is 
likely that this epitope may lie in the region surrounding the N-terminus or perhaps in one of the 
other regions that MD simulations revealed had different dynamics in each of the redox states. 
The antibody has a higher affinity for reduced angiotensinogen (KD = 103.1 nM compared with 
159 nM for oxidised), the redox form that displayed more dynamic regions in the MD 
simulations, particularly in the regions surrounding the N-terminus and the Cys 18 and Cys 138 
residues that form the disulfide bond. It may be that increased dynamics in the epitope region 
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mean there is less constraint when binding the antibody, and could in fact present the epitope to 
the antibody in a much more favourable conformation facilitating facile and tighter binding than 
the more constrained oxidised form of angiotensinogen is capable of. Determining the epitope on 
angiotensinogen that is bound by the antibody is a further avenue that does need to be addressed 
in future research, perhaps by methods such as tryptic digest. 
 The distinct dynamic differences between the two redox forms of angiotensinogen 
elucidated by MD simulation trajectories reveal a clear mechanistic explanation for the 
differential binding of the two forms by renin that has been reported,1 an idea that had already 
been hinted to in the literature. The increased dynamics in regions of angiotensinogen that form 
crucial contacts with renin on binding mean that the loss of the Cys 18 and Cys 138 disulfide 
bond likely disrupts the binding of renin to angiotensinogen. This is because several regions in 
reduced angiotensinogen are more dynamic and less likely to form the critical interfacial contacts 
required for binding to renin. It certainly would have been interesting to carry out the MD 
simulations on renin with reduced or oxidised angiotensinogen to further elucidate the reasoning 
behind renin’s differential binding of the two forms. However, because it would be a much 
bigger system being simulated, these simulations would require a considerable amount of time 
and resources that was beyond the scope of this master’s project. Further optimisation of the SPR 
assay using renin, if time had permitted, could have also facilitated the interaction between renin 
and the two redox forms of angiotensinogen to be studied. 
 
6.4 IMPLICATIONS FOR THE DEVELOPMENT OF A DIAGNOSTIC BIOASSAY FOR                     
PRE-ECLAMPSIA  
 
 Finally, the implications of the results presented here need to be considered in light of the 
development of a diagnostic bioassay for pre-eclampsia. The fact that an SPR-based assay for 
angiotensinogen now exists that displays differential binding affinity for the two redox states of 
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angiotensinogen, allowing them to be distinguished experimentally, is a significant step towards 
the development of a diagnostic bioassay. Because such a diagnostic assay would ideally involve 
the testing of plasma samples, the results presented here do raise some important considerations. 
Firstly, the concentration of angiotensinogen in plasma is approximately 0.8 μM,3 which falls 
well within the range of angiotensinogen concentrations tested in the SPR assay, making the 
assay ideal for measuring the plasma levels of angiotensinogen as they fall within the detectable 
limits of the assay. This assay was only tested on homogeneous reduced or oxidised 
angiotensinogen however, and whether the subtle differences between the two forms would be 
still be distinguishable in samples where both reduced and oxidised forms of angiotensinogen are 
present remains to be elucidated.  
In addition, plasma proteins are glycosylated and angiotensinogen is no exception. 
Human angiotensinogen contains four sites of N-glycosylation, and two of which are located at 
Asn 14 and Asn 137 in close proximity to the two cysteine residues involved in disulfide bond 
formation.21 Thus, it remains to be investigated as to whether glycosylated angiotensinogen will 
have any effect on the developed assay as it was only tested on non-glycosylated 
angiotensinogen. The immunogen used to raise these monoclonal antibodies in mice was a 
glycosylated form of human angiotensinogen, and since the antibody has been shown to bind to 
the non-glycosylated form of angiotensinogen, it is unlikely the epitope encompasses the 
glycosyl residues on the exterior of the protein. Nonetheless, it is unknown whether these 
glycosyl residues will mask the differential binding displayed for reduced and oxidised 
angiotensinogen and hence the sensitivity of the assay, and thus, this will require further enquiry. 
 Plasma samples are composed of a large variety of proteins, and this assay was developed 
using pure protein samples, so testing will need to be undertaken to ensure that no non-specific 
binding from other plasma proteins occurs, which would certainly complicate the binding 
responses obtained. R & D Systems have already tested the cross-reactivity of the antibody with 
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other human serpins (product datasheet) and the antibody was not found to cross-react with any 
of the other proteins that have a similar structure, which is promising but is another consideration 
that needs to be made, and careful choice of an appropriate reference surface, perhaps by 
employing the interspot referencing that is a handy feature of the ProteOnTM XPR36, will need to 
made to ensure accurate and reproducible results are obtained.     
 Finally a good diagnostic bioassay will only be a viable commercial product if it is low-
cost and will continue to generate consistent and reliable results for many samples over a good 
length of time. The stability of the anti-AGT mAb surface was not tested while this work was 
being undertaken, but is certainly something that would need to be carried out if this assay was 
continuing in assay development. However, the assay was reproducible and did give accurate 
replicable results over several injection runs while data collection was being undertaken. In 
addition, sensor chips, containing immobilised anti-AGT mAb ligand, that had been removed 
from the SPR and stored in the refrigerator, still displayed high levels of activity towards 
angiotensinogen when used again after several months, indicating that the antibody surface is 
relatively stable and would allow the collection of data for many samples. Although, the initial 
cost of buying a chip with immobilised antibody would be relatively costly, the cost would be 
balanced out if many samples could be tested on the same surface without significant loss of 
activity—it would certainly be a cost-effective method for quickly testing samples, and testing 
all samples on the same surface would ensure little variation in the results obtained from the 
entire pool of samples tested. Although the bioassay presented here could be adapted for a 
number of SPR instruments commercially available, an added bonus of employing the 
ProteOnTM XPR36 is that up to six samples can be tested simultaneously, greatly increasing the 
throughput when a large number of blood samples need to be screened in a timely manner.   
 In conclusion, the antibody-based SPR bioassay for reduced and oxidised 
angiotensinogen presented here shows good potential as a diagnostic test, but further studies will 
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need to be conducted to ensure that it is suitable and meets the scrutiny required as a diagnostic 
bioassay to measure levels of reduced and oxidised angiotensinogen in a clinical diagnostic 
setting to identify women prone to developing pre-eclampsia. 
 
6.5 FINAL REMARKS 
 
With all research there tends to be so many stones left unturned at the conclusion of a 
given project, and this project is no exception. With more time, it certainly would have been nice 
to tick off some of the experiments on the list, but this was not so in this case. Perhaps just as 
important as the results of this project is everything that has been learnt along the way. Many of 
the experiments underlying the results presented here did not work first time around but, in the 
end, persistence was the key to success. Looking back, I’m extremely thankful for all the 
stumbling blocks and learning curves along the way, as it was these experiences that taught me 
the most, and led me to learn new techniques and take the project into previously unexpected 
directions—which is, in a sense, exactly what undertaking a thesis is all about. 
 





 This project began with the main goal of developing a method to experimentally 
distinguish between the two redox states of angiotensinogen, states that are mediated by the 
disulfide bridge that exists between Cys 18 and Cys 138. These two forms exist in the plasma 
pool of healthy individuals in a stable ratio of 60:40 (oxidised to reduced, respectively) 
regardless of age and gender.1 Women who develop pre-eclampsia, a pregnancy condition that 
can be life-threatening for both mother and child and a leading cause of pre-mature births, 
display an alteration to this tight balance of reduced and oxidised angiotensinogen, and actually 
have a higher proportion of oxidised angiotensinogen in their plasma. This could have important 
clinical and physiological implications, especially in light of the findings that renin displays 
differential binding affinity for the two redox forms in the presence of the (P)RR with a four-fold 
higher catalytic efficiency for oxidised angiotensinogen.1 Thus, this alteration of the rate-limiting 
step of a pathway responsible for the regulation of blood pressure provides a direct mechanistic 
link as to the exacerbation, or even potentially causative nature, of the pathophysiology of pre-
eclampsia.   
 With this in mind, the undertaking of this thesis aimed from the outset to investigate 
angiotensinogen’s redox switch, and attempt to distinguish between the two forms, which differ 
only in the presence or absence of a disulfide bond. In order to do this, angiotensinogen was 
recombinantly expressed using the SUMO fusion system, and an SPR-based assay was 
developed that made use of a monoclonal antibody to detect angiotensinogen. A second SPR-
assay using renin was also developed that served as a proof of concept that the binding between 
angiotensinogen and renin can be investigated using SPR by utilising a direct coupling method 
of immobilisation.  
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 The antibody-based SPR assay was reproducible, and was able to generate reliable 
binding responses over multiple injection cycles, and using this assay it was possible to 
demonstrate that reduced and oxidised angiotensinogen bind to this antibody with differential 
affinity, due to significant differences in both the association and dissociation rates of the two 
forms with the anti-AGT mAb. Further elucidation of the intricate differences existing between 
the redox states were strikingly revealed by molecular dynamic simulations, which showed that 
loss of the disulfide bridge between Cys 18 and Cys 138 results in increased dynamics in regions 
crucial for forming important binding contacts with renin. 
 The results presented in this thesis are thus a significant step towards the development of 
a diagnostic assay for angiotensinogen to identify women prone to pre-eclampsia, and provides a 
sensitive assay capable of distinguishing the redox states of angiotensinogen. More work is still 
required to be undertaken to assess the viability of this assay in a clinical diagnostic setting, but 
the work outlined in this thesis thus far certainly highlights its potential.  
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Appendix 
RECIPES AND BUFFERS 
I SDS-PAGE RECIPES: 
 A) Sample Reducing Dye: 
 
SAMPLE REDUCING DYE VOLUME
BoltTM LDS Sample Buffer (4X)  25 μL 
BoltTM Reducing Agent (10X) 10 μL 
MQ water 15 μL 
Total Volume 50 μL 
 
  Mix well, and store aliquots at ‒20 °C. 
 B) Coomassie Blue Stain: 
 
COOMASSIE BLUE STAIN WEIGHT OR VOLUME 
MQ water 225 mL 
Methanol 225 mL 
Glacial Acetic Acid 50 mL 
Coomassie Blue  0.5 g 
Total Volume 500 mL 
 
Mix together with a magnetic stirrer until Coomassie Blue is completely 
dissolved. Store stain at room temperature. 
 C) Destain Solution (20% Methanol, 10% Acetic Acid): 
 
SAMPLE REDUCING DYE VOLUME
MQ water 700 mL 
Methanol 200 mL 
Glacial Acetic Acid 100 mL 
Total Volume 1000 mL
 
  Mix well, and store solution at room temperature. 
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II DNA Gel Electrophoresis: 
 
A) 6X DNA Loading Dye (0.25% w/v bromophenol blue, 30% v/v glycerol) 
 
6X DNA LOADING DYE WEIGHT OR VOLUME 
Glycerol 3 mL 
Bromophenol Blue  25 mg 
MQ water up to 10 mL 
Total Volume 10 mL 
 
 Mix well until all bromophenol blue is dissolved. Store solution at 4°C for several 
weeks or store aliquots at ‒20 °C. 
 
B) 50X Tris Acetate EDTA (TAE) Buffer: 
 
50X TAE BUFFER WEIGHT OR VOLUME 
Tris Base  242 g 
Glacial Acetic Acid 57.1 mL 
0.5 M EDTA pH 8.0 100 mL 
MQ water up to 1 L 
Total Volume 1 L 
 
 Store 50X buffer at 4°C. Prepare 1X TAE buffer by combining 20 mL TAE 
(50X) with 980 mL MQ water and mixing well. Final 1X TAE buffer is 40 mM 
Tris acetate and 1 mM EDTA. 
 
 
III o-Phthalaldehyde (OPA) Assay Reagent: 
 
 1.25 g of boric acid was dissolved in approximately 30 mL of MQ water, and then 
 the pH was adjusted to 10.4 with potassium hydroxide. Then, the following were added
 to the basic boric acid solution: 
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OPA ASSAY REAGENT VOLUME 
Boric acid solution pH 10.4 (as above) 30 mL 
Tween-20 150 μL 
2-Mercaptoethanol 150 μL 
o-Phthalaldehyde dissolved in 1 mL methanol 1 mL 
MQ water up to 50 mL 
Total Volume 50 mL 
Mix well and keep reagent at room temperature, protected from light. This reagent 
needs to be used immediately so must be prepared fresh, just before performing the 
assay. The reagent solution contains 0.4 M boric acid, 0.03% v/v Tween-20, 0.03% v/v  




A) SOC Media 
 
SOC RECOVERY MEDIA WEIGHT OR VOLUME 
Tryptone 2 g 
Yeast Extract 0.5 g 
1 M NaCl 1 mL 
1 M KCl 0.25 mL 
1 M MgCl2 1 mL 
1 M MgSO4 1 mL 
MQ water up to 100 mL 
Total Volume 100 mL 
 
Mix well, and then sterilise by autoclaving for 20 minutes at 121 °C. Allow to cool, then 
aseptically add 2 mL of 1 M glucose solution (filter sterilised), and mix well. Working 
aseptically, aliquot SOC media out into Eppendorf tubes and store in freezer at ‒20 °C. 
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Tryptone 12 g 
Yeast Extract 24 g 
Glycerol 4 mL 
MQ water up to 900 mL 
Total Volume 900 mL 
 
Make up the TB media and the potassium phosphate solutions separately, and sterilise 
each by autoclaving for 20 minutes at 121 °C. Once cool, add 100 mL of the potassium 
phosphate solution to the TB media aseptically and mix well.  
 
C) 2*TY Media 
 
TB MEDIA WEIGHT OR VOLUME 
Tryptone 16 g 
Yeast Extract 10 g 
NaCl 5 g 
MQ water up to  1L 
Total Volume 1 L 
   




 A) PBS  
 
Five PBS tablets (Sigma-Aldrich, St. Louis, Missouri, USA) were dissolved in 1 L of 
MQ water to give a buffer containing 0.01 M phosphate buffer, 2.7 mM potassium 
chloride, and 137 mM sodium chloride. For purification, imidazole was added at a 
concentration of 10 mM (68 mg) for washing or at concentrations of 50 mM (340 mg), 
and 150 mM (1.02 g) for elution. The pH was altered to either 7.2 or pH 7.4 as required. 
The buffer was filtered and stored at 4 °C.  




KH2PO4 23.1 g 
K2HPO4 125.4 g 
MQ water up to 1 L 
Total Volume 1 L 
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B) PBST (Phosphate buffered Saline with Tween-20) 
 
PBST BUFFER WEIGHT OR VOLUME 
NaCl 8 g 
KCl 0.2 g 
Na2HPO4 1.44 g 
KH2PO4 0.24 g 
Tween-20 50 μL 
MQ water up to  1L 
Total Volume 1 L 
 
Dissolve well in approximately 900 mL MQ water, and adjust pH to 7.4 to give a buffer 
containing 137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, and 0.005% 
Tween-20. Make volume up to 1 L with MQ water and mix well. Filter, sonicate for 20 
minutes, and store buffer at 4 °C.  
 
 
 C) Tris Buffer  
 
TRIS BUFFER WEIGHT OR VOLUME 
Tris Base 1.21 g 
NaCl 29.22 g 
MQ water up to  1L 
Total Volume 1 L 
 
Dissolve well in approximately 900 mL MQ water, and adjust pH to 7.4. Make volume 
up to 1 L with MQ water and mix well. Filter, and store buffer at 4 °C. Final buffer is 10 
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D) Lysis Buffer  
 
LYSIS BUFFER WEIGHT OR VOLUME 
1 M KH2PO4 3 mL 
1 M K2HPO4 47 mL 
NaCl 23 g 
KCl 7.5 g 
Glycerol 100 mL 
Triton X-100 5 mL 
Imidazole 68 mg 
MQ water up to 1L 
Total Volume 1 L 
 
Mix well in approximately 800 mL MQ water until completely dissolved. Adjust pH to 
7.8 with HCl, and bring volume up to 1 L with MQ water, and mix well. Filter buffer 
and store buffer at 4 °C. Final buffer is 50 mM potassium phosphate, 400 mM sodium 
chloride, 100 mM potassium chloride, 10% glycerol, 0.5% Triton X-100, and 10 mM 
imidazole at pH 7.8. 
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